Lymphotoxin-beta receptor (LTβr) agonists and antagonists uses thereof in cancer immunotherapy and other disorders
LTβR agonists like mAb 10G3 enhance immune cell infiltration and differentiation in tumors, addressing the challenge of insufficient immune cell presence in solid tumors and improving cancer therapy efficacy.
Patent Information
- Application Number
- PCT/US2026/025592
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-13
- Filing Date
- 2026-04-28
- Publication Date
- 2026-11-19
AI Technical Summary
Current immunotherapies for cancer, such as CAR T cell therapy and TIL therapy, face challenges due to insufficient immune cell infiltration in solid tumors, limiting their effectiveness.
LTβR agonists, such as monoclonal antibody mAb 10G3, are used to stimulate chemokine biosynthesis and immune cell recruitment into the tumor microenvironment, enhancing lymphocyte infiltration and differentiation.
LTβR agonists increase immune cell infiltration and differentiation, making tumors more responsive to conventional therapies and improving treatment outcomes for cancers resistant to standard treatments.
Smart Images

Figure IMGF000077_0001_TABLE 
Figure IMGF000077_0002_TABLE 
Figure 00000097_0000
Abstract
Description
[0001] SBMRI 22-006-03 PCT
[0002] LYMPHOTOXIN-BETA RECEPTOR (LTpR) AGONISTS AND ANTAGONISTS AND USES THEREOF IN CANCER IMMUNOTHERAPY AND OTHER DISORDERS
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS
[0004] This application claims the benefit of and priority to U. S. Provisional Application No. 63 / 805,258 filed on May 13, 2025, the contents of which is incorporated herein in its entirety.
[0005] REFERENCE TO THE SEQUENCE LISTING
[0006] The Sequence Listing submitted as an XML file named “SBMRI_22_006_03_PCT.xml”, created on April 27, 2026, and having a size of 26,945 bytes is hereby incorporated by reference pursuant to 37 C. F. R. § 1.834(c)(1).
[0007] FIELD OF THE INVENTION
[0008] The disclosed invention is generally in the field of enhancing immunotherapy for treatment of cancer and other disorders, and specifically via activating Lymphotoxin-beta receptor (LTPR) signaling using monoclonal antibodies in patients failing to respond to standard care treatment.
[0009] BACKGROUND OF THE INVENTION
[0010] The advent of modem immunotherapies, such as Chimeric Antigen Receptor (CAR) T cell therapy and Tumor Infiltrating Lymphocyte (TIT,) therapy, for cancer was heralded as an opportunity to dramatically improve response rates and long-term survival. However, clinical studies have shown that immune cell therapies have not resulted in meaningful patient benefit. It is believed that one of the challenges with cell-based immunotherapy is that in many solid tumors, there are insufficient immune cells present to mount a response. Current research is seeking new methods to enhance and improve immune cell infiltration into the tumor microenvironment (TME).
[0011] Therefore, it is an object of the invention to provide compositions and methods of use thereof for initiating and / or enhancing immune cell infiltration in tumors.
[0012] It is a further object of the invention to provide compositions and methods for enhancing recruitment of immune cells, lymphocyte infiltration, and immune cell and stromal cell differentiation in the tumor microenvironment.
[0013] SUMMARY OF THE INVENTION
[0014] It has been established that agonists of the Lymphotoxin-[3 Receptor (LT[3R) stimulate and induce the biosynthesis and secretion of chemokines in the TME. These chemokines can stimulate the migration of immune cells into the TME.
[0015] 45844288.1 1
[0016] SBMRI 22-006-03 PCT
[0017] The present disclosure generally involves LTpR agonists. In some aspects, the agonists are cross-reactive in that they act as agonists to both mouse LTpR and human LTpR. In some aspects, a subset of LTpR agonists also do not block the natural ligands to LTPR (i.e., hLIGHT and hLTaip2). In this way, the natural ligands and the agonists can cooperatively activate the LTpR.
[0018] Compositions of LTPR agonists that target and stimulate the LTPR are described. In some forms, the LTpR agonist is a monoclonal antibody (mAb). In some forms, the LTPR agonist is a monoclonal antibody as disclosed and described herein (e.g., mAb 10G3). or a variant, fragment, or fusion protein derived therefrom. For example, the LTpR agonist (such as mAb 10G3) can be an intact immunoglobulin, or a mono-, di-, or tri-valent or multivalent single chain variable fragment (scFv), Fab, F(ab’)2, minibody, scFv-Fc, diabody, triabody, or tetrabody, or other component or derivative of mAb 10G3 or a variant thereof. The LTpR agonist can be a mono-, di-, or tri-, or multi-valent single chain variable fragment (scFV) of a monoclonal antibody as disclosed and described herein (e.g., mAb 10G3), or a variant thereof.
[0019] In some forms, the LTpR agonist can, for example, include (i) a heavy chain including the three complementarity-determining regions (CDR) of SEQ ID NOs: 11-13, and / or light chain including the three CDR of SEQ ID NOs:14-16 or (ii) a heavy chain including the amino acid sequence from SEQ ID NO:9, or a variant therefore including at least 70% sequence identity to SEQ ID NO:9, and a light chain including the amino acid sequence of SEQ ID NO:10, or a variant therefore including at least 70% sequence identity to SEQ ID NO:10. In other forms, the LTpR agonist can, for example, include (i) a heavy chain including the three complementarity-determining regions (CDR) of SEQ ID NOsT 1, 12, 19, and light chain including the three CDR of SEQ ID NOs:20-22, or (ii) a heavy chain including the amino acid sequence from SEQ ID NO:17, or a variant therefore including at least 70% sequence identity to SEQ ID NO:17, and a light chain including the amino acid sequence of SEQ ID NOT 8, or a variant therefore including at least 70% sequence identity to SEQ ID NOT 8. In other forms, the LTPR agonist can, for example, include (i) a heavy chain including the three complementarity-determining regions (CDR) of SEQ ID NOS:3-5, and light chain including the three CDR of SEQ ID NOS:6-8, or (ii) a heavy chain including the amino acid sequence from SEQ ID NOT, or a variant therefore including at least 70% sequence identity to SEQ ID NOT, and a light chain including the amino acid sequence of SEQ ID NO:2, or a variant therefore including at least 70% sequence identity to SEQ ID NO:2.
[0020] 45844288.1 2
[0021] SBMRI 22-006-03 PCT
[0022] In some forms, the antibody or antigen binding fragment thereof the mAb binds to LTPR with an EC50 between about 0.01 nM and about 1 nM, inclusive, preferably between about 0.1 nM and about 0.5 nM, inclusive.
[0023] Pharmaceutical compositions including an effective amount of one or more LTPR agonists (e.g., mAb 10G3) and a pharmaceutically acceptable carrier for administration to a subject in need thereof are also provided.
[0024] Methods of treating a subject in need thereof by administering to the subject an effective amount of one or more LTPR agonists (e.g., mAb 10G3), typically in a pharmaceutical composition, are also disclosed. While not being bound by any mechanism of action, in some forms, the methods induce, promote, or enhance the biosynthesis of chemokines, immune cell infiltration of the TME, and / or Tertiary Lymphoid Structures (TLSs) formation by administering to the subject an effective amount of one or more LTPR agonists (e.g., mAb 10G3), typically in a pharmaceutical composition. In some forms, the subject has cancer. Thus, preferably, the biosynthesis of chemokines, immune cell infiltration, and / or TLSs formation is within a tumor microenvironment. T ypically, prior to the administration of the pharmaceutical composition including one or more LTPR agonists (e.g., mAb 10G3), the tumor microenvironment in the subject had low infiltration of immune cells, and / or high presence of immunosuppressive cells. Exemplary immunosuppressive cells are one or more regulatory T cells and / or type II macrophages. Therefore, in some forms, the pharmaceutical composition is administered in an amount effective to recruit immune cells, promote lymphocyte infiltration, and drive immune cell differentiation. In one form, the pharmaceutical composition is administered in an amount effective to recruit cytotoxic T cells into the tumor microenvironment, more than 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more than 90%, compared to the level prior to the administration of the pharmaceutical composition. In some forms, the methods further include the step of administering one or more cancer therapies, simultaneously or sequentially with the administration of the pharmaceutical composition including one or more LT[3R agonists (e.g., mAb 10G3). For example, cancer therapies include blockade of inhibitory check point receptors, activation of costimulatory receptors (e.g., anti-CD40), chemokines, and cytokines. Exemplary cancer therapies include conventional chemotherapy, immunotherapy, surgery, and radiation. In some forms, the immunotherapy is one or more check point receptor inhibitors selected from the group including PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists. Exemplary immune check point receptor inhibitors used in immunotherapy include Pembrolizumab
[0025] 45844288.1 3
[0026] SBMRI 22-006-03 PCT
[0027] (anti-PDl mAb), Durvalumab (anti-PDLl mAb), PDR001 (anti-PDl mAb), Atezolizumab (anti-PDLl mAb), Nivolumab (anti-PDl mAb), Tremelimumab (anti-CTLA4 mAb), Avelumab (anti-PDLl mAb), and RG7876 (CD40 agonist mAb).
[0028] In some forms, the compositions are suitable for sensitizing cancer cells to one or more existing cancer therapy such as check point receptor inhibitor therapy or conventional chemotherapy. Thus, in some forms, the tumor was resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to the administration of the pharmaceutical composition including one or more LTpR agonists (e.g., mAb 10G3). Typically, the effective amount of the pharmaceutical composition in combination with the one or more cancer therapies are effective to reduce or inhibit proliferation, migration, invasion, motility, and / or metastatic abilities of the cancer cells. Exemplary cancer suitable for the combination treatment includes lymphoma, leukemia, breast cancer, head and neck squamous cell carcinoma, glioblastoma, pancreatic cancer, lung cancer, melanoma, ovarian cancer, and sarcoma. In one form, the cancer is Triple Negative Breast Cancer.
[0029] Methods of administering LT0R agonist to treat cancers with resistance to existing cancer therapies such as check point receptor inhibitors are also provided. Typically, methods administer the subject an effective amount of the pharmaceutical composition including one or more LT[3R agonists e.g., mAb 10G3), and one or more conventional chemotherapeutic agents and / or immunotherapy to treat or alleviate one or more symptoms of cancer in the subject. The LT|3R agonist can be administered using any appropriate mode or route. Generally, these can depend on the nature of the LTpR agonist. Exemplary routes of delivery include intravenous, subcutaneous, and intratumoral, expressing on the cell-surface, immobilizing on cell-surface, and / or immobilizing on biocompatible materials. In some forms, the immunotherapy is one or more check point inhibitors selected from the group including PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists. In other forms, the conventional chemotherapeutic agents include anti-VEGF antibodies, Receptor Tyrosine Kinase (RTK) inhibitors, MEK inhibitors, and CXCR4 antagonists. In some forms, exemplary conventional chemotherapeutic agents include bevacizumab, cabozantinib, cobimetinib, and BL8040. Additional exemplary immune checkpoint receptors include TIGIT, LAG-3, TIM-3, VISTA, and BTLA. The therapies can include checkpoint receptors, costimulatory receptors (e.g., anti CD40), chemokines, and cytokines.
[0030] 45844288.1 4
[0031] SBMRI 22-006-03 PCT
[0032] The methods can generally increase the sensitivity of cancer cells to one or more existing cancer therapies such as check point receptor inhibitor therapy and conventional chemotherapy. Thus, in some forms, the cancer to be treated was resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to the administration of the disclosed pharmaceutical composition. In some forms, the administration of the one or more conventional chemotherapeutic agents and / or immunotherapy is simultaneous or sequential with the administration of the pharmaceutical composition including one or more LT|3R agonists (e.g., mAh 10G3). Preferably, the methods administer an effective amount of the pharmaceutical composition in combination with the one or more conventional chemotherapeutic agents and / or immunotherapy to reduce or inhibit proliferation, migration, invasion, motility, and / or metastatic abilities of the cancer cells. Exemplary cancer suitable for the combination treatment includes breast cancer, head and neck squamous cell carcinoma, glioblastoma, pancreatic cancer, lung cancer, melanoma, ovarian cancer, and sarcoma. In one form, the cancer is Triple Negative Breast Cancer.
[0033] Methods of screening for suitable LT0R agonists are also provided. In some forms, the LTpR agonists to be screened are monoclonal antibodies (mAbs).
[0034] Provided herein are antibodies that specifically bind to a human LTpR (hLT|3R) and / or a mouse LTPR (mouse LTPR) polypeptides; methods of generating the antibodies; methods of screening and selecting the antibodies; DNA sequences encoding the antibodies. Also provided herein are methods of determining the binding affinities of the LTPR agonistic antibodies using cells expressing hLTpR receptors or mouse LTPR (mLTpR); demonstrations on the binding of LTPR agonistic antibodies to hLTpR and mLTpR; methods of determining the agonistic activities of the LTPR agonistic antibodies on hLTPR receptor activation in a cell expressing hLTPR; and the observations of such activations.
[0035] Also disclosed are compositions comprising the antibody as described herein conjugated to tumor cells of a subject.
[0036] Also disclosed are methods including administering an effective amount of the described compositions including LTpR agonists to a subject to induce, promote, or enhance the biosynthesis and secretion of chemokines and / or infiltration of immune cells into the TME in the subject. In some forms, the enhancement of the biosynthesis and secretion of chemokines and / or immune cell infiltration is mediated by LTβR signaling within the TME. In some forms, the TME had low infiltration of immune cells, and / or
[0037] 45844288.1 5
[0038] SBMRI 22-006-03 PCT
[0039] high presence of immunosuppressive cells prior to the administration of the composition. In some forms, the immunosuppressive cells are one or more regulatory T cells and / or type II macrophages.
[0040] In some forms, the described composition is administered to a subject in an amount effective to recruit immune cells, promote lymphocyte infiltration, and drive immune cell differentiation in the TME of a subject. In some forms, the composition is administered in an amount effective to recruit cytotoxic T cells into the tumor microenvironment, for example, to increase the amount of cytotoxic T cells within the TME by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more than 90%, compared to the amount of cytotoxic T cells within the TME prior to the administration of the composition.
[0041] In some forms, the methods further include administering one or more additional cancer therapies to the subject. In some forms, the administration of the one or more additional cancer therapies is simultaneous or sequential with the administration of the composition. In some forms, the additional cancer therapy is one or more selected from conventional chemotherapy, immunotherapy, surgery, and radiation. In some forms, the immunotherapy includes one or more check point receptor inhibitor(s), e.g., selected from PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.
[0042] In some forms, a tumor in a subject is resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to the administration of the composition. In some forms, the effective amount of the composition in combination with the one or more additional cancer therapies is effective to reduce or inhibit proliferation, migration, invasion, motility, and / or metastatic abilities of the cancer cells.
[0043] In some forms, the composition is for use in a method of treatment of a proliferative disease or disorder in a subject in need thereof, including administering to the subject the pharmaceutical composition in an amount effective to treat or prevent one or more symptoms of the proliferative disease or disorder.
[0044] A method of treating melanoma in a subject, the method including administering to the subject a polynucleotide encoding one or more or the described LTPR agonistic antibodies or antigen binding fragment thereof of or a polynucleotide encoding a fusion protein including one or more or the described LTPR agonistic antibodies or antigen binding fragment thereof is also provided. In some forms, the polynucleotide is DNA, such as cDNA or RNA, such as mRNA. In some forms, the melanoma is refractory melanoma, such as dacarbazine-refractory melanoma, vemurafenib-refractory melanoma,
[0045] 45844288.1 6
[0046] SBMRI 22-006-03 PCT
[0047] trametinib-refractory melanoma or dasatinib-refractory melanoma. In some forms, the melanoma includes wild type BRAF, mutated BRAF, wild type NRAS, or mutated NRAS. In some forms, the melanoma is stage II melanoma, stage III melanoma, or stage IV melanoma. In some forms, the melanoma was resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to administering the polynucleotide. In some forms, the melanoma is metastatic melanoma. In some forms, the melanoma is acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma subungal melanoma, and superficial spreading melanoma.
[0048] In some forms, the subject has previously undergone tumor resection.
[0049] In some forms, the method further includes administering one or more additional cancer therapies to the subject. In some forms, the administration of the one or more additional cancer therapies is simultaneous or sequential with administering the polynucleotide. An exemplary additional cancer therapy includes an immune checkpoint inhibitor, such as pembrolizumab, nivolumab, ipilimumab, relatlimab, or combination thereof. In some forms, the additional cancer therapy includes a BRAF inhibitor, such as dabrafenib, vemurafenib, encorafenib, or combinations thereof. In some forms, the additional cancer therapy includes a MEK inhibitor, such as trametinib, cobimetinib, binimetinib, or combinations thereof. In some forms, the additional cancer therapy is selected from conventional chemotherapy, immunotherapy, surgery, and radiation.
[0050] In some forms, the additional cancer therapy is immunotherapy that includes one or more check point receptor inhibitor(s) selected from the group consisting of PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.
[0051] In some forms, the fusion protein is located on mammalian cells including a surface. In some forms, the fusion protein is covalently or non-covalently attached to the surface of one or more mammalian cell of the mammalian cells. In some forms, the fusion protein is non-covalently attached to the surface of the mammalian cell by way of hydrophobic interactions. For example, in some forms, the fusion protein further includes a membrane-anchoring domain and the fusion protein is non-covalently attached to the surface of the mammalian cell by way of hydrophobic interactions with a membraneanchoring domain. In some forms, the fusion protein further includes a signal peptide domain. In some forms, the fusion protein further a membrane-anchoring domain.
[0052] 7
[0053] 45844288.1
[0054] SBMRI 22-006-03 PCT
[0055] An antibody complex including the described LTPR agonistic antibodies or antigen binding fragment thereof is also provided. In some forms, the antibody complex includes a signal peptide domain. In some forms, the antibody complex further includes a membrane- anchoring domain. In some forms, the antibody complex further includes a cell. In some forms, the cell is a mammalian cell. In some forms, the antibody complex is located on the surface of the mammalian cell. In some forms, the antibody complex is covalently or non-covalently attached to the surface of the mammalian cell In some forms, the antibody complex is non-covalently attached to the surface of the mammalian cell by way of hydrophobic interactions. In some forms, the antibody complex is non-covalently attached to the surface of the mammalian cell by way of hydrophobic interactions with the membrane-anchoring domain.
[0056] Additional advantages of the disclosed method and compositions will be set forth in part in the description which follows, and in part will be understood from the description, or may be learned by practice of the disclosed method and compositions. The advantages of the disclosed method and compositions will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention as claimed.
[0057] BRIEF DESCRIPTION OF THE DRAWINGS
[0058] Figure 1 is a graph of binding curves of anti-LTpR antibodies to LTPR expressing 293T cells showing anti-LT|3R bound 293T-LTPR GFP (0-10,000 MFI) over graded concentrations of anti-LT|3R (pg / mL) for each of 6A4, 6G9, 7A3, 10C5, 10C12, 10G3, 11D9, 15E2, 17A2, and CBE11 (positive control), respectively.
[0059] Figure 2 is a graph of binding curves of anti-LTpR antibodies to mouse LTPR expressing 293T cells showing anti-LT R bound 293T-mLT[3R GFP (0-25,000 MFI) over graded concentrations of anti-LT|3R (pg / mL) for each of 6A4, 6G9, 7A3, 10C5, 10C12, 10G3, 11D9, 15E2, 17A2, CBE11, and 4H8 respectively.
[0060] Figure 3 is a graph of anii-LTpR activated HeLa-NFKB reporter cells showing anti-LTPR mediated LT R signal (0-40,000 RLU) over graded concentrations of anti-LTPR (pg / mL) for each of 6A4, 6G9, 7A3, 10C5, 10C12, 10G3, 11D9, 15E2, 17A2, and CBE11, respectively.
[0061] Figure 4 is graph of the co-binding curves with recombinant LIGHT, showing SLIGHT bound 293 T-Ll' R (0-2,000 MFI) over graded concentrations of anti-L IpR
[0062] 45844288.1 8
[0063] SBMRI 22-006-03 PCT
[0064] (pg / mL) for each of 6A4, 6G9, 7 A3, 10C5, 10C12. 10G3, 11D9. 15E2, 17A2, and CBE11, respectively.
[0065] Figure 5 is graph of the co-binding curves with recombinant LTaip2 binding for LTpR on 293T-LT0R cells, showing LTalp2 bound 293T-LT0R (0-2,000 MFI) over graded concentrations of anti-LT0R (pg / mL) for each of 6A4, 6G9, 7A3, 10C5, 10C12, 10G3, 11D9, 15E2, 17A2, and CBE11, respectively.
[0066] Figure 6 is a graph illustrating the in vitro characteristics of three anti-LTbR monoclonal antibody clones; 10G3, 15E2, 6G9 identified as having co-binding with LIGHT and LTal(32 to LT R, depicting target engagement, agonistic activity, co-binding with LIGHT, co-binding with LTal| 2 and binding with mouse LT| R, respectively.
[0067] Figure 7 is a schematic illustrating the development of the mouse EL4 syngeneic tumor model, showing sub-cutaneous implantation of EL4 cells into C57BL / 6 mice, then assessment of tumor formation after day 6, and measurement of tumor growth for a minimum of 10 days, respectively.
[0068] Figures 8A-8B are graphs depicting isoforms of LIGHT requirement for LIGHT-mediated anti-tumor response, showing Mean tumor volume (cm3) over days post-EL4 cells injection for each of EL4-EV and EL4-LIGHT (Fig. 8A), and in each of EL4-LIGHTATM and EL4-LIGHT-t66 (Fig. 8B), respectively.
[0069] Figures 9A-9B are graphs depicting receptor requirement for LIGHT-mediated anti-tumor response, showing Mean tumor volume (cm3) over days post-EL4 cells injection for each of EL4-EV and EL4- LIGHT, respectively, in each of LT R- / - (Fig. 9A), and HVEM - / - (Fig. 9B), respectively.
[0070] Figure 10 is a schematic depicting the vaccination approach for inhibition of tumor growth by LIGHT decorated EL4 cells, where recombinant soluble LIGHT was immobilized on EL4 cell-surface. (A) Prepared EL4 cells were injected subcutaneously (SC). After 14 days post EL4-NA-LIGHTinoculation, the mice were challenged with EL4 cells. (B) Graph of the EL4-NA-LIGHT vaccination-reduced tumor growth showing Average tumor volume (cm3) over days post-EL4 cells injection for each of EL4-NA (control) and EL4-NA-LIGHT, respectively.
[0071] Figure 11A is a schematic depicting the vaccination approach for inhibition of tumor growth by 10G3 decorated EL4 cells, where 10G3 was immobilized on the EL4 cell-surface. Prepared EL4 cells were injected subcutaneously. After 14 days postvaccination, the mice were challenged with EL4 cells. Fig. 11B is a graph showing the
[0072] 45844288.1 9
[0073] SBMRI 22-006-03 PCT
[0074] Average tumor volume (cm3) over days post-EL4 cells injection for each of EL4-CD16a control and EL4-CD16a-10G3 mouse.
[0075] Figures 12A-12C are graphs showing immune cell infiltration into EL4 tumors collected after 14 days post-vaccination; immunohistochemistry was performed and the percent (%) of positive staining was equal to the area of positive staining divided by the total area of staining on a tumor slide-section. Fig. 12A is a graph of infiltration of CD8+ T cells in El A tumors, showing positive CD8 staining (0-4 %) for each of EI4-CD16a and EL4-CD16a-10G3, respectively. Fig. 12B is a graph of the infiltration of F4 / 80+ macrophages in EL4 tumors, showing positive F4 / 80 staining (0-40 %) for each of EL4-CD16a and EL4-CD16a-10G3, respectively. Fig. 12C is a graph of the infiltration of NK1.1+ natural killer (NK) cells in EL4 tumors, showing positive NK1.1 staining (0-15 %) for each of EL4-CD16a and EL4-CD16a-10G3, respectively.
[0076] Figures 13A-13B are graphs showing post EL4 cell challenge, showing tumor-free mice (%) over days post EL4 challenge, for each of PBS control (•) and 10G3 (▼) groups, respectively (Fig. 13A); and tumor volume (cm3) over days post-EL4 cell injection for each of PBS control group and 10G3 groups, respectively (Fig. 13B).
[0077] Figures 14A-14C are graphs showing immune cell infiltration into EL4 tumors collected after the tumor challenge; immunohistochemistry was performed and the percent (%) of positive staining was equal to the area of positive staining divided by the total area of staining on a tumor slide- section. Fig. 14A is a graph of the infiltration of CD8+ T cells in EL4 tumors, showing positive CD8 staining (% area) for each of PBS control group and 10G3 groups; Fig. 14B is a graph of the infiltration of F4 / 80+ macrophages in EL4 tumors, showing positive F4 / 80 staining (% area) for each of PBS control group and 10G3 groups, respectively; and Fig. 14C is a graph of the infiltration of NK1.1+ natural killer (NK) cells in EL4 tumors, showing positive NK1.1 staining (% area) for each of PBS control group and 10G3 groups, respectively.
[0078] Figures 15A-15B are graphs showing Tumor infiltrating immune cells (%) for each of PBS control group and 10G3 groups, separated into each of CD8 T cells, macrophage and NK cells (Fig. 15A); and showing Tumor infiltrating immune cells (%) for each of CD8 T cells (■), macrophage (♦) and NK cells (•), separated into each of PBS control group and 10G3 groups, respectively (Fig. 15B).
[0079] Figures 16A-16C are graphs showing post EL4 cell challenge. Fig. 16A shows tumor volume (cm3) over days post-EL4 cell injection for each of PBS control group, EL4 vaccination group, and EL4-10G3 vaccination groups, respectively; Fig. 16B shows
[0080] 45844288.1 10
[0081] SBMRI 22-006-03 PCT
[0082] tumor-regression mice (%) over days post EL4 challenge, for each of EL4 vaccination group and EL4-10G3 vaccination groups, respectively; and Fig. 16C shows tumor volume (cm3) over days post-EL4 cell injection for each of the mice showing tumor regression from the EL4-10G3 vaccination group.
[0083] Figures 17A-17B are graphs showing post YUMM1.5 cell challenge. Fig. 17A shows tumor volume (cm3) over days post- YUMM 1.5 cell injection for each of PBS control group, YUMM1.5 vaccination group, and YUMM-10G3 vaccination groups, respectively; Fig. 17B shows tumor- free mice (%) over days post YUMM1.5 challenge, for each of PBS control group, YUMM 1.5 vaccination group, and YUMM-10G3 vaccination groups, respectively. Mantel-Cox test: YUMM1.5-10G3 vs. PBS (P = 0.0048); YUMM1.5 vs. PBS (P = 0.3813); YUMM1.5-10G3 vs. YUMM1.5 (P = 0.3107).
[0084] Figure 18 is a graph of anii-El jlR 10G3 activated 293T-NFKB reporter cells, showing anti-LTpR 10G3 or human IgG control mediated LTpR signal (0-500,000 RLU) over graded concentrations of anti-LTPR 10G3 or human IgG control (pg / mL) in the presence or absence of a fixed concentration of recombinant soluble LIGHT at EC70 signaling level.
[0085] Figure 19 is a graph of anti-LTpR 10G3 activated 293T-NFKB reporter cells showing anti-LTPR 10G3 or human IgG control mediated LTPR signal (0-500,000 RLU) over graded concentrations of anti-LTpR 10G3 or human IgG control (pg / mL) in the presence of a fixed concentration of recombinant soluble LTaip2 at EC70 signaling level.
[0086] The accompanying drawings illustrate several embodiments of the disclosed method and compositions and together with the description, serve to explain the principles of the disclosed method and compositions.
[0087] DETAILED DESCRIPTION OF THE INVENTION
[0088] A. Definitions
[0089] As used herein, the term “tumor” refers to an abnormal mass of tissue containing neoplastic cells. Tumors may be benign, premalignant, or malignant.
[0090] As used herein, the term “cancer” refers to a cell that displays uncontrolled growth and division, invasion of adjacent tissues, and often metastasizes to other locations of the body.
[0091] As used herein, the term “scFv” means a single chain variable fragment that includes a light chain variable region (VL) and a heavy chain variable region (VH) joined by a linker. The VL and VH regions may be derived from the parent antibody or may be chemically or recombinantly synthesized.
[0092] 45844288.1 11
[0093] SBMRI 22-006-03 PCT
[0094] As used herein, the term “variable region” is intended to distinguish such domain of the immunoglobulin from domains that are broadly shared by antibodies (such as an antibody Fc domain). The variable region includes a “hypervariable region” whose residues are responsible for antigen binding. The hypervariable region includes amino acid residues from a “Complementarity Determining Region” or “CDR” (z.e., typically at approximately residues 24-34 (LI), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and at approximately residues 27-35 (Hl), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and / or those residues from a “hypervariable loop” (i.e., residues 26-32 (LI), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (Hl), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk, 1987, J. Mol. Biol.
[0095] 196:901-917).
[0096] As used herein, the term “Framework Region” or “FR” residues are those variable domain residues other than the hypervariable region residues as herein defined.
[0097] As used herein, the term “antibody” refers to natural or synthetic antibodies that bind a target antigen. The term includes polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also included in the term “antibodies” are fragments or polymers of those immunoglobulin molecules, and human or humanized versions of immunoglobulin molecules that bind the target antigen.
[0098] As used herein, the term “specifically binds” refers to the binding of an antibody to its cognate antigen (for example LTpR) while not significantly binding to other antigens. Preferably, an antibody “specifically binds” to an antigen with an affinity constant (Ka) greater than about 105mol-1(e.g., 106mol-1, 107mol-1, 10smol-1, IO9mol-1, 1010mol-1, 1011mol-1, and 1012mol-1or more) with that second molecule.
[0099] As used herein, the term “monoclonal antibody” or “mAb” refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules.
[0100] As used herein, the term “individual,” “host,” “subject,” and “patient” are used interchangeably to refer to any individual who is the target of administration or treatment. The subject can be a vertebrate, for example, a mammal. Thus, the subject can be a human or veterinary patient.
[0101] 45844288.1 12
[0102] SBMRI 22-006-03 PCT
[0103] The term “effective amount” or “therapeutically effective amount” means a dosage sufficient to treat, inhibit, or alleviate one or more symptoms of a disease state being treated or to otherwise provide a desired pharmacologic and / or physiologic effect. In some forms, the effective amount refers to the amount which is able to treat one or more symptoms of hematological cancer and / or solid tumors, reverse the progression of one or more symptoms of hematological cancer and / or solid tumors, halt the progression of one or more symptoms of hematological cancer and / or solid tumors, or prevent the occurrence of one or more symptoms of hematological cancer and / or solid tumors in a subject to whom the formulation is administered, for example, as compared to a matched subject not receiving the compound. The precise dosage will vary according to a variety of factors such as subject-dependent variables (e.g., injury size / type, age, joint health, immune system health, etc.), the disease or disorder, and the treatment being administered. The effective amount can be relative to a control. Such controls are known in the art and discussed herein, and can be, for example the condition of the subject prior to or in the absence of administration of the drug.
[0104] The terms “treating” or “preventing” mean to ameliorate, reduce or otherwise stop a disease, disorder or condition from occurring or progressing in an animal which may be predisposed to the disease, disorder and / or condition but has not yet been diagnosed as having it; inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g., causing regression of the disease, disorder and / or condition. Treating the disease or condition includes ameliorating at least one symptom of the disease or condition, even if the underlying pathophysiology is not affected, such as treating the pain of a subject by administration of an analgesic agent even though such agent does not treat the cause of the pain. Desirable effects of treatment include decreasing the rate of disease progression, ameliorating, or palliating the disease state, and remission or improved prognosis. For example, an individual is successfully “treated” if one or more symptoms associated with hematological cancer and / or solid tumors are mitigated or eliminated, including, but are not limited to, reducing and / or inhibiting rate of tumor cell proliferation / growth, increasing the quality of life of those suffering from the disease, decreasing the dose of other medications required to treat the disease, delaying the progression of the disease, and / or prolonging survival of individuals.
[0105] The term “pharmaceutically acceptable” refers to compositions, polymers and other materials and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without
[0106] 45844288.1 13
[0107] SBMRI 22-006-03 PCT
[0108] excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio. The phrase “pharmaceutically acceptable carrier” refers to pharmaceutically acceptable materials, compositions or vehicles, such as a liquid or solid filler, diluent, solvent or encapsulating material involved in carrying or transporting any subject composition, from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of a subject composition and not injurious to the patient.
[0109] As used herein, the term “inhibit” means to decrease an activity, response, condition, disease, or other biological parameter. This can include, but is not limited to, the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels. In some forms, the inhibition and reduction are compared according to the level of mRNAs, proteins, cells, tissues, and organs.
[0110] As used herein, the term “variant” refers to a polypeptide or polynucleotide that differs from a reference polypeptide or polynucleotide but retains essential properties. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more modifications (e.g., substitutions, additions, and / or deletions). A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polypeptide may be naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally.
[0111] Modifications and changes can be made in the structure of the polypeptides of in disclosure and still obtain a molecule having similar characteristics as the polypeptide (e.g., a conservative amino acid substitution). For example, certain amino acids can be substituted for other amino acids in a sequence without appreciable loss of activity.
[0112] Because it is the interactive capacity and nature of a polypeptide that defines that polypeptide’s biological functional activity, certain amino acid sequence substitutions can be made in a polypeptide sequence and nevertheless obtain a polypeptide with like properties.
[0113] 45844288.1 14
[0114] SBMRI 22-006-03 PCT
[0115] In making such changes, the hydropathic index of amino acids can be considered. The importance of the hydropathic amino acid index in conferring interactive biologic function on a polypeptide is generally understood in the art. It is known that certain amino acids can be substituted for other amino acids having a similar hydropathic index or score and still result in a polypeptide with similar biological activity. Each amino acid has been assigned a hydropathic index on the basis of its hydrophobicity and charge characteristics. Those indices are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).
[0116] It is believed that the relative hydropathic character of the amino acid determines the secondary structure of the resultant polypeptide, which in turn defines the interaction of the polypeptide with other molecules, such as enzymes, substrates, receptors, antibodies, antigens, and cofactors. It is known in the art that an amino acid can be substituted by another amino acid having a similar hydropathic index and still obtain a functionally equivalent polypeptide. In such changes, the substitution of amino acids whose hydropathic indices are within + 2 is preferred, those within + 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.
[0117] Substitution of like amino acids can also be made on the basis of hydrophilicity, particularly where the biological functional equivalent polypeptide or peptide thereby created is intended for use in immunological embodiments. The following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 ± 1); glutamate (+3.0 ± 1); serine (+0.3); asparagine (+0.2); glutamnine (+0.2); glycine (0); proline (-0.5 + 1); threonine (-0.4); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent polypeptide. In such changes, the substitution of amino acids whose hydrophilicity values are within + 2 is preferred, those within + 1 are particularly preferred, and those within + 0.5 are even more particularly preferred.
[0118] As outlined above, amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the
[0119] 45844288.1 15
[0120] SBMRI 22-006-03 PCT
[0121] foregoing characteristics into consideration are well known to those of skill in the art and include (original residue: exemplary substitution): (Ala: Gly, Ser), (Arg: Lys), (Asn: Gin, His), (Asp: Glu, Cys, Ser), (Gin: Asn), (Glu: Asp), (Gly: Ala), (His: Asn, Gin), (He: Leu, Vai), (Leu: He, Vai), (Lys: Arg), (Met: Leu, Tyr), (Ser: Thr), (Thr: Ser), (Tip: Tyr), (Tyr: Trp, Phe), and (Vai: He, Leu). Some embodiments of this disclosure thus contemplate functional or biological equivalents of a polypeptide as set forth above. In particular, forms of the polypeptides can include variants having about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to the polypeptide of interest.
[0122] As used herein, the term “percent (%) sequence identity” is defined as the percentage of nucleotides or amino acids in a candidate sequence that are identical with the nucleotides or amino acids in a reference nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST- 2, ALIGN, AL1GN-2 or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared can be determined by known methods.
[0123] For purposes herein, the % sequence identity of a given nucleotides or amino acids sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given sequence C that has or includes a certain % sequence identity to, with, or against a given sequence D) is calculated as follows:
[0124] 100 times the fraction W / Z,
[0125] where W is the number of nucleotides or amino acids scored as identical matches by the sequence alignment program in that program’s alignment of C and D, and where Z is the total number of nucleotides or amino acids in D. It will be appreciated that where the length of sequence C is not equal to the length of sequence D, the % sequence identity of C to D will not equal the % sequence identity of D to C.
[0126] As used herein, “active agent” refers to a physiologically or pharmacologically active substance that acts locally and / or systemically in the body. An active agent is a substance that is administered to a patient for the treatment (e.g., therapeutic agent), prevention (e.g., prophylactic agent), or diagnosis (e.g., diagnostic agent) of a disease or disorder.
[0127] 45844288.1 16
[0128] SBMRI 22-006-03 PCT
[0129] B. Compositions
[0130] Compositions including agonistic monoclonal antibodies towards LT R, or antigen-binding compositions thereof, and fusion proteins including LT|3R binders are provided. Nucleic acids encoding or expressing the described LTpR binders are also described. Typically, the compositions include one or more agonistic monoclonal antibodies towards LTPR. In some forms, the compositions are suitable for initiating and / or enhancing immune cell infiltration formation via LTpR signaling in the tumor microenvironment (TME). In other forms, the compositions are suitable for immunologically transforming cold tumors into hot tumors. In other forms, the compositions are suitable for sensitizing cancer cells to one or more existing cancer therapy such as check point receptor inhibitor therapy or conventional chemotherapy.
[0131] 1. Lymphotoxin p Receptor (LT R)-Binding Proteins
[0132] Compositions of molecules that selectively and specifically bind to the Lymphotoxin p Receptor (LTpR) have been developed. LTpR (also known as tumor necrosis factor receptor superfamily member 3 (TNFRSF3)) is a cell surface receptor for lymphotoxin involved in apoptosis and cytokine release. It is a member of the tumor necrosis factor receptor superfamily. It is expressed on the surface of most cell types, including cells of epithelial and myeloid lineages, but not on T and B lymphocytes. The protein specifically binds the lymphotoxin membrane form (a complex of lymphotoxin-alpha and lymphotoxin-beta). The encoded protein and its ligand play a role in the development and organization of lymphoid tissue and transformed cells. Activation of the encoded protein can trigger apoptosis. Exemplary LTpR amino acid and nucleotide sequences are available at UniProt Accession No. P36941.
[0133] I’he described molecules, such as proteins, interact specifically with LTPR at the surface of cells and, in some forms, exert a physiological effect upon the cell. In some forms, the LT R-binding molecule has the same or overlapping epitope on the LTpR as one or more natural ligands of LT R. For example, in some forms, the described LTpR-binding molecule activates, induces or enhances one or more cellular functions through interaction with LT R. In some forms, the LT R-binding molecule has the same or similar physiological effect as one or more natural ligands of LTpR. For example, in some forms, the LTpR-binding molecule is a functional agonist of LTpR. In other forms, the LT R-binding molecule has the opposite effect of one or more physiological ligand of LTpR or inhibits one or more natural ligands of LT R from exerting a physiological effect on a
[0134] 45844288.1 17
[0135] SBMRI 22-006-03 PCT
[0136] cell. For example, in some forms, the LTpR-binding molecule is a functional antagonist of LTpR.
[0137] i. LTpR Agonists
[0138] In some forms, the compositions include one or more LTpR agonists. In some forms, the LTpR agonists bind to LTpR and cause the same general effect as the binding of the natural ligands to LTPR. In some forms, the LTPR agonists are effective to increase infiltration of lymphocytes into the TMF, increase cytokine expression to stimulate an immune response, promote immune cell differentiation, and / or drive anti-tumorigenic activity by the immune system. In some forms, the compositions improve the effectiveness of current therapies and improve patient outcomes. In some forms, the LTpR agonists do not interfere with and / or block the binding of the natural ligands to the LTPR.
[0139] a. Antibodies
[0140] In some forms, the LTpR agonists are monoclonal antibodies that selectively bind LTpR. In other forms, the LTpR agonists are human monoclonal antibodies or humanized monoclonal antibodies. In some forms, the antibodies are effective in initiating and / or enhancing the biosynthesis and secretion of chemokines and / or immune cells infiltration into the TME.
[0141] In some forms, the antibodies specifically bind to the extracellular domain of LTPR (such as human LTPR) and achieve the function of inducing signaling within the cell through the LTPR, for example, through intracellular components of the LTPR. In some forms, the antibody includes two or more LTpR binding components, such that simultaneous binding of one antibody molecule to two or more LTpR molecules on the surface of the same cell forces sustained close contact between the extracellular and / or intracellular components of the two Ll'PRs sufficient to initiate intracellular signaling between by the two LTpRs. Therefore, in some forms, the antibody that is an LTpR agonist has the function of (i) specifically binding to an LTpR, (ii) initiating, inducing or enhancing signaling by LTpR, and (iii) inhibiting the growth of a solid tumor including tumor cells.
[0142] The disclosed antibodies provide alternative LTPR agonist antibodies. These LTPR agonistic antibodies are able to bind LTpR from multiple species such as humans and mice. These LTPR agonist antibodies are useful in the treatment of cancer. In one form, these LTpR agonistic antibodies provided herein can activate hL pR biological activity in vitro (e.g., the hLTPR-mediated activation of transcription factor NF-KB from a cell expressing hLTpR). In some forms, a subset of these LTpR agonistic antibodies, such
[0143] 45844288.1 18
[0144] SBMRI 22-006-03 PCT
[0145] clone 10G3, can co-bind with the natural ligands of hLT0R (i.e., hLIGHT and hLTal|32) to hLT R. In other forms, a subset of LT^R agonistic antibodies can function cooperatively with hLIGHT and / or hLTal 2 to activate hLT R signaling in a cell expressing hLT R. In some fomrs, a subset of LTpR agonistic antibodies provide an additive or more-than-additive effect with hLIGHT and / or hLTaip2 on the activation of LTPR signaling in a cell expressing hLTpR.
[0146] In some forms, the compositions include fully human LTpR agonistic monoclonal antibodies. In some forms, the compositions include bispecific fully human LTpR agonistic monoclonal antibodies. In other forms, the compositions include mono-, di-, tri-, or multi-valent fully human LTpR antagonistic monoclonal antibodies. In some cases, the compositions arc therapeutic cells that express or display LTpR agonistic monoclonal antibodies on the cell-surface. In some cases, the compositions are therapeutic antibodies that are immobilize on biocompatible surface.
[0147] Exemplary antibodies that can be used include whole immunoglobulin (i.e., an intact antibody) of any class, fragments thereof, and synthetic proteins containing at least the antigen binding variable domain of an antibody. The variable domains differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (ER). The variable domains of native heavy and light chains each include four FR regions, largely adopting a beta-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies. Therefore, the antibodies can contain the components of the CDRs necessary to penetrate cells and bind guanosine.
[0148] The antibody can be a human antibody, such as antibodies identified using phage display technology leveraging a fully human gene library as described in the Examples. Such techniques can be used to isolate the genes encoding the antigen binding (Fc) portions of antibodies (variable heavy (VH) and variable light (VL) chains) that bind the target (LTpR herein). The genetic sequences of the variable regions were determined and used to select a panel of antibodies with unique variable chain sequences. From this
[0149] 45844288.1 19
[0150] SBMRI 22-006-03 PCT
[0151] knowledge, antibodies in their various forms can be produced, such as via recombinant production.
[0152] The antibody can be a humanized or chimeric antibody, or a fragment, variant, or fusion protein thereof. Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as “import” residues, which are typically taken from an “import” variable domain. Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule.
[0153] Humanization can be essentially performed by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, a humanized form of a non-human antibody (or a fragment thereof) is a chimeric antibody or fragment, wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.
[0154] The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important in order to reduce antigenicity. According to the “best-fit” method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody. Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies.
[0155] It is further important that antibodies be humanized with retention of high affinity for the antigen and other favorable biological properties. To achieve this goal, humanized antibodies are preferably prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of
[0156] 45844288.1 20
[0157] SBMRI 22-006-03 PCT
[0158] selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.
[0159] Antibodies can also include their derivatives such as a scFv or Fab. ScFv molecules are known in the art and are produced using recombinant DNA technology. The disclosed immunoglobulin or antibody molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule. The disclosed antibodies can include antibodies, digestion fragments, portions or variants thereof, including antibody mimetics, or including portions of antibodies that mimic the structure and / or function of an antibody or fragment or portion thereof, including single chain antibodies and fragments thereof. The important function to be preserved in each case is recognition of (i.e., effective binding to) the target, LTPR. This recognition / binding function is mediated by the complementarity determining regions (CDRs) of the antibody. Thus, useful fragments and variants can, for example, share the same CDRs as present in the disclosed monoclonal antibodies.
[0160] In some forms, the antibody is modified to alter its half-life. In some forms, it is desirable to increase the half-life of the antibody so that it is present in the circulation or at the site of treatment for longer periods of time. In other forms, the half-life of the antibody is decreased to reduce potential side effects. Antibody fragments are expected to have a shorter half-life than full size antibodies. Other methods of altering half-life are known and can be used in the described methods. For example, antibodies can be engineered with Fc variants that extend half-life, e.g., using Xtend™ antibody half-life prolongation technology (Xencor, Monrovia, CA).
[0161] The antibody can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including IgGi, IgG2, IgGj and IgG4. In some embodiments, the constant domain is a complement fixing constant domain where it is desired that the antibody exhibit cytotoxic activity, and the class is typically IgGi. In other forms, where cytotoxic activity is not desirable, the constant domain can be of the IgG2 or IgCi4class. Exemplary Antibodies include monoclonal antibodies 10G3, 15E2 and 6G9.
[0162] 45844288.1 21
[0163] SBMRI 22-006-03 PCT
[0164] The amino acid sequences for the heavy and light chain variable regions of 10G3, 15E2 and 6G9 are provided below as SEQ ID NOS: 1-22, and include the CDRs (CDRL1, CDRL2, CDRL3, and CDRH1, CDRH2, CDRH3 according to the Kabat numbering system; Kabat and Wu, Ann N Y Acad Sci 1971;190:382-93. 10.1111 / j.1749-6632.1971. tbl3550.), in bold font text.
[0165] (A)6G9
[0166] In some forms, the LTpR agonists is or includes monoclonal antibody clone 6G9.
[0167] (1) 6G9 Light Chain Variable Region
[0168] In one form, the LTpR agonist is monoclonal antibody 6G9.
[0169] An amino acid sequence for the light chain variable region (VL) of mAb 6G9 is: QSWTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKVLIYDNNKRPSGIP DRFSGSKSGTSATLGITGLQTGDEADYYCGGWDSSLSSGVFGTGTKVTVL (SEQ ID NO.2; the complementarity determining regions (CDRs) according to the Kabat numbering system are shown in bold font).
[0170] In some forms, the LTPR agonist is or includes a monoclonal antibody including one or more of the Light chain CDRs of mAb 6G9. For example, in some forms the LTpR agonists is or includes a monoclonal antibody including CDRL1 having the amino acid sequence of SGSSSNIGNNYVS (SEQ ID NO.6); in some forms the LTpR agonists is or includes a monoclonal antibody including CDRL2 having the amino acid sequence of DNNKRP S (SEQ ID NO.7); in some forms the LTpR agonists is or includes a monoclonal antibody including CDRL3 having the amino acid sequence of GGWDSSLSSGV (SEQ ID NO.8).
[0171] (2) 6G9 Heavy Chain Variable Region
[0172] An amino acid sequence for the heavy chain variable region (VH) of mAb 6G9 is: QVQLVQSGAEVKKPGESLKISCKGSGYTFSTSWIGWVRQMPGKGLEWMGMIYPDGSNTRY SPSFQGQVTMSADKSINTAYLQWSSLKASDTAMYFCARLWDAFYEDGYNYAFDIWGQGTL VTVSS (SEQ ID NO.l; the complementarity determining regions (CDRs) according to the Kabat numbering system are shown in bold font).
[0173] In some forms the LTpR agonist is or includes a monoclonal antibody including one or more of the Heavy chain CDRs of mAb 6G9. For example, in some forms the LTPR agonists is or includes a monoclonal antibody including CDR Hl having the amino acid sequence of TSWIG (SEQ ID NO.3); in some forms the LTpR agonists is or includes a monoclonal antibody including CDR 112 having the amino acid sequence of MIYPDGSNTRYSPSFQG (SEQ ID NO.4); in some forms the LTpR agonists is or includes
[0174] 45844288.1 22
[0175] SBMRI 22-006-03 PCT
[0176] a monoclonal antibody including CDR H3 having the amino acid sequence of LWDAFYEDGYNYAFDI (SEQ ID NO.5).
[0177] (3) Variants of mAb clone 6G9
[0178] Monoclonal antibodies that are or include variants of mAb clone 6G9 are also described.
[0179] The variant can be composed of an antibody fragment or fusion protein including an amino acid sequence of a variable heavy chain and / or variable light chain that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of the variable heavy chain (SEQ ID NO:2), and / or light chain of 6G9 (SEQ ID NO:1, respectively), and which binds to the epitope of 6G9. The variant can be composed of an antibody fragment or fusion protein that includes a CDR that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of a CDR of the variable heavy chain (SEQ ID NO.2), and / or light chain of 6G9 (SEQ ID NO.l), respectively, and which binds to the epitope of 6G9, or a combination thereof. The determination of percent identity of two amino acid sequences can be determined by BLAST protein comparison. In some forms, a variant includes one, two, three, four, five, or all six of the CDRs of the above-described preferred variable domains and which binds to the epitope of 6G9, or a combination thereof.
[0180] Predicted complementarity determining regions (CDRs) of the light chain variable sequence for 6G9 are provided above.
[0181] (B) 10G3
[0182] In some forms, the LT[3R agonists is or includes monoclonal antibody clone 10G3.
[0183] (1) 10G3 Light (Kappa) Chain Variable Region
[0184] In some forms, the LTpR agonist has a light chain of monoclonal antibody 10G3.
[0185] An amino acid sequence for the light chain variable region (VL) of mAb 10G3 is: ETTLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIP DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPPYTFGQGTKLEIK (SEQ ID NO.10; the complementarity determining regions (CDRs) according to the Kabat numbering system are shown in bold font).
[0186] In some forms, the LTPR agonists is or includes a monoclonal antibody including one or more of the Light chain CDRs of mAb 10G3. For example, in some forms the LTPR agonists is or includes a monoclonal antibody including CDR LI having the amino
[0187] 45844288.1 23
[0188] SBMRI 22-006-03 PCT
[0189] acid sequence of RASQSVSSSYLA (SEQ ID NO.14); in some forms the LTpR agonists is or includes a monoclonal antibody including CDR L2 having the amino acid sequence of GASSRAT (SEQ ID NO.15); in some forms the LTpR agonists is or includes a monoclonal antibody including CDR L3 having the amino acid sequence of QQYGSSPPYT (SEQ ID NO.16).
[0190] (2) 10G3 Heavy Chain Variable Region
[0191] In some forms, the LTpR agonist has a heavy chain of monoclonal antibody 10G3.
[0192] An amino acid sequence for the heavy chain variable region (VH) of mAb 10G3 is: EVQLVESGAEVKKP GASVKVSCKASGYTFTSYGISWVRQAP GQGLEWMGWISAYNGNTNY AQKLQGRVTMTTDTSTSTAYMELSSLSSEDTAVYYCVRGSWYYSYWGQGTLVTVSS
[0193] (SEQ ID NO.9; the complementarity determining regions (CDRs) according to the Kabat numbering system are shown in bold font).
[0194] In some forms the LTpR agonists is or includes a monoclonal antibody including one or more of the Heavy chain CDRs of mAb 10G3. For example, in some forms the LTPR agonists is or includes a monoclonal antibody including CDR Hl having the amino acid sequence of SYGIS (SEQ ID NO.11); in some forms the LTpR agonists is or includes a monoclonal antibody including CDR H2 having the amino acid sequence of WISAYNGNTNYAQKLQG (SEQ ID NO.12); in some forms the LTpR agonists is or includes a monoclonal antibody including CDR H3 having the amino acid sequence of GSWYYSY (SEQ ID NO.13).
[0195] (3) Variants of mAb clone 10G3
[0196] Monoclonal antibodies that are or include variants of mAb clone 10G3 are also described.
[0197] The variant can be composed of an antibody fragment or fusion protein including an amino acid sequence of a variable heavy chain and / or variable light chain that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of the variable heavy chain (SEQ ID NO: 10), and / or light chain of 10G3 (SEQ ID NO:9, respectively), and which binds to the epitope of 10G3. The variant can be composed of an antibody fragment or fusion protein that includes a CDR that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of a CDR of the variable heavy chain (SEQ ID NO.10), and / or light chain of 10G3 (SEQ ID NOV), respectively, and which binds to the epitope of 10G3, or a
[0198] 45844288.1 24
[0199] SBMRI 22-006-03 PCT
[0200] combination thereof. The determination of percent identity of two amino acid sequences can be determined by BLAST protein comparison. In some forms, a variant includes one, two, three, four, five, or all six of the CDRs of the above-described preferred variable domains and which binds to the epitope of 10G3, or a combination thereof.
[0201] Predicted complementarity determining regions (CDRs) of the light chain variable sequence for 10G3 are provided above.
[0202] (C) 15E2
[0203] In some forms, the LTpR agonist has a light chain of monoclonal antibody 15E2.
[0204] (1) 15E2 Light (Kappa) Chain Variable Region
[0205] In some forms, the LTpR agonist has a light chain of monoclonal antibody 15E2.
[0206] An amino acid sequence for the light chain variable region (VL) of mAb 15E2 is:
[0207] AIRMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTR ESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPPTFGQGTKVEIK (SEQ ID NO: 18; the complementarity determining regions (CDRs) according to the Kabat numbering system are shown in bold font).
[0208] In some forms, the LTpR agonists is or includes a monoclonal antibody including one or more of the Light chain CDRs of mAb 15E2. For example, in some forms the LTPR agonists is or includes a monoclonal antibody including CDR LI having the amino acid sequence of KSSQSVLYSSNNKNYLA (SEQ ID NO:20); in some forms the LTPR agonists is or includes a monoclonal antibody including CDR L2 having the amino acid sequence of WASTRES (SEQ ID NO:21); in some forms the LTpR agonists is or includes a monoclonal antibody including CDR L3 having the amino acid sequence of QQYYSTPPT (SEQ ID NO:22).
[0209] (2) L5E2 Heavy Chain Variable Region
[0210] An amino acid sequence for the heavy chain variable region (VH) of mAb 15E2 is:
[0211] EVQLVQSGAEVKKP GASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNY AQKLQGRVTMTTETSTSTVYMELRSLRSDDTAVYFCARDFRWLQDYLFDYWGQGTLVTVS
[0212] S (SEQ ID NO:17; the complementarity determining regions (CDRs) according to the Kabat numbering system are shown in bold font).
[0213] In some forms, the LTpR agonists is or includes a monoclonal antibody including one or more of the Heavy chain CDRs of mAb L5E2. For example, in some forms the LTPR agonists is or includes a monoclonal antibody including CDR Hl having the amino acid sequence of SYGIS (SEQ ID NO:11); in some forms the LTpR agonists is or includes a monoclonal antibody including CDR H2 having the amino acid sequence of
[0214] 45844288.1 25
[0215] SBMRI 22-006-03 PCT
[0216] WISAYNGNTNYAQKLQG (SEQ ID NO: 12); in some forms the LTpR agonists is or includes a monoclonal antibody including CDR H3 having the amino acid sequence of DFRWLQDYLFDY (SEQ ID NO: 19).
[0217] (3) Variants of mAh clone 15E2
[0218] Monoclonal antibodies that are or include variants of mAb clone 15E2 are also described.
[0219] The variant can be composed of an antibody fragment or fusion protein including an amino acid sequence of a variable heavy chain and / or variable light chain that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of the variable heavy chain (SEQ ID NO:18), and / or light chain of 15E2 (SEQ ID NO: 17, respectively), and which binds to the epitope of 15E2. The variant can be composed of an antibody fragment or fusion protein that includes a CDR that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of a CDR of the variable heavy chain (SEQ ID NO.18), and / or light chain of 15E2 (SEQ ID NO.17), respectively, and which binds to the epitope of 15E2, or a combination thereof. The determination of percent identity of two amino acid sequences can be determined by BLAST protein comparison. In some forms, a variant includes one, two, three, four, five, or all six of the CDRs of the above-described preferred variable domains and which binds to the epitope of 15E2, or a combination thereof.
[0220] Predicted complementarity determining regions (CDRs) of the light chain variable sequence for 15E2 are provided above.
[0221] b. Fragments and Fusion Proteins
[0222] In some forms, the LTpR agonist is or includes two or more antigen binding antibody fragment(s) (such as an isolated Fab molecule) and / or antigen binding fusion proteins of the LTPR agonist antibody. In some forms, the LTPR agonist is composed of two or more antigen binding antibody fragments and / or antigen binding fusion proteins of one or more of mAb clone 6G9, mAb clone 10G3, or mAb clone L5E2, or a variant thereof. Antibody complexes, including multimers of one or more of the described LTpR agonist antibodies, are also described. The multimers may include two or more, such as 3, 4, 5, 6, 7, 8, 9 or 10 or more copies of one or more of the described LT R agonist antibodies. Exemplary antibody complexes include one or more of mAb clone 6G9, mAb
[0223] 45844288.1 26
[0224] SBMRI 22-006-03 PCT
[0225] clone 10G3, or mAb clone 15E2, or a variant thereof, conjugated together. The antibodies within an antibody complexes may be covalently or non-covalently associated.
[0226] In some forms, an LT|3R agonist is or includes a molecule having two or more binding receptors that specifically bind to the same or different sites of the extracellular component of the LT R. It may be that LTpR signaling in a cell is induced or enhanced by aggregation or multimerization of two or more LTPR molecules at the surface of the cell. Therefore, in some forms, a LTpR agonist binds two or more molecules of LTpR simultaneously to bring and / or maintain the two or more molecules of LTpR together at the cell surface. In some forms, the LTPR agonist, such as an intact antibody, binds to an epitope on LTpR that does not overlap or only slightly overlaps with an epitope of one of more natural LTPR ligands. Therefore, in some forms, an LTPR agonist, such as an intact antibody, binds to an epitope on LTpR that permits the co-binding of one of more natural LTPR ligands. In other forms, a multi-valent LTpR agonist, such as an intact antibody, binds to LTpR by occluding an epitope of one or more natural ligands of LTpR.
[0227] Therefore, in some forms, an LTPR agonist, such as an intact antibody, prevents cobinding of one or more natural ligands of LTpR. When a multivalent LTpR agonist, such as an intact antibody, shares all or part of an epitope of one or more natural ligands of LTPR, a monovalent form of the LTpR agonist, such as an isolated Fab fragment of the antibody, acts as an inhibitor of the one or more natural ligands of LTPR. Therefore, in some forms, an inhibitor of LTPR is an isolated Fab fragment of an antibody that is an LTPR agonist.
[0228] Exemplary fragments and fusions having two or more antigen binding domains include, but are not limited to, single chain antibodies, single chain variable fragments (scFv), disulfide-linked Fvs (sdFv), F(ab')2. and multimers including two or more Fab's, Fvs or single domain antibody fragments (sdAb).
[0229] In some forms, the molecule includes two or more scFv. Each scFv can include one, two, or all three complementarity determining regions (CDRs) of the heavy chain variable region (VL) of any one of mAb clone 6G9, mAb clone 10G3, or mAb clone 15E2, or a variant thereof. The scFv can include one, two, or all three CDRs of the light chain variable region (VL) of mAb clone 6G9, mAb clone 10G3, or mAb clone 15E2, or a variant thereof. The molecule can include the heavy chain variable region and / or light chain variable region of mAb clone 6G9, mAb clone 10G3, or mAb clone 15E2, or a variant thereof. For example, in some forms, the described fusion proteins include two or more copies of SEQ ID NOs: 1 and 2, and / or SEQ ID NOs:9 and 10, and / or SEQ ID
[0230] 45844288.1 27
[0231] SBMRI 22-006-03 PCT
[0232] NOs:17 and 18, or LTpR binding proteins including the CDRs of SEQ ID NOs: 1 and 2, and / or SEQ ID NOs:9 and 10, and / or SEQ ID NOs: 17 and 18. In some forms, the LT R agonist fusion peptide includes a bivalent LT0R-binder having CDRs of the immunoglobulin heavy variable (IgHv) domain of SEQ ID NO: 17, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:l 1, 12, 19, and CDRs of the immunoglobulin light variable (IgLv) domain of SEQ ID NO: 18, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:20-22. In some forms, the LTPR agonist fusion peptide includes a bivalent LTpR-binder having complementarity-determining regions (CDRs) of the immunoglobulin heavy variable (IgHv) domain of SEQ ID NO: 9, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs: 11-13; and CDRs of the immunoglobulin light variable (IgLv) domain of SEQ ID NO:10, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:14-16. In some forms, the LTpR agonist fusion peptide includes a bivalent LTpR-binder having complementarity-determining regions (CDRs) of the immunoglobulin heavy variable (IgHv) domain of CDRs of the IgHv domain of SEQ ID NO:1, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:3-5; and CDRs of the immunoglobulin light variable (IgLv) domain of SEQ ID NO: 2, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:6-8.
[0233] A single chain variable fragment can be created by fusing together the variable domains of the heavy and light chains using a short peptide linker, thereby reconstituting an antigen binding site on a single molecule. Single-chain antibody variable fragments (scFvs) in which the C-terminus of one variable domain is tethered to the N-terminus of the other variable domain via a linker have been developed without significantly disrupting antigen binding or specificity of the binding. The linker is chosen to permit the heavy chain and light chain to bind together in their proper conformational orientation. The linker is usually rich in glycine for flexibility, and typically also includes serine or threonine for solubility. The linker can link, for example, the N-terminus of the VH with the C-terminus of the VL, or vice versa. scFv can also be created directly from subcloned heavy and light chains derived from a hybridoma. The scFv can retain or improve or increase the specificity of the original immunoglobulin, while removing of the constant regions and introducing the linker.
[0234] For example, in some forms, the LTpR agonist is or includes a molecule that includes two or more single chain variable fragments (scFv) including the light chain
[0235] 45844288.1 28
[0236] SBMRI 22-006-03 PCT
[0237] variable region (VL) of mAb clone 10G3, or a variant thereof, and the heavy chain variable region (VH) of mAb clone 10G3, or a variant thereof of the antibody 10G3, including but not limited to, divalent-scFv (di-scFv), trivalent-scFv (tri-scFv), multivalent-scFv (multi-scFv), diabodies, triabodies, tetrabodies, etc., of scFvs. In other forms, the LTpR agonist is or includes a molecule including two or more single chain variable fragments (scFv), including the light chain variable region (VL) of mAb clone 6G9, or a variant thereof, and the heavy chain variable region (VH) of mAb clone 6G9, or a variant thereof of the antibody 6G9, including but not limited to divalent-scFv (di-scFv), trivalent-scFv (tri-scFv), multivalent-scFv (multi-scFv), diabodies, triabodies, tetrabodies, etc., of scFvs. In other forms, the LTpR agonist is or includes a molecule that includes two or more single chain variable fragments (scFv), including the light chain variable region (VL) of mAb clone 15E2, or a variant thereof, and the heavy chain variable region (VH) of mAb clone 15E2, or a variant thereof of the antibody 15E2, including but not limited to, divalent-scFv (di-scFv), trivalent-scFv (tri-scFv), multivalent-scFv (multi-scFv), diabodies, triabodies, tetrabodies, etc., of scFvs. In further forms, the LTPR agonist is or includes a molecule that includes two or more single chain variable fragments (scFv), including the light chain variable region (VL) of one mAb clone (such as 6G9) or a variant thereof, and the heavy chain variable region (VH) of a different mAb clone (such as 15E2 or 10G3, or a variant thereof). Therefore, in some forms, the LTPR agonist is or includes an antigen-binding component of any two or more of mAb clones 10G3, 15E2 and 6G9.
[0238] Divalent single chain variable fragments can be engineered by linking two scFvs. This can be done by producing a single peptide chain with two VH and two VL regions, yielding a di-scFvs referred to as a tandem di-scFv. ScFvs can also be designed with linker peptides that are too short for the two variable regions to fold together (about five amino acids), forcing scFvs to dimerize and form a divalent single chain variable fragment referred to as a diabody. Diabodies have been shown to have dissociation constants up to 40-fold lower than corresponding scFvs, indicating that they have a much higher affinity to their target. Even shorter linkers (one or two amino acids) lead to the formation of trimers (triabodies or tribodies). Tetrabodies have also been produced and have been shown to exhibit an even higher affinity to their targets than diabodies.
[0239] In some forms, the disclosed LTpR agonists include antigen binding antibody fragments and fusion proteins of mAb clone 6G9, mAb clone 10G3, or mAb clone 15E2 and variants thereof that typically bind to the same epitope as the parent antibody mAb clone 6G9, mAb clone 10G3, or mAb clone 15E2, respectively. In some forms, the antigen
[0240] 45844288.1 29
[0241] SBMRI 22-006-03 PCT
[0242] binding molecule is a di-, tri-, or multivalent scFv. Although the antigen binding antibody fragment or fusion protein of the antigen binding molecule can include additional antibody domains (e.g., constant domains, hinge domains, etc.,), in some forms it does not.
[0243] (A) Single Chain Variable Fragments
[0244] In some forms, an LTpR agonist is or includes a fusion protein including two or more single chain variable fragments (scFv) attached with a synthetic linker. The variable domains differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR). The variable domains of native heavy and light chains each include four FR regions, largely adopting a beta-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies.
[0245] In some forms, one component of an LT R agonist includes a single chain variable fragment (scFv) including the light chain variable region (VL) of mAb clone 15E2, or a variant thereof, and the heavy chain variable region (VH) of mAb clone L5E2. Therefore, in some forms, the LTpR agonist includes a protein having the amino acid sequence of SEQ ID NO: 18 and / or the amino acid sequence of SEQ ID NO: 17. In some forms, the LTpR agonist includes a bivalent LTpR-binding Ig domain having (i) CDRs of the immunoglobulin heavy variable (IgHv) domain of SEQ ID NO: 17, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:l 1, 12, 19, and CDRs of the immunoglobulin light variable (IgLv) domain of SEQ ID NO: 18, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:20-22.
[0246] In some forms, one component of an LTPR agonist includes a single chain variable fragment (scFv), including the light chain variable region (VL) of mAb clone 10G3, or a variant thereof, and the heavy chain variable region (VH) of mAb clone 10G3. Therefore, in some forms, the LTpR agonist includes a bivalent LTpR-binding protein having the amino acid sequence of SEQ ID NO: 10 and / or the amino acid sequence of SEQ ID NO:9. For example, in some forms, the LTpR agonist includes a bivalent LTpR-binding Ig domain having complementarity-determining regions (CDRs) of the immunoglobulin
[0247] 45844288.1 30
[0248] SBMRI 22-006-03 PCT
[0249] heavy variable (IgHv) domain of SEQ ID NO:9, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs: 11-13; and CDRs of the immunoglobulin light variable (IgLv) domain of SEQ ID NO: 10, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:14-16.
[0250] In some forms, the LT R agonist includes a single chain variable fragment (scFv), including the light chain variable region (VL) of mAb clone 6G9, or a variant thereof, and the heavy chain variable region (VH) of mAb clone 6G9. Therefore, in some forms, the LTPR agonist includes a protein having the amino acid sequence of SEQ ID NO:2 and / or the amino acid sequence of SEQ ID NO:1. For example, in some forms, the LT0R agonist includes a bivalent LTpR-binding Ig domain having complementarity-determining regions (CDRs) of the immunoglobulin heavy variable (IgHv) domain of CDRs of the IgHv domain of SEQ ID NO:1, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:3-5; and CDRs of the immunoglobulin light variable (IgLv) domain of SEQ ID NO: 2, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:6-8.
[0251] (B) Linkers
[0252] The term “linker” as used herein includes, without limitation, peptide linkers. The peptide linker can be any size provided it does not interfere with the binding of the epitope by the variable regions. In some forms, the linker includes one or more glycine and / or serine amino acid residues. Monovalent single-chain antibody variable fragments (scFvs) in which the C-terminus of one variable domain is typically tethered to the N-terminus of the other variable domain via a 15 to 25 amino acid peptide or linker. The linker is chosen to permit the heavy chain and light chain to bind together in their proper conformational orientation. Linkers in diabodies, triabodies, etc., typically include a shorter linker than that of a monovalent scFv as discussed above. Di-, tri-, and other multivalent scFvs typically include three or more linkers. The linkers can be the same, or different, in length and / or amino acid composition. Therefore, the number of linkers, composition of the linker(s), and length of the linker(s) can be determined based on the desired valency of the scFv as is known in the art. The linker(s) can allow for or drives formation of a di-, tri-, and other multivalent scFv.
[0253] For example, a linker can include 4-8 amino acids. In particular forms, a linker includes the amino acid sequence GQSSRSS (SEQ ID NO:23). In other forms, a linker includes 15-20 amino acids, for example 18 amino acids. In particular forms, the linker includes the amino acid sequence GQSSRSSSGGGSSGGGGS (SEQ ID NO:24). Other
[0254] 45844288.1 31
[0255] SBMRI 22-006-03 PCT
[0256] flexible linkers include, but are not limited to, the amino acid sequences Gly-Ser, Gly-Ser-Gly-Ser (SEQ ID NO:25), Ala-Ser, Gly-Gly-Gly-Ser (SEQ ID NO:26), (Gly4-Ser)2(SEQ ID NO:27) and (Gly4-Ser)4(SEQ ID NO:28), and (Gly-Gly-Gly-Gly-Ser)3(SEQ ID NO:29).
[0257] (C) Other Functional Peptide Domains
[0258] In some forms, the described fusion peptides or antibody complexes include one or more additional functional domains, such as a signal peptide domain and / or a membrane anchoring domain. Any suitable signal peptide and / or membrane anchoring domain may be implemented in the described fusion peptides. An exemplary signal peptide includes the human IL-2 signal peptide or murine immunoglobulin heavy chain (Ig HC) signal peptide. In some forms, the described fusion peptides include a membrane anchoring domain that includes all or part of a transmembrane region, such as a transmembrane polypeptide isolated from a naturally -occurring membrane-bound protein or polypeptide. The described fusion peptides can include any suitable transmembrane domain. An exemplary transmembrane domain includes a transmembrane domain derived from the human CD28 transmembrane domain peptide or human Platelet-Derived Growth Factor Receptor (PDGFR).
[0259] ii. LTpR Antagonists
[0260] In some forms, the compositions include one or more LT[3R antagonists. In some forms, the LTPR antagonists bind to LT R and prohibits, precludes or reduces the general effect of binding of natural ligands to LTpR. In some forms, the LTpR antagonists are effective to decrease infiltration of lymphocytes, decrease cytokine expression, reduce or prevent an immune response, reduce or prevent immune cell differentiation, and / or generally reduce activity by the immune system. In some forms, the compositions can modulate and / or otherwise control immune processes. In some forms, an LTpR antagonist is or includes a molecule having one single LT R binding domain that specifically binds the extracellular component of the LTpR. It may be that LTpR signaling in a cell is induced or enhanced by aggregation or multimerization of two or more LTPR molecules at the surface of the cell. Therefore, in some forms, a LTPR antagonist binds LTpR to prevent and / or disrupt two or more molecules of LTpR coming together at the cell surface. Typically, antagonists of LT R (i) lack the ability to cluster LT R or activating LTPR signaling on their own; and (ii) prevent binding of natural LTPR ligands are antagonists of LTPR. In some forms, the LTpR antagonists interfere with and / or block the binding of the
[0261] 45844288.1 32
[0262] SBMRI 22-006-03 PCT
[0263] natural ligands to the LTPR. Exemplary antagonists of LTpR include single Fab molecules of antibodies that compete with natural ligands of LTPR.
[0264] a. Antibody fragments
[0265] In some forms, the E'l’PR antagonist is or includes one antigen binding antibody fragment(s) (such as an isolated Fab molecule) and / or antigen binding fusion proteins of a LTPR agonist antibody.
[0266] In some forms, a multi-valent LT R agonist, such as an intact antibody, binds to LTPR by occluding an epitope of one or more natural ligands of LT R. Therefore, in some forms, an LTPR agonist, such as an intact antibody, prevents co-binding of one or more natural ligands of LTPR. When a multivalent LTPR agonist, such as an intact antibody, shares all or part of an epitope of one or more natural ligands of LTPR, a monovalent form of the LTPR agonist, such as an isolated Fab fragment of the antibody, acts as an inhibitor of the one or more natural ligands of LTPR. Therefore, in some forms, an inhibitor of LTPR is an isolated Fab fragment of an antibody that is an LT R agonist.
[0267] In some forms, the isolated Fab of an antibody that specifically binds to the extracellular domain LTPR (such as human LT R) to achieve the function of inducing signaling within the cell through the LTPR, for example, through intracellular components of the LTPR, acts as an antagonist of LT R signaling. In some forms, the isolated Fab of antibody includes a single LT R binding component, such that binding of the isolated Fab prevents the simultaneous binding of a natural ligand of LTPR molecules on the surface of the same cell. Therefore, in some forms, the forces sustained close contact between the extracellular and / or intracellular components of the two LTpRs sufficient to initiate intracellular signaling between by the two LTPRs. Therefore, in some forms, the isolated Fab of an antibody that is an LTPR agonist has the function of (i) specifically binding to an LTPR, (ii) preventing, reducing or ablating signaling by LT R, and (iii) inhibiting inflammatory processes associated with LTPR signaling.
[0268] In some forms, the LT R antagonist, such as an isolated Fab of an intact antibody, binds to an epitope on LT R that overlaps or slightly overlaps with an epitope of one of more natural LTPR ligands. Therefore, in some forms, an LTPR antagonist, such as an isolated Fab of an intact antibody, binds to an epitope on LTPR that does not permit the co-binding of one of more natural LT R ligands.
[0269] Therefore, in some forms, monovalent forms of intact (i.e., divalent) antibodies that act as LTPR agonists can function as antagonists of LTPR if they compete with natural ligands as LTPR. Therefore, in some forms, monovalent forms, single Fab molecules,
[0270] 45844288.1 33
[0271] SBMRI 22-006-03 PCT
[0272] and / or one-armed antibodies of 6G9 and 15E2 are antagonists of LT0R by competing against one or more natural ligands for their binding sites on LTflR, preventing or reducing the natural ligands from binding to LTpR on the cell-surface. In exemplary forms, the LT0R antagonist is composed of one antigen binding antibody fragment and / or antigen binding fusion proteins of any one or more of mAb clone 6G9, or mAb clone 15E2, or a variant thereof. Exemplary fragments and fusions include, but are not limited to, Fab', Fv, and single domain antibody fragments (sdAb).
[0273] b. Exemplary Antagonists
[0274] Exemplary the LT0R antagonists are provided.
[0275] In some forms, an LT|3R antagonist is or includes a single chain variable fragment (scFv) including the light chain variable region (VL) of mAb clone 15E2, or a variant thereof, and the heavy chain variable region (VH) of mAb clone 15E2. Therefore, in some forms, the LT R antagonist includes a protein having the amino acid sequence of SEQ ID NO: 18 and / or the amino acid sequence of SEQ ID NO: 17. In some forms, the LTpR antagonist includes a monovalent LT0R-binding Ig domain having (i) CDRs 1-3 of the immunoglobulin heavy variable (IgHv) domain of SEQ ID NO: 17, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:l 1, 12, 19, and (ii) CDRs 1-3 of the immunoglobulin light variable (IgLv) domain of SEQ ID NO: 18, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:20-22.
[0276] In some forms, the LTpR antagonist is or includes a single chain variable fragment (scFv), including the light chain variable region (VL) of mAb clone 6G9, or a variant thereof, and the heavy chain variable region (VH) of mAb clone 6G9. Therefore, in some forms, the LTpR antagonist is or includes a protein having the amino acid sequence of SEQ ID NO:2 and / or the amino acid sequence of SEQ ID NO:1. For example, in some forms, the LTpR antagonist is or includes a monovalent LTpR-binding Ig domain having complementarity-determining regions (CDRs) of the immunoglobulin heavy variable (IgHv) domain of CDRs of the IgHv domain of SEQ ID NO: 1, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:3-5; and CDRs of the immunoglobulin light variable (IgLv) domain of SEQ ID NO: 2, optionally whereby the CDRs include amino acid sequences according to SEQ ID NOs:6-8.
[0277] iii. Natural LTpR ligands
[0278] In some forms, an agonist or antagonist of LTpR binds to the same or different epitope on LTpR as one or more natural LTpR ligands. Natural LTpR ligands are known in the art and include the LTaip2 heterotrimers, and LIGHT (lymphotoxin-like, exhibits
[0279] 45844288.1 34
[0280] SBMRI 22-006-03 PCT
[0281] inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes; TNFSF14). Therefore, in some forms, an agonist or antagonist of LTpR binds to the same or different epitope on LT0R as LIGHT. In some forms, an agonist or antagonist of LTpR binds to the same or different epitope on LTpR as LTaip2. The molecular structure of heterotrimeric lymphotoxin LTaip2 bound to lymphotoxin beta receptor LTPR and anti-LTa Fab is known in the art (see, for example, Sudhamsu, et al., (2013) Proc Natl Acad Sci U S A 110: 19896-19901, the content of which is hereby incorporated herein by reference in its entirety). In some forms, an antagonist of LTpR binds to the same or to an overlapping epitope of LTpR as LTaip2 and / or LIGHT. In some forms, an antagonist of LTpR precludes, inhibits or reduces binding of LTPR by LTaip2 and / or LIGHT.
[0282] 2. Nucleic Acids
[0283] Nucleic acids and vectors encoding or expressing the described LTpR binders and domains thereof are also described.
[0284] i. Isolated Nucleic Acid Molecules of LTpR binders
[0285] Isolated nucleic acid sequences encoding the described LTpR binders are disclosed. In some forms, the isolated nucleic acid sequences encode the described LTpR binders. In some forms, an isolated nucleic acid sequence encodes the described LTpR binders set forth in any one of SEQ ID NOs: 1 and 2, or 9 and 10, or 17 and 18.
[0286] The term “isolated nucleic acid” refers to a nucleic acid that is separated from other nucleic acid molecules that are present in a mammalian genome, including nucleic acids that normally flank one or both sides of the nucleic acid in a mammalian genome. An isolated nucleic acid can be, for example, a DNA molecule, provided one of the nucleic acid sequences normally found immediately flanking that DNA molecule in a naturally-occurring genome is removed or absent. Thus, an isolated nucleic acid includes, without limitation, a DNA molecule that exists as a separate molecule independent of other sequences (e.g., a chemically synthesized nucleic acid, or a cDNA or genomic DNA fragment produced by PGR or restriction endonuclease treatment), as well as recombinant DNA that is incorporated into a vector, an autonomously replicating plasmid, a virus (e.g., a retrovirus, lentivirus, adenovirus, or herpes virus), or into the genomic DNA of a prokaryote or eukaryote. In addition, an isolated nucleic acid can include an engineered nucleic acid such as a recombinant DNA molecule that is part of a hybrid or fusion nucleic acid. A nucleic acid existing among hundreds to millions of other nucleic acids within, for
[0287] 45844288.1 35
[0288] SBMRI 22-006-03 PCT
[0289] example, a cDNA library or a genomic library, or a gel slice containing a genomic DNA restriction digest, is not to be considered an isolated nucleic acid.
[0290] Nucleic acids can be in sense or antisense orientation, or can be complementary to a reference sequence encoding the described the described LT R binders. Thus, nucleic acids encoding a the described LTPR binders set forth in any one of SEQ ID NOs:l and 2; or 9 and 10; or 17 and 18, and fragments and variants thereof, in sense and antisense, and in single stranded and double stranded forms, are provided. The nucleic acids can be DNA, RNA, or nucleic acid analogs. Nucleic acid analogs can be modified at the base moiety, sugar moiety, or phosphate backbone. Such modification can improve, for example, stability, hybridization, or solubility of the nucleic acid. Modifications at the base moiety can include deoxyuridine for deoxythymidine, and 5-methyl-2’-deoxycytidine or 5-bromo-2’ -deoxycytidine for deoxycytidine. Modifications of the sugar moiety can include modification of the 2’ hydroxyl of the ribose sugar to form 2’-O-methyl or 2’-O-allyl sugars. The deoxyribose phosphate backbone can be modified to produce morpholino nucleic acids, in which each base moiety is linked to a six membered, morpholino ring, or peptide nucleic acids, in which the deoxyphosphate backbone is replaced by a pseudopeptide backbone and the four bases are retained. See, for example, Summerton and Weller (1997) Antisense Nucleic Acid Drug Dev. 7:187-195; and Hyrup et al. (1996) Bioorgan. Med. Chem. 4:5-23. In addition, the deoxyphosphate backbone can be replaced with, for example, a phosphorothioate or phosphorodithioate backbone, a phosphoroamidite, or an alkyl phosphotriester backbone.
[0291] An exemplary isolated polynucleotide encoding one or more of the described LTPR agonists, or a fusion protein including an antibody or antigen binding fragment thereof is an isolated DNA molecule, or an isolated cDNA molecule.
[0292] Isolated RNA molecules encoding one or more of the described LTPR agonists, or a fusion protein including an antibody or antigen binding fragment thereof are also provided. An exemplary isolated RNA encoding one or more of the described LTPR agonists, or a fusion protein including an antibody or antigen binding fragment thereof is an isolated mRNA molecule. In some forms, the isolated RNAs molecule(s) encode or express monoclonal antibody 10G3, or a fusion protein including the antigen binding component(s) of mAb 10G3, for example, an mRNA encoding SEQ ID NO:9, or an mRNA encoding SEQ ID NO:10, or an mRNA encoding a fusion protein that includes SEQ ID NO:9 and SEQ ID NO: 10. In some forms, the isolated RNAs molecule(s) encode or express monoclonal antibody 6G9, or a fusion protein including the antigen binding
[0293] 45844288.1 36
[0294] SBMRI 22-006-03 PCT
[0295] component(s) of mAb 6G9, for example, an mRNA encoding SEQ ID NO: 1, or an mRNA encoding SEQ ID NO:2, or an mRNA encoding a fusion protein that includes SEQ ID NO:1 and SEQ ID NO:2. In some forms, the isolated RNAs molecule(s) encode or express the monoclonal antibody 15E2, or a fusion protein including the antigen binding component(s) of mAb 15E2, for example, an mRNA encoding SEQ ID NO: 17, or an mRNA encoding SEQ ID NO: 18, or an mRNA encoding a fusion protein that includes SEQ ID NO: 17 and SEQ ID NO: 18.
[0296] ii. Vectors Expressing or Encoding the described LT0R binders
[0297] In some forms, nucleic acids encoding the described LT R binders are present within vectors. In some forms, the vectors encode or express the described LT0R binders, such as those including any one of the antigen-binding domains encompassed by SEQ ID NOs:l and 2, or 9 and 10, or 17 and 18, optionally further including one or more additional peptide domains or motifs.
[0298] In some forms, the vectors encode or express an LT0R agonist, such as a monoclonal antibody that acts as an LT[3R agonist, or a fusion protein including an antibody or antigen binding fragment thereof. In some forms, the vectors encode or express monoclonal antibody 10G3, or a fusion protein including the antigen binding component(s) of mAb 10G3. In some forms, the vectors encode or express monoclonal antibody 6G9, or a fusion protein including the antigen binding component(s) of mAb 6G9. In some forms, the vectors encode or express the monoclonal antibody 15E2, or a fusion protein including the antigen binding component(s) of mAb 15E2. An exemplary polynucleotide expression vector includes or encodes one or more RNAs encoding monoclonal antibody 10G3, or a fusion protein including the antigen binding component(s) of mAb 10G3, or monoclonal antibody 6G9, or a fusion protein including the antigen binding component(s) of mAb 6G9, or monoclonal antibody 15E2, or a fusion protein including the antigen binding component(s) of mAb 15E2.
[0299] Vectors including an isolated polynucleotide encoding the described LT0R binders within a host cell are described.
[0300] The term “vector” is a nucleic acid molecule used to carry genetic material into another cell, where it can be replicated and / or expressed. Any vector known to those skilled in the art in view of the present disclosure can be used. Examples of vectors include, but are not limited to, plasmids, viral vectors (bacteriophage, animal viruses, and plant viruses), cosmids, and artificial chromosomes (e.g., YACs). A vector can be a DNA vector or an RNA vector. In some forms, a vector is a DNA plasmid. One of ordinary skill
[0301] 45844288.1 37
[0302] SBMRI 22-006-03 PCT
[0303] in the art can construct a vector of the application through standard recombinant techniques in view of the present disclosure.
[0304] In some forms, the vector including nucleic acids encoding described LTpR binders is an expression vector. The term “expression vector” refers to any type of genetic construct including a nucleic acid coding for an RNA capable of being translated.
[0305] Expression vectors include, but are not limited to, vectors for recombinant protein expression, such as a DNA plasmid or a viral vector, and vectors for delivery of nucleic acid into a subject for expression in a tissue of the subject, such as a DNA plasmid or a viral vector. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.
[0306] In some forms, vectors contain one or more regulatory sequences. The term “regulatory sequence” refers to any sequence that allows, contributes or modulates the functional regulation of the nucleic acid molecule, including replication, duplication, transcription, splicing, translation, stability and / or transport of the nucleic acid or one of its derivative (i.e. mRNA) into the host cell or organism. In the context of the disclosure, this term encompasses promoters, enhancers and other expression control elements (e.g., polyadenylation signals and elements that affect mRNA stability).
[0307] In some forms, the vector is a non-viral vector. Examples of non- viral vectors include, but are not limited to, DNA plasmids, bacterial artificial chromosomes, yeast artificial chromosomes, bacteriophages, etc. Examples of non-viral vectors include, but are not limited to, RNA replicon, mRNA replicon, modified mRNA replicon or selfamplifying mRNA, closed linear deoxyribonucleic acid, e.g., a linear covalently closed DNA, e.g., a linear covalently closed double stranded DNA molecule. Preferably, a non-viral vector is a DNA plasmid. A “DNA plasmid”, which is used interchangeably with “DNA plasmid vector,” “plasmid DNA” or “plasmid DNA vector,” refers to a doublestranded and generally circular DNA sequence that is capable of autonomous replication in a suitable host cell. DNA plasmids used for expression of an encoded polynucleotide typically include an origin of replication, a multiple cloning site, and a selectable marker, which for example, can be an antibiotic resistance gene. Examples of suitable DNA plasmids that can be used include, but are not limited to, commercially available expression vectors for use in well-known expression systems (including both prokaryotic and eukaryotic systems), such as pSE420 (Invitrogen, San Diego, Calif.), which can be used for production and / or expression of protein in Escherichia coli; pYES2 (Invitrogen,
[0308] 45844288.1 38
[0309] SBMRI 22-006-03 PCT
[0310] Thermo Fisher Scientific), which can be used for production and / or expression in Saccharomyces cerevisiae strains of yeast; MAXBAC®. complete baculovirus expression system (Thermo Fisher Scientific), which can be used for production and / or expression in insect cells; pcDNA™. or pcDNA3™ (Life Technologies, Thermo Fisher Scientific), which can be used for high level constitutive protein expression in mammalian cells; and pVAX or pVAX-1 (Life Technologies, Thermo Fisher Scientific), which can be used for high-level transient expression of a protein of interest in most mammalian cells. The backbone of any commercially available DNA plasmid can be modified to optimize protein expression in the host cell, such as to reverse the orientation of certain elements (e.g., origin of replication and / or antibiotic resistance cassette), replace a promoter endogenous to the plasmid (e.g., the promoter in the antibiotic resistance cassette), and / or replace the polynucleotide sequence encoding transcribed proteins (e.g., the coding sequence of the antibiotic resistance gene), by using routine techniques and readily available starting materials. (See e.g., Sambrook et al., Molecular Cloning a Laboratory Manual, Second Ed. Cold Spring Harbor Press (1989)).
[0311] Preferably, a DNA plasmid is an expression vector suitable for protein expression in mammalian host cells. Expression vectors suitable for protein expression in mammalian host cells include, but are not limited to, pcDNA™, pcDNA3™, pVAX, pVAX-1, ADVAX, NTC8454, etc. In some forms, an expression vector is based on pVAX-1, which can be further modified to optimize protein expression in mammalian cells. pVAX-1 is a commonly used plasmid in DNA vaccines, and contains a strong human immediate early cytomegalovirus (CMV-IE) promoter followed by the bovine growth hormone (bGH)-derived polyadenylation sequence (pA). pVAX-1 further contains a pLJC origin of replication and a kanamycin resistance gene driven by a small prokaryotic promoter that allows for bacterial plasmid propagation.
[0312] In some forms the vector is a viral vector. In general, viral vectors are genetically engineered viruses carrying modified viral DNA or RNA that has been rendered non-infectious, but still contains viral promoters and transgenes, thus allowing for transcription of the transgene through a viral promoter. Because viral vectors are frequently lacking infectious sequences, they require helper viruses or packaging lines for large-scale transfection. Examples of viral vectors that can be used include, but are not limited to, adenoviral vectors, adeno-associated virus vectors, pox vims vectors, enteric vims vectors, Venezuelan Equine Encephalitis vims vectors, Semliki Forest Vims vectors. Tobacco Mosaic Vims vectors, lentiviral vectors, arenavims viral vectors, replication-deficient
[0313] 45844288.1 39
[0314] SBMRI 22-006-03 PCT
[0315] arenavirus viral vectors or replication-competent arenavirus viral vectors, bi-segmented or tri-segmented arenavirus, infectious arenavirus viral vectors, nucleic acids which include an arenavirus genomic segment wherein one open reading frame of the genomic segment is deleted or functionally inactivated (and replaced by a nucleic acid encoding described LTPR binders, are an arenavirus such as lymphocytic choriomeningitidis virus (LCMV), e.g., clone 13 strain or MP strain, and arenavirus such as Junin virus e.g., Candid #1 strain, etc.
[0316] In some forms, the viral vector is an adenovirus vector, e.g., a recombinant adenovirus vector. A recombinant adenovirus vector can for instance be derived from a human adenovirus (HAdV, or AdHu), or a simian adenovirus such as chimpanzee or gorilla adenovirus (ChAd, AdCh, or SAdV) or rhesus adenovirus (rhAd). Preferably, an adenovirus vector is a recombinant human adenovirus vector, for instance a recombinant human adenovirus serotype 26, or any one of recombinant human adenovirus serotype 5, 4, 35, 7, 48, etc. In other forms, an adenovirus vector is a rhAd vector, e.g. rhAd51, rhAd52 or rhAd53. In some forms, a recombinant viral vector is prepared using methods known in the art in view of the present disclosure. For example, in view of the degeneracy of the genetic code, several nucleic acid sequences can be designed that encode the same polypeptide. In some forms, a polynucleotide encoding described LTPR binders is codon-optimized to ensure proper expression in the host cell (e.g., bacterial or mammalian cells). Codon-optimization is a technology widely applied in the art, and methods for obtaining codon-optimized polynucleotides will be well known to those skilled in the art in view of the present disclosure.
[0317] In some forms, the vectors, e.g., a DNA plasmid or a viral vector (particularly an adenoviral vector), include any regulatory elements to establish conventional function(s) of the vector, including but not limited to replication and expression of the described LTPR binders encoded by the polynucleotide sequence of the vector.
[0318] In some forms, the described LTPR binders are designed to be administered via mRNA(s) encoding the described LTPR binders, such as fusion proteins. Systems and reagents for delivery of mRNAs that are known in the art can be implemented.
[0319] 3. Formulations and Compositions
[0320] Formulations and compositions of, and pharmaceutical compositions including, one or more LTPR agonists are provided. The formulations can include one or more one or more LTPR agonists. In some forms, the pharmaceutical compositions include one or more additional active agents. Therefore, in some forms, the pharmaceutical composition
[0321] 45844288.1 40
[0322] SBMRI 22-006-03 PCT
[0323] includes two, three, or more active agents. The pharmaceutical compositions can be formulated as a pharmaceutical dosage unit, referred to as a unit dosage form.
[0324] In some forms, the compositions include one or more one or more LTpR agonists conjugated to tumor cells of a subject. In some forms, the compositions include one or more antibodies as described herein conjugated to tumor cells of a subject.
[0325] Formulations and compositions typically include an effective amount of one or more LTpR agonistic monoclonal antibodies such as mAh clone 6G9, mAb clone 10G3, or mAb clone 15E2. Effective amounts of the active agents are discussed in more detail below. It will be appreciated that in some forms the effective amount of a conventional chemotherapeutic agent and / or immunotherapy in a combination therapy with the disclosed composition including an LTPR agonist is different from the amount that would be effective for the conventional chemotherapeutic agents and / or immunotherapy group to achieve the same result when administered individually. For example, in some forms, the effective amount of a conventional chemotherapeutic agent and / or immunotherapy is a lower dosage in a combination therapy with the disclosed composition including an LTPR agonist than the dosage of the conventional chemotherapeutic agent and / or immunotherapy that is effective when administered alone. In other forms, the conventional chemotherapeutic agent and / or immunotherapy alone is not effective, i.e., cancer cells are resistant or have become resistant.
[0326] i. Pharmaceutical Compositions
[0327] Pharmaceutical compositions including LTpR agonists are provided.
[0328] Pharmaceutical compositions can be used for administration by parenteral (intramuscular, intraperitoneal, intravenous (IV) or subcutaneous injection), enteral, or transmucosal (nasal, vaginal, rectal, or sublingual) routes of administration or using bioerodible inserts and can be formulated in dosage forms appropriate for each route of administration.
[0329] In certain forms, the compositions are administered locally, for example, by injection directly into a site to be treated (e.g., into a tumor). In some forms, the compositions are injected or otherwise administered directly into the vasculature onto vascular tissue at the intended site of treatment. In some forms, the compositions are injected or otherwise administered directly into the vasculature onto vascular tissue adjacent to the intended site of treatment. Typically, local administration causes an increased localized concentration of the compositions which is greater than that which can be achieved by systemic administration. Targeting of the molecules or formulation can be used to achieve more selective delivery.
[0330] 45844288.1 41
[0331] SBMRI 22-006-03 PCT
[0332] a. Formulations for Parenteral Administration
[0333] LTPR agonists and pharmaceutical compositions thereof can be administered in an aqueous solution, by parenteral injection. The formulation may also be in the form of a suspension or emulsion. In general, pharmaceutical compositions are provided including effective amounts of the active agent(s) and optionally include pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and / or carriers. Such compositions include diluents sterile water, buffered saline of various buffer content (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength; and optionally, additives such as detergents and solubilizing agents (e.g., TWEEN® 20, TWEEN® 80 also referred to as polysorbate 20 or 80), antioxidants e.g., ascorbic acid, sodium metabisulfite), and preservatives (e.g., Thimersol, benzyl alcohol) and bulking substances (e.g., lactose, mannitol). Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and com oil, gelatin, and injectable organic esters such as ethyl oleate. The formulations may be lyophilized and redissolved / resuspended immediately before use. The formulation may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.
[0334] ii. Delivery Vehicles
[0335] In some forms, the compositions include delivery vehicles conjugated or complexed with the described LTPR agonist molecules. Exemplary delivery vehicles include a particle suitable for administration to a subject in vivo. Exemplary particles include liposomes or micelles, polymeric particles, viral particles and protein carriers.
[0336] Microparticles, microspheres, and microcapsules, referred to herein collectively as “microparticles”, are solid or semi-solid particles having a diameter of less than one millimeter, typically less than 100 microns, which can be formed of a variety of materials, including synthetic polymers, proteins, lipids and polysaccharides. Nanoparticles, nanospheres, and nano-capsules, referred to herein collectively as “nanoparticles”, are solid or semi-solid particles having a diameter of less than one micrometer, typically less than 999 nanometers, which can be formed of a variety of materials, including synthetic polymers, proteins, and polysaccharides.
[0337] Nanoparticles and microparticles have been used in many different applications, primarily separations, diagnostics, and drug delivery. In the controlled drug delivery area, therapeutic molecules are encapsulated within nanoparticles or microparticles or
[0338] 45844288.1 42
[0339] SBMRI 22-006-03 PCT
[0340] incorporated into a monolithic matrix, for subsequent release. A number of different techniques are routinely used to make these nanoparticles or microparticles from synthetic polymers, natural polymers, proteins and polysaccharides, including phase separation, solvent evaporation, emulsification, and spray drying. Generally, the polymers form the supporting structure of these nanospheres and microspheres, and the therapeutic agent of interest is incorporated into the polymer structure. Exemplary polymers used for the formation of nanospheres and microspheres that are conjugated or complexed with the infected tissue binding molecules include homopolymers and copolymers of lactic acid and glycolic acid (PLGA).
[0341] In some forms, the particles are sized for uptake within the gut following oral administration, or for uptake via the mucosa of the lung following inhalation, or for administration into the bloodstream, i.e., by intravenous injection. In some forms, the delivery vehicle includes a viral-like particle (VLP), or vesicle, composed of a bacteriophage capsid protein. In some forms, the bacteriophage is an RNA or DNA phage that infects a bacteria.
[0342] In some forms, the delivery vehicle is a particles that includes one or more biocompatible polymer(s) including, but not limited to, polyamino acids; cyclodextrin-containing polymers, in particular cationic cyclodextrin-containing polymers, such as those described in U. S. Patent No. 6,509,323: polymers prepared from lactones such as poly(caprolactone) (PCL); polyhydroxy acids and copolymers thereof such as poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D, L-lactide) (PDLA), poly(D, L-lactide-co-caprolactone), poly(D, L-lactide-co-caprolactone-co-glycolide), poly(D, L-lactide-co-PEO-co-D, L-lactide), poly(D, L-lactide-co-PPO-co-D, L-lactide), and blends thereof, polyalkyl cyanoacralate, polyurethanes, poly(valeric acid), and poly-L-glutamic acid; hydroxypropyl methacrylate (HPMA); poly anhydrides; other polyesters; poly orthoesters; poly(ester amides); polyamides; poly(ester ethers); polycarbonates; polyalkylenes such as polyethylene and polypropylene; polyalkylene glycols such as poly(ethylene glycol) (PEG) and polyalkylene oxides (PEG), and block copolymers thereof such as polyoxyalkylene oxide (“PLURONICS®” or block copolymers containing PEG where PEG has a molecular weight of any values within the range of 300 Daltons to 1 MDa); polyalkylene terephthalates such as poly(ethylene terephthalate); ethylene vinyl acetate polymer (EVA); polyvinyl alcohols (PVA); polyvinyl ethers; polyvinyl esters such as poly(vinyl acetate); polyvinyl halides such as
[0343] 45844288.1 43
[0344] SBMRI 22-006-03 PCT
[0345] poly(vinyl chloride) (PVC), polyvinylpyrrolidone; poly siloxanes; polystyrene (PS); and celluloses including alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, hydroxypropylcellulose, and carboxymethylcellulose; polymers of acrylic acids including poly(methyl(meth)acrylate) (PMMA), poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and poly(octadecyl acrylate) (jointly referred to herein as "polyacrylic acids"); polydioxanone and its copolymers; poly hydroxy alkanoates; polypropylene fumarate; polyoxymethylene; poloxamers; poly(butyric acid); trimethylene carbonate; and polyphosphazenes.
[0346] Examples of preferred natural polymers include proteins such as albumin, collagen, gelatin and prolamines, for example, zein, and polysaccharides such as alginate.
[0347] Copolymers of the above, such as random, block, or graft copolymers, or blends of the polymers listed above can also be used. In some forms, the delivery vehicles are particles modified with one or more surfactants. Examples of surfactants include, but are not limited to, L-a-phosphatidylcholine (PC), 1,2-dipalmitoylphosphatidycholine (DPPC), oleic acid, sorbitan trioleate, sorbitan mono-oleate, sorbitan monolaurate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monooleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene, synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, isopropyl myristate, glyceryl monooleate, glyceryl monostearate, glyceryl monoricinoleate, cetyl alcohol, stearyl alcohol, polyethylene glycol 400, cetyl pyridinium chloride, benzalkonium chloride, olive oil, glyceryl monolaurate, com oil, cotton seed oil, and sunflower seed oil, lecithin, oleic acid, and sorbitan trioleate. In some forms where poly alkylene glycol (e.g., PEG) is used in a composition of polymers to modify the particles, PEG surface density may be controlled by varying the amount of PEG in the polymer composition or by mixing a blend of pegylated polymer component and non-pegylated polymer component. The density of PEG or polyalkylene glycol on the surface of formed particles may be evaluated using several techniques.
[0348] In some forms, the particles are lipidic particles, such as liposomes, or micelles. Lipidic particles include uni-lamellar phospholipid vesicles, liposomes, or lipoprotein particles. Liposomal encapsulation may be used and the liposomes may be derivatized
[0349] 45844288.1 44
[0350] SBMRI 22-006-03 PCT
[0351] with various polymers (e.g., U. S. Pat. No. 5,013,556). See also Marshall, K. In: Modem Pharmaceutics Edited by G. S. Banker and C. T. Rhodes, Chapter 10, 1979.
[0352] Formulations of liposomes and methods of making such formulations are well known to one of ordinary skill in the art. Liposomes are formed from commercially available phospholipids supplied by a variety of vendors including Avanti Polar Lipids, Inc. (Birmingham, Ala.). For example, in some forms, the liposome include the infected tissue binding molecules on the surface to direct the liposome to the infected tissue.
[0353] Suitable methods, materials and lipids for making liposomes are known in the art. Liposome delivery vehicles are commercially available from multiple sources. The liposome may be formed from a single lipid; however, in some embodiments, the liposome is formed from a combination of more than one lipid. The lipids can be neutral, anionic or cationic at physiologic pH. In some forms, the liposomes incorporate PEG, or PEGylated lipid derivatives. Incorporation of one or more PEGylated lipid derivatives can result in a liposome which displays polyethylene glycol chains on its surface. The resulting liposomes may possess increased stability and circulation time in vivo as compared to liposomes lacking PEG chains on their surfaces. Liposomes are formed from one or more lipids, which can be neutral, anionic, or cationic at physiologic pH. Suitable neutral and anionic lipids include, but are not limited to, sterols and lipids such as cholesterol, phospholipids, lysolipids, lysophospholipids, sphingolipids or pegylated lipids. Neutral and anionic lipids include, but are not limited to, phosphatidylcholine (PC) (such as egg PC, soy PC), including, but limited to, 1,2-diacyLglycero-3-phosphocholines; phosphatidylserine (PS), phosphatidylglycerol, phosphatidylinositol (PI); glycolipids; sphingophospholipids such as sphingomyelin and sphingoglycolipids (also known as 1-ceramidyl glucosides) such as ceramide galactopyranoside, gangliosides and cerebrosides; fatty acids, sterols, containing a carboxylic acid group for example, cholesterol; 1,2-diacyl-sn-glycero-3-phosphoethanolamine, including, but not limited to, 1,2-dioleylphosphoethanolamine (DOPE), 1,2-dihexadecylphosphoethanolamine (DHPE), 1,2-distearoylphosphatidylcholine (DSPC), 1,2-dipalmitoyl phosphatidylcholine (DPPC), and 1,2-dimyristoylphosphatidylcholine (DMPC). The lipids can also include various natural (e.g., tissue derived L-a-phosphatidyl: egg yolk, heart, brain, liver, soybean) and / or synthetic (e.g., saturated and unsaturated l,2-diacyl-sn-glycero-3-phosphocholines, 1-acyl-2-acyl-sn-glycero-3-phosphocholines, l,2-diheptanoyl-SN-glycero-3-phosphocholine) derivatives of the lipids. In some forms, the liposomes contain a phosphaditylcholine (PC) head group, and preferably sphingomyelin. In another form, the liposomes contain DPPC.
[0354] 45844288.1 45
[0355] SBMRI 22-006-03 PCT
[0356] In a further form, the liposomes contain a neutral lipid, preferably 1,2-dioleoylphosphatidylcholine (DOPC).
[0357] In certain forms, the liposomes are generated from a single type of phospholipid. In such forms, preferably the phospholipid has a phosphaditylcholine head group, and, most preferably is sphingomyelin. The liposomes may include a sphingomyelin metabolite. Sphingomyelin metabolites used to formulate the liposomes include, without limitation, ceramide, sphingosine, or sphingosine 1 -phosphate. The concentration of the sphingomyelin metabolites included in the lipids used to formulate the liposomes can range from about 0.1 mol % to about 10 mol %. Preferably from about 2.0 mol % to about 5.0 mol %, and more preferably can be in a concentration of about 1.0 mol %.
[0358] Suitable cationic lipids in the liposomes include, but are not limited to, N-[ l-(2,3-dioleoyloxy)propyl]-N, N, N-trimethyl ammonium salts, also references as TAP lipids, for example methylsulfate salt. Suitable TAP lipids include, but are not limited to, DOTAP (dioleoyl-), DMTAP (dimyristoyl-), DPTAP (dipalmitoyl-), and DSTAP (distearoyl-). Suitable cationic lipids in the liposomes include, but are not limited to, dimethyldioctadecyl ammonium bromide (DDAB), 1,2-diacyloxy-3-trimethylammonium propanes, N-[l-(2,3-dioloyloxy)propyl]-N, N-dimethyl amine (DODAP), 1,2-diacyloxy-3-dimethylammonium propanes, N-[l-(2,3-dioleyloxy)propyl]-N, N, N-trimethylammonium chloride (DOTMA), 1,2-dialkyloxy-3-dimethylammonium propanes, dioctadecylamidoglycylspermine (DOGS), 3 -[N-(N', N'-dimethylamino-ethane)carbamoyl]cholesterol (DC-Chol); 2,3-dioleoyloxy-N-(2-(sperminecarboxamido)-ethyl)-N, N-dimethyl-l-propanaminium trifluoro- acetate (DOSPA), -alanyl cholesterol, cetyl trimethyl ammonium bromide (CTAB), di Cl 4- amidine, N-ferf-butyl-N'-tetradecyl-3-tetradecylamino-propionamidine, N-(alpha-trimethylammonioacetyl)didodecyl-D-glutamate chloride (TMAG), ditetradecanoyl-N-(trimethylammonio-acetyl)diethanolamine chloride, l,3-dioleoyloxy-2-(6-carboxy-spermyl)-propylamide (DOSPER), and N, N, N’, N’-tetramethyl-, N'-bis(2-hydroxylethyl)-2,3-dioleoyloxy- 1,4-butanediammonium iodide. In one form, the cationic lipids can be l-[2-(acyloxy)ethyl]2-alkyl(alkenyl)-3-(2-hydroxyethyl)-imidazolinium chloride derivatives, for example, l-[2-(9(Z)-octadecenoy loxy )ethy 1] - 2- (8 (Z) -heptadeceny 1-3 - ( 2-hy droxyethyl)imidazolinium chloride (DOTIM), and l-[2-(hexadecanoyloxy)ethyl]-2-pentadecyl-3-(2-hydroxyethyl)imidazolinium chloride (DPTIM). In one embodiment, the cationic lipids can be 2,3-dialkyloxypropyl quaternary ammonium compound derivatives containing a hydroxyalkyl moiety on the quaternary amine, for example, 1,2-dioleoyl-3-dimethyl-
[0359] 45844288.1 46
[0360] SBMRI 22-006-03 PCT
[0361] hydroxyethyl ammonium bromide (DORI), 1,2-dioleyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DORIE), 1,2-dioleyloxypropyl-3-dimetyl-hydroxypropyl ammonium bromide (DORIE-HP), 1,2-dioleyl-oxy-propyl-3-dimethyl-hydroxybutyl ammonium bromide (DORIE-HB), 1,2-dioleyloxypropyl-3-dimethyl-hydroxypentyl ammonium bromide (DORIE-Hpe), 1,2-dimyristyloxypropyl-3-dimethyl-hydroxylethyl ammonium bromide (DMRIE), 1,2-dipalmityloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DPRIE), and 1,2-disteryloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide (DSRIE).
[0362] The lipids may be formed from a combination of more than one lipid, for example, a charged lipid may be combined with a lipid that is non-ionic or uncharged at physiological pH. Non-ionic lipids include, but are not limited to, cholesterol and DOPE (1,2-dioleolylglyceryl phosphatidylethanolamine), with cholesterol being most preferred. The molar ratio of a first phospholipid, such as sphingomyelin, to second lipid can range from about 5:1 to about 1:1 or 3:1 to about 1:1, more preferably from about 1.5:1 to about 1:1, and most preferably, the molar ratio is about 1:1.
[0363] In some forms, a delivery vehicle is or includes a cell, such as a prokaryotic cell or a eukaryotic cell. An exemplary cell is a mammalian cell.
[0364] In some forms, when the described LT R agonists or antagonists are formulated with a delivety vehicle, the LT R agonists or antagonists are conjugated to the delivery vehicle, for example, to a surface of the delivery vehicle, such as to an exposed outer surface of a particle. In some forms, the LTpR agonists or antagonists are conjugated to a surface of a delivery vehicle via covalent or non-covalent attachment. For example in some forms, the LTpR agonists or antagonists are conjugated to a surface of a delivery vehicle via hydrophobic interactions. For example, in some forms, the LTPR agonists or antagonists are conjugated to a surface of a delivery vehicle via a membrane-anchoring domain and the fusion protein is non-covalently attached to the surface of the mammalian cell by way of hydrophobic interactions with a membrane-anchoring domain.
[0365] 4. Adjunct and Additional Therapies and Procedures
[0366] Compositions of one or more LTPR agonists, preferably mAbs such as 10G3, can be administered to a subject in combination with one or more adjunct therapies or procedures or can be an adjunct therapy to one or more primary therapies or producers. The additional therapy or procedure can be simultaneous or sequential with the one or more LTpR agonists. In some forms, the additional therapy is a conventional treatment for cancer. For example, in some forms, the additional therapy or procedure is surgery,
[0367] 45844288.1 47
[0368] SBMRI 22-006-03 PCT
[0369] transplant surgery, a radiation therapy, or chemotherapy. For example, in a particular form, one or more LT|3R agonists are administered to a subject simultaneously or sequentially with a regime of a chemotherapeutic agent, e.g., Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), Cisplatin, Doxorubicin (pegylated liposomal doxorubicin), Capecitabine (Xeloda), Mitoxantrone (Novantrone), docetaxel or cabazitaxel.
[0370] Representative chemotherapeutic agents include, but are not limited to, amsacrine, bleomycin, busulfan, camptothecin, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, clofarabine, crisantaspase, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, epipodophyllotoxins, epirubicin, etoposide, etoposide phosphate, fludarabine, fluorouracil, gemcitabine, hydroxycarb amide, idarubicin, ifosfamide, innotecan, leucovorin, liposomal doxorubicin, liposomal daunorubici, lomustine, mechlorethamine, melphalan, mercaptopurine, mesna, methotrexate, mitomycin, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, pentostatin, procarbazine, raltitrexed, satraplatin, streptozocin, teniposide, tegafur-uracil, temozolomide, teniposide, thiotepa, tioguanine, topotecan, treosulfan, vinblastine, vincristine, vindesine, vinorelbine, vorinostat, taxol, trichostatin A and derivatives thereof, trastuzumab (HERCEPTIN®), cetuximab, and rituximab (RITUXAN® or MABTHERA®), bevacizumab (AVASTIN®), and combinations thereof. Representative pro-apoptotic agents include, but are not limited to, fludarabinetaurosporine, cycloheximide, actinomycin D, lactosylceramide, 15d-PGJ(2)5 and combinations thereof.
[0371] In some forms, the additional agents are one or more anti-VEGF antibodies such as bevacizumab (AVASTIN®), Receptor Tyrosine Kinase (RTK) inhibitors such as Cabozantinib, MEK inhibitor such as Cobimetinib, and CXCR4 antagonists such as BL8040.
[0372] In some forms, the compositions and methods are used prior to or in conjunction with an immunotherapy such inhibition of checkpoint proteins such as components of the PD-1 / PD-L1 axis or CD28-CTLA-4 axis using one or more immune checkpoint modulators (e.g., PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists), adoptive T cell therapy, and / or a cancer vaccine. Exemplary immune checkpoint modulators used in immunotherapy include Pembrolizumab (anti-PDl mAb), Durvalumab (anti-PDLl mAb), PDR001 (anti-PDl mAb), Atezolizumab (anti-PDLl mAb), Nivolumab (anti-PDl mAb), Tremelimumab (anti-CTLA4 mAb), Avelumab (anti-PDLl mAb), and RG7876 (CD40 agonist mAb). Additional exemplary immune checkpoints include TIGIT, LAG-3, TIM-3, VISTA, CD160, and BTLA.
[0373] 45844288.1 48
[0374] SBMRI 22-006-03 PCT
[0375] In some forms, the compositions and methods are used prior to or in conjunction with adoptive T cell therapy.
[0376] In some forms, the compositions and methods are used prior to or in conjunction with a cancer vaccine, for example, a dendritic cell cancer vaccine. Vaccination typically includes administering a subject an antigen (e.g., a cancer antigen) together with an adjuvant to elicit therapeutic T cells in vivo. In some forms, the cancer vaccine is a dendritic cell cancer vaccine in which the antigen delivered by dendritic cells primed ex vivo to present the cancer antigen. Examples include PROVENGE® (sipuleucel-T), which is a dendritic cell-based vaccine for the treatment of prostate cancer (Ledford, et al., Nature, 519, 17-18 (2015). Such vaccines and other compositions and methods for immunotherapy are reviewed in Palucka, et al., Nature Reviews Cancer, 12, 265-277 (2012).
[0377] In some forms, the compositions and methods are used prior to or in conjunction with surgical removal of tumors, for example, in preventing primary tumor metastasis and / or reoccurrence. In some forms, LT|3R agonistic mAb are administrated as a therapeutic cancer vaccine, in which the LTPR agonistic mAb are expressed or immobilized on the patient’s removed tumor cell-surface. In an exemplary form, the I.'fpR agonistic mAb expressing tumor cells are irradiated and reintroduced back to the same patient.
[0378] C. Methods of Screening for LTpR Agonists and development of LTfR Antagonists
[0379] Methods of screening for LTpR agonists and / or antagonists are described. In some forms, the LT R agonists to be screened are monoclonal antibodies (mAbs).
[0380] In some forms, an initial screen is first conducted to identify anti-LT R mAbs. In one form, phage display technology leveraging a fully human gene library is used to isolate the genes encoding the antigen binding (Fc) portions of antibodies (variable heavy (VH) and variable light (VL) chains, respectively) that bind to LTPR. In some forms, the genetic sequences of the variable regions are determined and used to select a panel of antibodies with unique variable chain sequences. In some forms, recombinant DNA methods are used to create a complete mAb and the mAbs are then manufactured and purified. In further forms, identified mAbs are subsequently subjected to functional screening, for example, to identify mAbs that function as agonists, i.e., to trigger, enhance or induce signaling via the LTpR, for example, by inducing receptor multimerization. Conversely, as blockade of LTPR multimerization inhibits signaling, methods for screening of LTPR antagonists include screening for molecules that compete with binding
[0381] 45844288.1 49
[0382] SBMRI 22-006-03 PCT
[0383] of natural LT0R agonists and which do not permit or induce LT0R co-localization at the cell surface. Therefore, in some forms, the methods further include one or more steps for developing LTPR antagonists (e.g., monovalent antigen-binding fragments of mAbs identified in the agonist screen) that bind the LT R and prevent access of natural ligands of LTpR, and thereby block signaling via the LTpR.
[0384] Therefore, methods for selecting molecules that bind LTpR and induce signaling through multimerization of LTPR are provided, and bivalent ligands or antibodies that meditate activation of LT0R signaling through multimerization of LTPR on the cellsurface identified according to the methods are also provided. For example in some forms, a bivalent LTPR agonist is a mAb that binds to a certain site on the extracellular domain (ECD) of LTpR, which enables and / or promotes the multimerization of LTPR. Methods for selecting molecules that bind LTPR and prevent or block signaling through multimerization of LTPR are also provided, and monovalent ligands, such as single Fab molecules identified according to the methods are also provided.
[0385] In some forms, the bivalent agonists of LTPR do not share one or more components of an epitope for a natural ligand, and therefore do not block one or more natural ligands, such as LTaip2 and LIGHT, from binding to LTPR, such the agonists permit co-binding of natural ligands, such as LTaip2 and LIGHT. In other forms, both bivalent LTpR-binding molecules (i.e., agonists of LTPR) and monovalent LTpR-binding molecules (i.e., antagonists of LTPR) block or partially block one or more natural ligands, such as LTocip2 and LIGHT, from binding to LTPR. Blockade of binding of a natural ligand by an antagonists of LTPR can occur through sharing one or more components of an epitope of a natural ligand, or through steric occlusion that prevents close association or contact of the natural ligand and its binding site on the LTPR. In an exemplary form, monovalent forms of agonist mAbs, such as single Fab molecules, and / or one-armed antibodies, lack the capability of multimerizing LTPR, but maintain the ability to inhibit or reduce the binding between the natural ligands and LTPR on the cell-surface, therefore inhibiting or reducing ligand mediated LTPR signaling.
[0386] In some forms, one or more functional screens selects potential LT R agonist molecules with some, all, or combinations of the following characteristics:
[0387] • Specificity and high affinity (0.1-1 nM range) for LT R to achieve therapeutic characteristics and drug quality (PK / PD);
[0388] • Activation of the cellular signaling pathways of LT R, mimicking native ligands;
[0389] 45844288.1 50
[0390] SBMRI 22-006-03 PCT
[0391] • Co-binding with native ligands to avoid disrupting homeostatic functions of LTPR (e.g., lymph node and splenic organization);
[0392] • Fully humanized mAh to minimize stimulating anti-drug antibodies (ADA);
[0393] • Species cross-reactivity, enabling the candidate to be tested in mouse cancer models; and
[0394] • Ideal biophysical properties for manufacturing and drug delivery.
[0395] Suitable candidates from the functional screen(s) bind to human membrane associated LTPR with high affinity (EC50 = 0.1 nM range) and demonstrate agonist activity.
[0396] In further forms, one or more functional screens selects potential LTPR agonist mAbs with some, or combinations of the following functional features:
[0397] • mAb that inhibit binding of native ligands to LTPR;
[0398] • mAb that bind LTPR in the presence of the native ligands, LIGHT and (LT«P) expressed on the cell membrane or as soluble proteins;
[0399] • mAb that activate the LTPR signaling pathway supplanting the native ligands (agonist) with competitive binding for native ligands;
[0400] • mAb that activate the transcription factor NFKB (agonist);
[0401] • mAb competitive with the native ligands, LIGHT and LTocip2, that activate the
[0402] LTPR signaling pathway supplanting the native ligands (antagonist-agonist functionality); and
[0403] • mAb with non-competitive binding of the native ligands that activate the LTPR signaling pathway allowing the native ligands to signal (agonist).
[0404] In some forms, candidates that co-bind with LIGHT and have species crossreactivity with mouse LTPR, such as mAb 10G3, are selected as the lead candidates.
[0405] Methods for selecting a molecule that selectively binds to the Lymphotoxin-P Receptor (LTPR) are also described. Typically, the methods include the steps of:
[0406] (i) providing an antibody or antigen binding fragment thereof that binds to the LTPR as a positive binding control. An exemplary positive binding control is an intact immunoglobulin of mAbs 10G3, 6G9 and / or 15E2 described herein, or a variant thereof that binds to LTPR. For example, in some forms, the positive binding control is an intact immunoglobulin including a heavy chain having amino acid sequences according to SEQ ID NOs: 11-13; and / or light chain having amino acid sequences according to SEQ ID NOs: 14-16. In other forms, the positive binding control is an intact immunoglobulin including a heavy chain having amino acid sequences according to SEQ ID NOs:ll, 12,
[0407] 45844288.1 51
[0408] SBMRI 22-006-03 PCT
[0409] 19, and / or a light chain having amino acid sequences according to SEQ ID NOs:20-22. In other forms, the positive binding control is an intact immunoglobulin including a heavy chain having amino acid sequences according to SEQ ID NOs:3-5; and / or a light chain having amino acid sequences according to SEQ ID NOs:6-8 or antigen binding fragment thereof including an intact immunoglobulin, or a mono-, di-, or tri-valent or multivalent single chain variable fragment (scFv), Fab, F(ab’)2, minibody, scFv-Fc, diabody, triabody, or tetrabody;
[0410] (ii) providing a first or further sample including one or more test molecules, for example, a pool of two or more different test molecules, such as two or more species of immunoglobulins, such as two or more species of monoclonal antibodies;
[0411] (iii) screening for a LTβR-binding molecule within the first or further sample. An exemplary screening includes contacting the first or further sample with a native LTβR ligand molecule in the presence of the positive binding control: and
[0412] (iv) selecting a molecule from the first or further sample as a LTPR-binding molecule when the molecule remains bound to LTβR in the presence of the native LTβR ligand and / or in the presence of the positive binding control.
[0413] In some forms, the positive binding control is mixed with the first or further sample including one or more test molecules prior to contacting the first or further sample with the native LTPR ligand in step (iii). In other forms, the positive binding control is contacted with the native LTpR ligand after the first or further sample including one or more test molecules is contacted with the native LTPR ligand in step (iii). In some forms, the one or more test molecule includes a detectable label or dye. Therefore, in some forms, the selecting in step (iv) includes detecting the label or dye.
[0414] LTPR-binding molecules selected according to the described methods are also described. Exemplary LTPR-binding molecules include immunoglobulin(s), or an antigenbinding fragment thereof. In some forms, the LTPR-binding molecule is conjugated or complexed with a bacterium or viral particle, such as a bacteriophage.
[0415] In some forms, the methods further include one or more steps to assess the biological function of LTPR-binding molecules selected according to the described methods. For example in some forms the methods select the LTPR-binding molecule as an LTPR agonist or antagonist. An exemplary method includes contacting the LTPR-binding molecule with cells expressing LTPR, and selecting the LTPR-binding molecule as an agonist when the LTPR-binding molecule induces LTPR signaling in the cells, or selecting
[0416] 45844288.1 52
[0417] SBMRI 22-006-03 PCT
[0418] the LTpR-binding molecule as an I. TpR antagonist when the LT R-binding molecule prevents or reduces LT R signaling in the cells, for example, in the presence of one or more natural LTpR-ligands or functional fragments or variants thereof. An LTPR functional assay can be in vitro or in vivo. In some forms, the functional assay is carried out in a cell line in vitro. In some forms, one or more LTpR-binding molecule identified as an LTpR-binding agonist according to the described methods includes an immunoglobulin, for example, an intact antibody including two or more antigen-binding Fabs. It may be that the multimerization of the LT R at the surface of a cell induces or enhances LTPR signaling in the cell. Therefore, in some forms, when one or more LTPR-binding molecule identified as an LTpR-binding agonist according to the described methods includes an intact antibody, the methods include one or more further steps of isolating one Fab from the antibody, and repeating the functional assay using the isolated Fab. When the isolated Fab fails to induce LTPR signaling in the cell, the methods repeat the assay in the presence of an effective amount of one or more natural ligands of LTPR. If the isolated Fab prevents LTPR signaling in the cell in the presence of the one or more natural ligands of LTPR, the methods select the isolated Fab as an LTpR antagonist. Methods for isolating a Fab fragment from an intact antibody are known in the art. LTPR agonist molecules and LTPR antagonist molecules selected according to the described methods are also provided.
[0419] D. Methods of Use for Treating Cancer
[0420] Methods of treating one or more symptoms of cancer in a subject are provided. In some forms, the methods are particularly suited for treating hematological cancer and / or solid tumors, such as lymphoma, head and neck squamous cell carcinoma, and pancreatic adenocarcinoma. In some forms, the methods are suited for treating tumors that demonstrate acquired resistance to immune check point receptor inhibitor therapies, such as non-small cell lung cancer. In some forms, the methods are suited for treating tumors that are that are immunologically cold.
[0421] 1. Selecting Patients for Combination Therapies
[0422] All the methods described can also include the step of identifying and selecting a subject in need of treatment, or a subject who would benefit from administration with the described compositions. For example, in some forms, the methods include one or more steps of identifying a subject in need of the disclosed cancer therapy. In some instances, the subject has one or more solid tumors. A solid tumor is an abnormal mass of tissue that
[0423] 45844288.1 53
[0424] SBMRI 22-006-03 PCT
[0425] usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancerous), or malignant (cancerous). Examples of solid tumors are sarcomas, carcinomas, and lymphomas.
[0426] In some forms, the cancer may be unresponsive to one or more previously administered therapies. Therefore, in some forms, the subject population being treatment is one in which the cancer being treated is resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy.
[0427] In some forms, the cancer may have developed a resistance to the previously administered therapies. For example, in some forms, the cancer has acquired resistance to one or more chemotherapies or immunotherapies. A cancer that has reacquired an ability to grow can be an increase in tumor growth, the emergence, reemergence, or aggravation of symptoms, or new sites of metastasis. Thus, in some forms, the methods treat a cancer that has reacquired an ability to grow following prior treatment.
[0428] In some forms the methods characterize tumors and / or characterize the tumor microenvironment (TME) in a subject with cancer. For example, in some forms, the methods identify tumor cells and / or tumor infiltrating cells or tumor associated cells that are sensitive to therapy with one or more LTpR agonists.
[0429] Methods for assessing the anti-cancer efficacy of one or more LTpR agonists combined with one or more existing cancer therapies such as check point receptor inhibitor therapy or conventional chemotherapy are also disclosed. In some forms the methods include steps of assessing tumor size and viability in a subject prior to and following administration to the subject. For example, in some forms, tumor samples from cancer patients are characterized prior to and following treatment with one or more LTpR agonists, in order to monitor changes in tumor size and viability as well as phenotypic and / or genetic changes within the TME.
[0430] In some forms the methods reduce or prevent undesired inflammation, such as chronic or acute inflammation in a subject in need thereof. For example, in some forms, the methods administer an effective amount of one or more LTPR antagonists, such as an isolated Fab of mAh 6G9 or mAh 15E2, to a subject to treat or prevent one or more symptoms of an inflammatory disease or disorder in the subject.
[0431] 2. Methods of Administration and Dosage Regimes
[0432] The methods and treatment regimens typically include administering to a subject with cancer an effective amount of a therapeutic agent that initiates and / or enhances the
[0433] 45844288.1 54
[0434] SBMRI 22-006-03 PCT
[0435] biosynthesis and secretion of chemokines and / or immune cell infiltration into the TME, preferably via LTpR signaling.
[0436] In some forms, the therapeutic agents include one or more of the described LTpR agonists. In some forms, the therapeutic agent is a monoclonal antibody that acts as an LT R agonist. In some forms, the therapeutic agent is the monoclonal antibody 10G3, or a fusion protein encoding the antigen binding component(s) of mAb 10G3. In some forms, the therapeutic agent is the monoclonal antibody 6G9, or a fusion protein encoding the antigen binding component(s) of mAb 6G9. In some forms, the therapeutic agent is the monoclonal antibody 15E2, or a fusion protein encoding the antigen binding component(s) of mAb 15E2.
[0437] In some forms, the therapeutic LTPR agonists are administered as polynucleotides for expression within a subject. For example, in some forms the methods include administering to a subject a polynucleotide encoding an LTpR agonist, such as a polynucleotide encoding a monoclonal antibody that acts as an LTpR agonist, or encoding a fusion protein including an antibody or antigen binding fragment thereof. In some forms, the methods include administering to a subject a polynucleotide encoding monoclonal antibody 10G3, or encoding a fusion protein encoding the antigen binding component(s) of mAb 10G3. In some forms, the methods include administering to a subject a polynucleotide encoding the monoclonal antibody 6G9, or encoding a fusion protein encoding the antigen binding component(s) of mAb 6G9. In some forms, the methods include administering to a subject a polynucleotide encoding the monoclonal antibody 15E2, or encoding a fusion protein encoding the antigen binding component(s) of mAb 15E2. An exemplary polynucleotide is an RNA.
[0438] The methods can effectively decrease or inhibit the proliferation and / or viability of the cancer cells compared to control cancer cells treated using a similar cancer therapy alone, i.e., without being used in combination with the disclosed composition. The therapeutic agent(s) can be administered locally or systemically to the subject, or coated or incorporated onto, or into a cell, biocompatible materials, or a device.
[0439] In other forms, the therapeutic agents include one or more LTPR antagonists. In some forms, the LTpR antagonist is an isolated Fab of a monoclonal antibody that acts as an LTPR agonist. For example, in some forms, the therapeutic agent is the isolated Fab of monoclonal antibody 15E2 or mAb 6G9. The methods can effectively decrease or inhibit inflammation compared to a control. The therapeutic agent(s) can be administered locally
[0440] 45844288.1 55
[0441] SBMRI 22-006-03 PCT
[0442] or systemically to the subject, or coated or incorporated onto, or into a cell, biocompatible materials, or a device.
[0443] The amount of a LTβR agonist or LTβR antagonist present in a pharmaceutical dosage unit, or otherwise administered to a subject can be the amount effective to achieve the intended therapeutic effect. The amount of a LTPR agonist present in a pharmaceutical dosage unit, or otherwise administered to a subject can be the amount effective to reduce the proliferation, viability, size, metastasis, or a combination thereof of the cancer cells, when combined with one or more existing cancer therapies such as check point receptor inhibitor therapy and conventional chemotherapy. The amount of the active agents effective to decrease or inhibit the proliferation and / or viability of the cancer cells can be compared to control cancer cells equivalently treated but without the disclosed compositions. In some forms, the amount of the active agents is effective to reduce, slow or halt tumor progression, or to reduce tumor burden in one or more tumors in the recipient, or a combination thereof. Tumor burden (tumor load - TB) is defined as the total amount of tumor (cells / mass) distributed in the patients' body, including bone marrow. In Response Evaluation Criteria in Solid Tumors (RECIST) analysis TB is considered the sum of the longest diameters of all measurable lesions. In some forms, the amount of the active agents is effective to alter a measurable biochemical or physiological marker. For example, in some forms, administration of a LTPR agonist, such as mAb 10G3, decreases cancer cell viability by up to 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or up to 100% after a time (e.g., 1 week, 2 weeks, 3 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, or more than 5 months) following combination treatment with one or more existing cancer therapies such as check point receptor inhibitor therapy and conventional chemotherapy.
[0444] An effective amount of each of the agents in the combination treatment can be administered as a single unit dosage (e.g., as dosage unit), or sub-therapeutic doses that are administered over a finite time interval. Such unit doses may be administered on a once daily, twice weekly, once weekly, twice monthly, once monthly basis for a finite time period, such as up to 3 days, or up to 5 days, or up to 7 days, or up to 10 days, or up to 15 days, or up to 20 days, or up to 25 days, or up to 30 days, are all specifically contemplated.
[0445] In some forms, the methods also include steps to monitor the effects of the treatment. For example, in some forms the methods identify the suppression of a cancer’s ability to grow. Suppression of a cancer can be measured using a biochemical assay, for example, measuring a decline in one or more biomarkers for the cancer in the blood, or by
[0446] 45844288.1 56
[0447] SBMRI 22-006-03 PCT
[0448] a morphometric analysis, for example by computerized tomography (CT), magnetic resonance imaging (MRI) or ultrasound. Therefore, in some forms the methods include the step of measuring the concentration of one or more biomarkers in the blood of the recipient. The measurements can be made before and after administration of the combination of the disclosed composition and one or more existing cancer therapies such as check point receptor inhibitor therapy and conventional chemotherapy to the subject.
[0449] 3. Diseases to be Treated
[0450] It has been established that methods including administering one or more LTpR agonists or antagonists, optionally together with one or more additional therapies, are effective for treating multiple types of disease or disorders in a subject in need thereof. Exemplary diseases or disorders that can be treated with LTPR agonists include proliferative diseases or disorders, such as cancer. Exemplary diseases that can be treated with LTPR antagonists include inflammatory diseases or disorders, such as Arthritis Asthma, Colitis, Diabetes, Lupus, Periodontitis or Psoriasis
[0451] i. Cancer
[0452] It has been established that methods including administering one or more LTpR agonists, together with one or more existing cancer therapies, are effective for treating multiple types of cancer in a subject in need thereof.
[0453] Therefore, methods for treating and preventing cancer in a subject by administering to the subject the described compositions are provided.
[0454] In some forms, the methods are particularly effective for enabling tumor associated antigens (TAA) to be recognized as non-self antigens by the immune system, for example, by increasing the recruitment of immune cells, lymphocyte infiltration, and / or promoting immune cell differentiation in the TME. Thus, in some forms, the methods can be used to treat “cold tumors”, characterized by low infiltration of immune cells into the TME. In some forms, the methods sensitize cancer cells within the “cold tumors” to one or more existing cancer therapies such as check point receptor inhibitor therapy or conventional chemotherapy. In further forms, the methods treat “innate immune-inactivated tumors,” characterized by infiltration of immunosuppressive cells, such as regulatory T cells and type II macrophages. In some forms, the methods increase infiltration of cytotoxic T cells, and / or reduce the levels of immunosuppressive cells in the TME.
[0455] The disclosed compositions and methods of treatment thereof are generally suited for treatment of carcinomas, sarcomas, lymphomas and leukemias. For example, the described compositions and methods are useful for treating, or alleviating subjects having
[0456] 45844288.1 57
[0457] SBMRI 22-006-03 PCT
[0458] benign or malignant tumors by delaying or inhibiting the growth / proliferation or viability of tumor cells in a subject, reducing the number, growth or size of tumors, inhibiting or reducing metastasis of the tumor, and / or inhibiting or reducing symptoms associated with tumor development or growth.
[0459] The types of cancer that can be treated with the described compositions and methods include, but are not limited to, cancers such as vascular cancer such as multiple myeloma, adenocarcinomas and sarcomas, of bone, bladder, brain, breast, cervical, colorectal, esophageal, kidney, liver, lung, nasopharyngeal, pancreatic, prostate, skin, stomach, and uterine. In some forms, the compositions are used to treat multiple cancer types concurrently. The compositions can also be used to treat metastases or tumors at multiple locations.
[0460] Exemplary cancers that can be treated according to the described methods include: leukemias, such as acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myelodysplastic syndrome, chronic leukemias such as, but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas such as, but not limited to, Hodgkin’s disease, non Hodgkin’s disease; multiple myelomas such as, but not limited to, smoldering multiple myeloma, non-secretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom’s macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas such as, but not limited to, bone sarcoma, osteosarcoma, chondrosarcoma, Ewing’s sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi’s sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma, rhabdomyosarcoma, synovial sarcoma; brain tumors including, but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendroglioma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma; breast cancer including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget’s disease, and inflammatory breast cancer; adrenal cancer, including, but not limited to, pheochromocytom and adrenocortical carcinoma; thyroid cancer such as but not limited to papillary or follicular
[0461] 45844288.1 58
[0462] SBMRI 22-006-03 PCT
[0463] thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer, including, but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatinsecreting tumor, and carcinoid or islet cell tumor; pituitary cancers including, but not limited to, Cushing’s disease, prolactin-secreting tumor, acromegaly, and diabetes insipius; eye cancers including, but not limited to, ocular melanoma such as iris melanoma, choroidal melanoma, and ciliary body melanoma, and retinoblastoma; vaginal cancers, including, but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer, including, but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancers including, but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancers including, but not limited to, endometrial carcinoma and uterine sarcoma; ovarian cancers including, but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; esophageal cancers including, but not limited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancers including, but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancers; rectal cancers; liver cancers including, but not limited to, hepatocellular carcinoma and hepatoblastoma, gallbladder cancers including, but not limited to, adenocarcinoma; cholangiocarcinomas including, but not limited to, papillary, nodular, and diffuse; lung cancers including, but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; testicular cancers including, but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, non-seminoma, embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk-sac tumor), prostate cancers including, but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penal cancers; oral cancers including, but not limited to, squamous cell carcinoma; basal cancers; salivary gland cancers including, but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancers including, but not limited to, squamous cell cancer, and verrucous; skin cancers including, but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, acral lentiginous melanoma; kidney cancers including, but not limited to, renal cell cancer,
[0464] 45844288.1 59
[0465] SBMRI 22-006-03 PCT
[0466] adenocarcinoma, hypernephroma, fibrosarcoma, transitional cell cancer (renal pelvis and / or uterus); Wilms’ tumor; bladder cancers including, but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, and carcinosarcoma. For a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J. B. Lippincott Co., Philadelphia and Murphy et al., 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery, Viking Penguin, Penguin Books U. S. A., Inc., United States of America).
[0467] In some forms, the methods are administered to treat or prevent one or more symptoms of refractory melanoma. In some forms, the refractory melanoma is dacarbazine-refractory melanoma, vemurafenib-refractory melanoma, trametinib-refractory melanoma or dasatinib-refractory melanoma.
[0468] In some forms, the methods are administered to treat or prevent one or more symptoms of a melanoma that is acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma subungal melanoma, and superficial spreading melanoma. In some forms, the methods are administered to treat or prevent one or more symptoms of a melanoma including wild type BRAF, mutated BRAF, wild type NRAS, or mutated NRAS.
[0469] In some forms, the methods are administered to treat or prevent one or more symptoms of a melanoma that is stage II melanoma, stage III melanoma, or stage IV melanoma.
[0470] In some forms, the subject is a subject with cancer who has previously undergone tumor resection. In some forms, the methods are administered to treat or prevent one or more symptoms of melanoma that is resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to administering the described polynucleotides. Therefore, in some forms, the described methods sensitize the melanoma to one or more conventional chemotherapeutic agents and / or immunotherapy
[0471] In some forms, the methods are administered to treat or prevent one or more symptoms of metastatic melanoma. Metastatic melanoma is an advanced (Stage IV) skin cancer that has spread from its original site to distant organs, such as the lungs, liver, brain, or bones.
[0472] In certain forms, the subject is a patient presenting with a malignancy requiring surgical, or other interventions, for example, where the subject is administered the polynucleotides described herein prior to a procedure such as a tumor resection. In some forms, the methods described herein induce or enhance immunological memory directed
[0473] 45844288.1 60
[0474] SBMRI 22-006-03 PCT
[0475] against Minimal Residual Disease (MRD). Accordingly, in some forms, the methods described herein are effective for preventing, reducing, or delaying the rate of cancer recurrence. In some forms, the methods prevent, reduce, or delay the onset or occurrence of Minimal Residual Disease (MRD) in a subject in need thereof.
[0476] In exemplary forms, the methods are administered to treat or prevent one or more symptoms of a cancer in a subject in need thereof, such as a symptom of breast cancer, head and neck squamous cell carcinoma, glioblastoma, prostate cancer, pancreatic cancer, lung cancer, melanoma, ovarian cancer, or sarcoma.
[0477] ii. Inflammatory Diseases
[0478] In some forms, the methods treat or prevent one or more inflammatory diseases or disorders in a subject in need thereof.
[0479] It has been established that methods including administering one or more LTpR antagonists, optionally together with one or more pre-existing therapies, are effective for reducing one or more symptoms of undesirable or uncontrolled inflammation in a subject in need thereof. For example, in some forms, one or more LTPR antagonists are effective to reduce or prevent chronic inflammation or acute inflammation in a subject.
[0480] Therefore, methods for treating and preventing one or more inflammatory diseases or disorders in a subject by administering to the subject the described compositions are provided.
[0481] The described LTPR antagonists are suitable for preventing or treating an inflammatory disease or disorder, or treating or ameliorating one or more symptoms associated with an inflammatory disease or disorder in a subject in need thereof. Both acute and chronic inflammatory diseases or disorders can be treated by the disclosed methods. Fxamples of suitable inflammatory diseases or disorders and symptoms associated with the inflammatory diseases or disorders that can be treated by the disclosed methods include, but are not limited to, asthma, chronic peptic ulcer, tuberculosis, rheumatoid arthritis, periodontitis, ulcerative colitis, Crohn’s disease, sinusitis, active hepatitis, acute bronchitis, appendicitis, ingrown toenail, sore throat, and physical trauma or wound, and a combination thereof.
[0482] The method for treating an inflammatory disease or disorder in a subject in need of include administering to the subject, a therapeutically effective amount of a formulation containing one or more LTpR antagonists to treat the inflammatory disease or disorder, for example, to reduce the severity or prevent one or more symptoms of the inflammatory disease or disorder. The step of administering an effective amount of the LTpR antagonists
[0483] 45844288.1 61
[0484] SBMRI 22-006-03 PCT
[0485] can be achieved in a single administration step or using multiple steps of administering the LTPR antagonists, for example, as a pharmaceutical formulation.
[0486] 4. Dosage and Effective Amounts
[0487] Dosage and dosing regimens are dependent on the severity of the disorder and / or methods of administration. A therapeutically effective amount of compositions including one or more LTPR agonists, or LTPR antagonists or pharmaceutical formulation thereof used in the treatment of cancer is typically sufficient to reduce or alleviate one or more symptoms associated with the disease or disorder.
[0488] In some forms, the compositions are effective to increase the sensitivity of cancer cells to one or more existing cancer therapies such as check point receptor inhibitor therapy and conventional chemotherapy. In some forms, the compositions in combination with one or more cancer therapies reduce or inhibit proliferation, migration, invasion, motility, and / or metastatic abilities of the cancer cells. In further some forms, the compositions are effective to reduce or inhibit tumor growth, tumor burden, and / or increase survival of the subject.
[0489] The actual effective amounts can vary according to factors including the specific agent administered, the particular composition formulated, the mode of administration, and the age, weight, condition of the subject being treated, as well as the route of administration and the disease or disorder.
[0490] In general, the timing and frequency of administration will be adjusted to balance the efficacy of a given treatment schedule with the side-effects of the given delivery system. Exemplary dosing frequencies include continuous infusion, single and multiple administrations such as daily, weekly, monthly, or yearly dosing.
[0491] The composition or pharmaceutical formulation thereof can be administered daily, biweekly, weekly, every two weeks, monthly, or less frequently in an amount to provide a therapeutically effective increase in the blood level of the therapeutic agent. Alternatively, the compositions can be formulated for controlled release, wherein the composition is administered as a single dose that is repeated on a regimen of once a week, or less frequently.
[0492] Dosage can vary, and can be administered in one or more doses daily, once daily, twice weekly, once a week, once every two weeks, once monthly, or less frequently.
[0493] In some forms, the compositions are administered to a subject for between 1 to 20 years, e.g., 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19
[0494] 45844288.1 62
[0495] SBMRI 22-006-03 PCT
[0496] years, or 20 years. Optionally, the compositions are administered for 10 years. In one form, the effects of treatment last for at least 1 year.
[0497] In some forms, the regimen includes one or more cycles of a round of therapy followed by a drug holiday (e.g., no drug). The drug holiday can be 1, 2, 3, 4, 5, 6, or 7 days, or 1, 2, 3, 4 weeks, or 1, 2, 3, 4, 5, or 6 months.
[0498] In some forms, the amount of compositions administered to a subject changes over time following an initial dose. Therefore, in some forms, the amount of compositions administered to a subject changes over time following an initial dose.
[0499] 5. Combination Therapy
[0500] Methods for administering the described LTpR agonists, or LTβR antagonists together with one or more additional active agents or therapy are also described. In some forms, the methods administer one or more additional cancer therapies simultaneous or sequential with administering the described LTpR agonists, or LTpR antagonists.
[0501] In some forms, the methods include administering one or more LTpR agonistic mAbs, such as 10G3, in combination with one or more conventional chemotherapeutic agents and / or one or more immunotherapeutic agents. In some forms, the therapy is one or more one or more LTpR agonistic mAbs such as 10G3, in combination with one or more check point receptor inhibitors, with or without conventional chemotherapeutic agents or immunotherapeutic agents. In other forms, the methods include administering one or more LTPR antagonists, such as an isolated Fab of mAb 6G9 or an isolated Fab of mAb 15E2, optionally in combination with one or more conventional anti-inflammatory agents and / or one or more immunotherapeutic agents.
[0502] An additional therapy or procedure can be combined with the combination therapy. In some forms, the additional therapy is performed between drug cycles or during a drug holiday that is part of the combination therapy dosage regime. In some forms, the additional therapy is a conventional treatment for cancer, more preferably a conventional treatment for liver cancer. For example, in some forms, the additional therapy or procedure is surgery, transplant surgery, or a radiation therapy.
[0503] In some forms, the methods of administering the disclosed compositions are used prior to or in conjunction with an immunotherapy such as inhibition of checkpoint proteins such as components of the PD-1 / PD-L1 axis or CD28-CTLA-4 axis using one or more immune checkpoint modulators (e.g., PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists), adoptive T cell therapy, and / or a cancer vaccine. Additional exemplary immune checkpoints include TIGIT, LAG-3, TIM-3, VISTA, CD160, and
[0504] 45844288.1 63
[0505] SBMRI 22-006-03 PCT
[0506] BTLA. In some forms, the methods of administering the disclosed compositions are used prior to or in conjunction with an immunotherapy immune checkpoint inhibitor, such as pembrolizumab, nivolumab, ipilimumab, relatlimab, or combination thereof. In some forms, the methods of administering the disclosed compositions are used prior to or in conjunction with an immunotherapy including one or more check point receptor inhibitor(s) selected from the group consisting of PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.
[0507] In other forms, the methods of administering the disclosed compositions are used prior to or in conjunction with one or more conventional chemotherapeutic agents, immunotherapy, surgery, and radiation. In some forms, the methods of administering the disclosed compositions are used prior to, subsequent to, or in conjunction with an additional cancer therapy, such as a BRAF inhibitor. Exemplary BRAF inhibitors include dabrafenib, vemurafenib, encorafenib, or combination thereof. In some forms, the methods of administering the disclosed compositions are used prior to or in conjunction with an MEK inhibitor, such as trametinib, cobimetinib, binimetinib, or combination thereof.
[0508] In some forms, the compositions and methods are used prior to or in conjunction with surgical removal of tumors, for example, in preventing primary tumor metastasis. In some forms, the compositions and methods are used to enhance body’ s own anti-tumor immune functions.
[0509] 6. Exemplary Methods
[0510] In some forms, the describes methods treat melanoma, such as refractory melanoma, in a subject in need thereof, by administering to the subject a polynucleotide encoding the described LTpR agonists, or a polynucleotide encoding a fusion protein including of the described LTPR agonist. In some forms, the methods administer a polynucleotide encoding a fusion protein including the described LTpR agonists in combination with an immune checkpoint inhibitor, such as pembrolizumab, nivolumab, ipilimumab, relatlimab, or combination thereof, wherein the immune checkpoint inhibitor is administered simultaneously or sequentially with administering the polynucleotide. In some forms, the methods administer a polynucleotide encoding a fusion protein including the described LTPR agonists in combination with an a BRAF inhibitor, such as dabrafenib, vemurafenib, encorafenib, or combination thereof, wherein the BRAF inhibitor is administered simultaneously or sequentially with administering the polynucleotide. In some forms, the methods administer a polynucleotide encoding a fusion protein including the described LTpR agonists in combination with an immune checkpoint
[0511] 45844288.1 64
[0512] SBMRI 22-006-03 PCT
[0513] inhibitor, such as PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists, or combinations thereof, wherein the immune checkpoint inhibitor is administered simultaneously or sequentially with administering the polynucleotide.
[0514] E. Kits
[0515] Medical kits are also disclosed. The medical kits can include, for example, a dosage supply of one or more LTβR agonistic mAbs such as 10G3, supplied alone (e.g., lyophilized), or in a pharmaceutical composition. The active agent(s) can be in a unit dosage, or in a stock that should be diluted prior to administration. In some forms, the kit includes a supply of pharmaceutically acceptable carrier. The kit can also include devices for administration of the active agents or compositions, for example, syringes. The kits can include printed instructions for administering the compound in a method as described above.
[0516] The disclosed compositions and methods can be further understood through the following numbered paragraphs.
[0517] 1. An antibody or antigen binding fragment thereof including
[0518] (i) complementarity-determining regions (CDRs) of the immunoglobulin heavy variable (IgVH) domain of SEQ ID NO:9, optionally wherein the CDRs according to the Kabat numbering system include amino acid sequences according to SEQ ID NOs: 11-13; and / or
[0519] (ii) CDRs of the immunoglobulin light variable (IgV ) domain of SEQ ID NO:10, optionally wherein the CDRs according to the Kabat numbering system include amino acid sequences according to SEQ ID NOs:14-16.
[0520] 2. The antibody or antigen binding fragment thereof of paragraph 1, wherein the antibody or antigen binding fragment thereof includes:
[0521] an IgVH domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:9; and / or
[0522] an IgV domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:10.
[0523] 3. An antibody or antigen binding fragment thereof including
[0524] (i) CDRs of the IgVn domain of SEQ ID NO:17,
[0525] optionally wherein the CDRs according to the Kabat numbering system include amino acid sequences according to SEQ ID NOs:11, 12, 19, and / or
[0526] (ii) CDRs of the IgVL domain of SEQ ID NO:18,
[0527] 45844288.1 65
[0528] SBMRI 22-006-03 PCT
[0529] optionally wherein the CDRs according to the Kabat numbering system include amino acid sequences according to SEQ ID NOs:20-22.
[0530] 4. The antibody or antigen binding fragment thereof of paragraph 3, wherein the antibody or antigen binding fragment thereof includes:
[0531] an IgVu domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 17; and / or
[0532] an IgVL domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 18.
[0533] 5. An antibody or antigen binding fragment thereof including
[0534] (i) CDRs of the IgVu domain of SEQ ID NO: 1, optionally wherein the CDRs according to the Kabat numbering system include amino acid sequences according to SEQ ID NOs:3-5; and / or
[0535] (ii) CDRs of the IgVL domain of SEQ ID NO:2, optionally wherein the CDRs according to the Kabat numbering system include amino acid sequences according to SEQ ID NOs:6-8.
[0536] 6. The antibody or antigen binding fragment thereof of paragraph 5, wherein the antibody or antigen binding fragment thereof includes:
[0537] an IgVH domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:1; and / or
[0538] an IgVL domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:2.
[0539] 7. The antibody or antigen binding fragment thereof of any one of paragraphs 1-6, including an intact immunoglobulin, or a mono-, di-, or tri-valent or multivalent single chain variable fragment (scFv), Fab, F(ab’)2, minibody, scFv-Fc, diabody, triabody, or tetrabody.
[0540] 8. The antibody of any one of paragraphs 1-7, wherein the antibody binds to Lymphotoxin P Receptor (LTpR) with an EC50 between about 0.01 nM and about 1 nM, inclusive, preferably between about 0.1 nM and about 0.5 nM, inclusive.
[0541] 9. The antibody or antigen binding fragment thereof of any one of paragraphs 1-8, wherein the antibody or antigen binding fragment thereof is an LT R agonist.
[0542] 10. A pharmaceutical composition including the antibody according to paragraph 9 and a pharmaceutically acceptable excipient.
[0543] 11. The pharmaceutical composition of paragraph 10, for use in a method of treatment of a proliferative disease or disorder in a subject in need thereof, including
[0544] 45844288.1 66
[0545] SBMRI 22-006-03 PCT
[0546] administering to the subject the pharmaceutical composition in an amount effective to treat or prevent one or more symptoms of the proliferative disease or disorder.
[0547] 12. The LT R antagonist of paragraph 9, for use in formulation of a composition for the treatment of a proliferative disease or disorder in a subject in need thereof, including administering the composition to the subject in an amount effective to treat or prevent one or more symptoms of a proliferative disease or disorder.
[0548] 13. A method of inducing, promoting, or enhancing biosynthesis and secretion of chemokines by immune cells, and / or infiltration of immune cells into a tumor microenvironment (TME) in a subject having a tumor, including
[0549] administering to the subject an effective amount of the pharmaceutical composition of paragraph 10 to induce, promote, or enhance the biosynthesis and secretion of chemokines and / or infiltration of immune cells into the TME in the subject.
[0550] 14. The method of paragraph 13, wherein the enhancement of the biosynthesis and secretion of chemokines and / or immune cell infiltration is mediated by LTpR signaling within the TME.
[0551] 15. The method of paragraph 14, wherein the TME had low infiltration of immune cells, and / or high presence of immunosuppressive cells prior to the administration of the pharmaceutical composition.
[0552] 16. The method of paragraph 15, wherein the immunosuppressive cells are one or more regulatory T cells and / or type II macrophages.
[0553] 17. The method of any one of paragraphs 13-16, wherein the pharmaceutical composition is administered in an amount effective to recruit immune cells, promote lymphocyte infiltration, and drive immune cell differentiation.
[0554] 18. The method of any one of paragraphs 13-16, wherein the pharmaceutical composition is administered in an amount effective to recruit cytotoxic T cells into the tumor microenvironment, more than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more than 90%, compared to the level prior to the administration of the pharmaceutical composition.
[0555] 19. The method of any one of paragraphs 11-18, further including administering one or more additional cancer therapies to the subject.
[0556] 20. The method of paragraph 19, wherein the administration of the one or more additional cancer therapies is simultaneous or sequential with the administration of the pharmaceutical composition.
[0557] 45844288.1 67
[0558] SBMRI 22-006-03 PCT
[0559] 21. The method of paragraph 19 or 20, wherein the additional cancer therapy is selected from the group consisting of conventional chemotherapy, immunotherapy, surgery, and radiation.
[0560] 22. The method of paragraph 21, wherein the immunotherapy includes one or more check point receptor inhibitor(s) selected from the group consisting of PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.
[0561] 23. The method of any one of paragraphs 1 -22, wherein the tumor was resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to the administration of the pharmaceutical composition.
[0562] 24. The method of any one of paragraphs 1 -23, wherein the effective amount of the pharmaceutical composition in combination with the one or more additional cancer therapies is effective to reduce or inhibit proliferation, migration, invasion, motility, and / or metastatic abilities of the cancer cells.
[0563] 25. The pharmaceutical composition for use according to paragraph 11, or the LTpR antagonist for use according to paragraph 12, or the method according to any one of paragraphs 13-24, wherein the subject has a proliferative disease or disorder is a cancer selected from the group consisting of breast cancer, head and neck squamous cell carcinoma, glioblastoma, pancreatic cancer, prostate cancer, lung cancer, melanoma, ovarian cancer, and sarcoma.
[0564] 26. The method of any one of paragraphs 13-25, the cancer is Triple Negative Breast Cancer.
[0565] 27. A method of treating cancer in a subject in need thereof including administering to the subject an effective amount of the pharmaceutical composition of paragraph 10 and one or more conventional chemotherapeutic agents and / or immunotherapy to treat or alleviate one or more symptoms of the cancer in the subject.
[0566] 28. The method of paragraph 27, wherein the immunotherapy is one or more check point receptor inhibitors selected from the group consisting of PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.
[0567] 29. The method of paragraph 27, wherein the one or more conventional chemotherapeutic agent(s) is selected from the group consisting of anti-VEGF antibodies, Receptor Tyrosine Kinase (RTK) inhibitors, MEK inhibitors, and CXCR4 antagonists.
[0568] 30. The method of paragraph 27 or 29, wherein the one or more conventional chemotherapeutic agent(s) is selected from the group consisting of bevacizumab, cabozantinib, cobimetinib, and BL8040.
[0569] 45844288.1 68
[0570] SBMRI 22-006-03 PCT
[0571] 31. The method of any one of paragraphs 27-30, wherein the cancer was resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to the administration of the pharmaceutical composition.
[0572] 32. The method of any one of paragraphs 27-31, wherein the administration of the one or more conventional chemotherapeutic agent(s) and / or immunotherapy is simultaneous or sequential with the administration of the pharmaceutical composition.
[0573] 33. The method of any one of paragraphs 27-32, wherein the effective amount of the pharmaceutical composition in combination with the one or more conventional chemotherapeutic agent(s) and / or immunotherapy are effective to reduce or inhibit proliferation, migration, invasion, motility, and / or metastatic abilities of the cancer cells.
[0574] 34. The method of any one of paragraphs 27-33, wherein the cancer is selected from the group consisting of breast cancer, head and neck squamous cell carcinoma, glioblastoma, pancreatic cancer, lung cancer, melanoma, ovarian cancer, and sarcoma.
[0575] 35. The method of any one of paragraphs 27-34, the cancer is Triple Negative Breast Cancer.
[0576] 36. A means for agonizing the Lymphotoxin β Receptor (LTβR) without blocking its natural ligands including a compound that binds to LTβR but does not compete with hLIGHT or hLTα1β2 for binding to LTβR.
[0577] 37. The means of paragraph 36, wherein the means includes one or more complementarity-determining regions (CDRs) according to SEQ ID NOs:ll-16, SEQ ID NOs:ll, 12, 19-22, or SEQ ID NOs:3-8.
[0578] 38. A method of selecting a molecule that selectively binds to the Lymphotoxin-β Receptor (LTβR), including
[0579] (i) providing an antibody or antigen binding fragment of any one of paragraphs 1-7 and / or a native LTβR-binding ligand as a positive binding control;
[0580] (ii) providing a first or further sample including one or more test molecules;
[0581] (iii) screening for a LTβR-binding test molecule within the first or further sample, wherein the screening includes contacting the first or further sample with a LTβR molecule in the presence of the positive binding control; and
[0582] (iv) selecting a test molecule from the first or further sample as a LTβR-binding molecule when the test molecule remains bound to LTβR in the presence of the native LTβR ligand, or in the presence of the positive binding control.
[0583] 45844288.1 69
[0584] SBMRI 22-006-03 PCT
[0585] 39. The method of paragraph 38, wherein the positive binding control is mixed with the first or further sample including one or more test molecules prior to contacting the first or further sample with the native LTβR ligand in step (iii).
[0586] 40. The method of paragraph 38, wherein the positive binding control is contacted with the native LTβR ligand after the first or further sample including one or more test molecules is contacted with the native LTPR ligand in step (iii).
[0587] 41. The method of any one of paragraphs 38-40, wherein the one or more test molecule includes a detectable label or dye, and
[0588] wherein the selecting in step (iv) includes detecting the label or dye.
[0589] 42. An LTpR-binding molecule selected according to the method of any one of paragraphs 38 to 41.
[0590] 43. 1’he Ll'PR-binding molecule of paragraph 42, wherein the Ll'PR-binding molecule includes an immunoglobulin, or an antigen-binding fragment thereof.
[0591] 44. The LTpR-binding molecule of paragraph 42 or 43, wherein the LTPR-binding molecule is conjugated or complexed with a bacterium or viral particle.
[0592] 45. The LTpR-binding molecule of paragraph 44, wherein the viral particle includes a bacteriophage.
[0593] 46. The method of any one of paragraphs 38-41, further including
[0594] (v) selecting the LTPR-binding molecule as an LTPR agonist or antagonist, including contacting the LTpR-binding molecule with cells including LTPR expression; and
[0595] (vi) selecting the LTβR-binding molecule as an agonist when the LTβR-binding molecule induces LTβR signaling in the cells, or
[0596] selecting the LTpR-binding molecule as an LTPR antagonist when the LTPR-binding molecule prevents LTPR signaling in cells in the presence of one or more natural LTPR-Iigands or functional fragments or variants thereof.
[0597] 47. An LTPR agonist selected according to the method of paragraph 46.
[0598] 48. The LTPR agonist of paragraph 47, including an immunoglobulin including two or more antigen-binding Fab domains.
[0599] 49. An isolated antigen binding Fab domain protein including one of the two or more antigen-binding Fab domains of the immunoglobulin of paragraph 48.
[0600] 50. An LTPR antagonist selected according to the method of paragraph 47.
[0601] 51. An LTPR antagonist including an isolated Fab molecule, including
[0602] 45844288.1 70
[0603] SBMRI 22-006-03 PCT
[0604] (i) complementarity-determining regions (CDRs) of the immunoglobulin heavy variable (IgVu) domain of SEQ ID NO: 17, optionally wherein the CDRs include amino acid sequences according to SEQ ID NOs:l 1, 12, 19, and / or
[0605] (ii) CDRs of the immunoglobulin heavy variable (IgVL) domain of SEQ ID NO: 18, optionally wherein the CDRs include amino acid sequences according to SEQ ID NOs: 20-22.
[0606] 52. The LTPR antagonist of paragraph 51, wherein the isolated Fab includes an IgVu domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 17; and / or
[0607] an IgVLdomain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:18.
[0608] 53. An LTPR antagonist including an isolated Fab molecule including
[0609] (i) complementarity-determining regions (CDRs) of the immunoglobulin heavy variable (IgVu) domain of SEQ ID NO:1, optionally wherein the CDRs include amino acid sequences according to SEQ ID NOs:3-5, and / or
[0610] (ii) CDRs of the immunoglobulin heavy variable (IgVL) domain of SEQ ID NO:2, optionally wherein the CDRs include amino acid sequences according to SEQ ID NOs:6-8.
[0611] 54. The LTPR antagonist of paragraph 53, wherein the isolated Fab includes an IgVu domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 1; and / or
[0612] an IgV domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:2.
[0613] 55. A pharmaceutical formulation including the LTPR antagonist of any one of paragraphs 48-52 and a pharmaceutically acceptable excipient.
[0614] 56. A method for the treatment of an inflammatory disease or disorder in a subject in need thereof, including administering to the subject one or more LTPR antagonist(s) in an amount effective to treat or prevent one or more symptoms of an inflammatory disease or disorder in the subject.
[0615] 57. The method of paragraph 56, wherein the one or more LTPR antagonist(s) bind to an epitope on LTPR that overlaps with an epitope on LTPR of one or more natural LTPR ligands.
[0616] 58. The method of paragraph 57, wherein the one or more natural LTPR ligands is selected from the group consisting of LIGHT and LTaip2.
[0617] 45844288.1 71
[0618] SBMRI 22-006-03 PCT
[0619] 59. The method of paragraph 57 or 58, wherein the one or more LTpR antagonist(s) inhibit or reduce the binding between one or more natural LTPR ligands and LTpR.
[0620] 60. The method of any one of paragraphs 57-59, wherein the one or more LTPR antagonist(s) include an isolated antigen binding domain (Fab) of an immunoglobulin.
[0621] 61. The method of paragraph 60, wherein the isolated Fab includes one or more of the LTPR antagonists of any one of paragraphs 48-52.
[0622] 62. The pharmaceutical formulation of paragraph 55, for use in a method of treatment of an inflammatory disease or disorder in a subject in need thereof, including administering to the subject the formulation in an amount effective to treat or prevent one or more symptoms of an inflammatory disease.
[0623] 63. The LTPR antagonist of any one of paragraphs 50-54, for use in formulation of a composition for the treatment of an inflammatory disease or disorder in a subject in need thereof, including administering the composition to the subject in an amount effective to treat or prevent one or more symptoms of an inflammatory disease.
[0624] 64. The method of any one of paragraphs 56-61, or the pharmaceutical formulation for use according to paragraph 62, wherein the inflammatory disease or disorder is selected from the group consisting of asthma, chronic peptic ulcer, tuberculosis, rheumatoid arthritis, periodontitis, ulcerative colitis, Crohn’s disease, sinusitis, active hepatitis, acute bronchitis, appendicitis, ingrown toenail, sore throat, and physical trauma or wound, or a combination thereof.
[0625] 65. A composition including the antibody according to paragraph 9 conjugated to tumor cells of a subject.
[0626] 66. A method including
[0627] administering an effective amount of the composition of paragraph 65 to the subject to induce, promote, or enhance the biosynthesis and secretion of chemokines and / or infiltration of immune cells into the TME in the subject.
[0628] 67. The method of paragraph 66, wherein the enhancement of the biosynthesis and secretion of chemokines and / or immune cell infiltration is mediated by LT R signaling within the TME.
[0629] 68. The method of paragraph 67, wherein the TME had low infiltration of immune cells, and / or high presence of immunosuppressive cells prior to the administration of the composition.
[0630] 45844288.1 72
[0631] SBMRI 22-006-03 PCT
[0632] 69. The method of paragraph 68, wherein the immunosuppressive cells are one or more regulatory T cells and / or type II macrophages.
[0633] 70. The method of any one of paragraphs 66-69, wherein the composition is administered in an amount effective to recruit immune cells, promote lymphocyte infiltration, and drive immune cell differentiation.
[0634] 71. The method of any one of paragraphs 66-69, wherein the composition is administered in an amount effective to recruit cytotoxic T cells into the tumor microenvironment, more than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more than 90%, compared to the level prior to the administration of the composition.
[0635] 72. The method of any one of paragraphs 65-71, further including administering one or more additional cancer therapies to the subject.
[0636] 73. The method of paragraph 72, wherein the administration of the one or more additional cancer therapies is simultaneous or sequential with the administration of the composition.
[0637] 74. The method of paragraph 72 or 73, wherein the additional cancer therapy is selected from the group consisting of conventional chemotherapy, immunotherapy, surgery, and radiation.
[0638] 75. The method of paragraph 74, wherein the immunotherapy includes one or more check point receptor inhibitor(s) selected from the group consisting of PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.
[0639] 76. The method of any one of paragraphs 66-75, wherein the tumor was resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to the administration of the composition.
[0640] 77. The method of any one of paragraphs 72-76, wherein the effective amount of the composition in combination with the one or more additional cancer therapies is effective to reduce or inhibit proliferation, migration, invasion, motility, and / or metastatic abilities of the cancer cells.
[0641] 78. The pharmaceutical composition of paragraph 65, for use in a method of treatment of a proliferative disease or disorder in a subject in need thereof, including administering to the subject the pharmaceutical composition in an amount effective to treat or prevent one or more symptoms of the proliferative disease or disorder.
[0642] 79. A method of formulating a pharmaceutical composition of paragraph 55, including mixing the LTPR antagonist of any one of paragraphs 48-52 with a pharmaceutically acceptable excipient,
[0643] 45844288.1 73
[0644] SBMRI 22-006-03 PCT
[0645] 80. A method of making the LTpR antagonist of any one of paragraphs 48-52, including recombinantly expressing the LTpR antagonist in vitro,
[0646] optionally wherein the recombinant expressing comprises expression in cell culture, and / or
[0647] optionally wherein the method further includes isolating the expressed LT0R antagonist.
[0648] The disclosed compositions and methods can be further understood through the following examples.
[0649] EXAMPLES
[0650] Example 1: Identification of LTpR agonistic mAbs
[0651] Desirable LTpR agonistic mAbs were identified based on their abilities to selectively and specifically bind human LT|3R as well as activating LTPR signaling. A subset of antibody clones, such as 10G3, 15E2 and 6G9, that showed strong target engagement and activation of LT R signaling were identified, as set forth in Figs.1-5. Methods
[0652] A fully human antigen-binding fragment (Fab) phage display library was used to isolate and identify the unique heavy and light variable chains (VH and VL) of the antibodies binding to LTBR in-solution Recombinant DNA methods were used to format the Fabs to full mAbs and that were expressed and purified. The genetic sequences of the identified variable regions were determined and used to select a panel of antibodies with unique variable chain sequences.
[0653] The genetic sequences of the variable regions were determined and used to select a panel of antibodies with unique variable chain sequences.
[0654] Recombinant DNA methods were used to create complete mAbs and the mAbs were then manufactured and purified. Eight mAbs were identified and underwent functional screening.
[0655] The functional screen was designed to yield leads with the following characteristics:
[0656] • Specificity and high affinity (0.1-1 nM range) for LTPR to achieve therapeutic characteristics and drug quality (PK / PD);
[0657] • Activation of the cellular signaling pathways of LTpR, mimicking native ligands;
[0658] • Co-binding with native ligands to avoid disrupting homeostatic functions of LT R (e.g., lymph node and splenic organization);
[0659] • Fully humanized mAb to minimize stimulating anti-drug antibodies (ADA);
[0660] 45844288.1 74
[0661] SBMRI 22-006-03 PCT
[0662] • Species cross-reactivity, enabling the candidate to be tested in mouse cancer models; and
[0663] • Ideal biophysical properties for manufacturing and drug delivery.
[0664] Results
[0665] As depicted in Figure 1, equilibrium binding of anli-LTpR antibodies to LT0R expressing 293T cells was demonstrated. Transduced 293T cells stably expressing LTβR (human embryonic kidney cell line; 293T-LTβR) were used for the flow cytometric-based binding analysis. 293T-LTPR cells were incubated with anii-Ll’pR human IgGl clones (graded concentration from 13 pg / mL to 64 pg / mL) for 40 min at 4°C. Alexa Fluor 647 conjugated donkey F(ab’)2 fragment anti-human IgG FCy polyclonal antibody (Jackson Immuno Research, West Grove, PA) was used for detecting anti-LT R IgG bound 293T-LTPR cells. Prism (Version 6.01) was used to calculate EC50 (GraphPad Software, San Diego, CA). CBE11 is a commercially available Ab to human LTBR and is a positive control. Note that 10G3, 15E2, and 16G9 have EC50 values that are comparable to CBE11.
[0666] As depicted in Figure 2, equilibrium binding of anti-LT R antibodies to mouse LT R expressing 293T cells was demonstrated. 293T cells stably expressing mouse LT R (human embryonic kidney cell line; 293T-mLTpR) were used for the flow cytometrybased binding analysis. 293T-mLT R cells were incubated with anti-LT R human IgGl clones (graded concentration from 13 pg / mL to 64 pg / mL) for 40 min at 4°C. Alexa Fluor 647 conjugated donkey F(ab’)2 fragment anti-human IgG FCy polyclonal antibody fragment specific polyclonal antibody (Jackson Immuno Research, West Grove, PA) was used for detecting anti-LT R IgG bound 293T-LT R cells. Prism (Version 6.01) was used to calculate EC50 (GraphPad Software, San Diego, CA). Anti-mouse LTPR 4H8 was used as positive control. Anti-human LT R CBE11 was used as negative control. Figure 2 is similar to Figure 1 but showing binding to mouse LTBR. Note that neither CBE nor 6G9 cross-react with mouse LTPR. Other antibodies do cross-react with mouse LTPR, including 10G3. Cross-reactivity of an antibody allows its use as a tool in both human and mouse models of cancer.
[0667] As depicted in Figure 3, anti-LTpR mAbs activated HeLa-NFKB reporter cells. HeLa-NFKB reporter cells (human cervical cancer cell line expressing endogenous LTPR with NFKB-driven alkaline phosphatase reporter) were plated in a 96-well plate at a density of 100,000 cells / well. Cells were left to adhere for one hour. Serial dilutions of
[0668] 45844288.1 75
[0669] SBMRI 22-006-03 PCT
[0670] anti-LTpR human IgGl clones (3 ng / mL to 48 pg / mL) were added to cells. The samples were incubated at 37°C for 24 hours. Alkaline phosphatase detection assay using DuoLux chemiluminescent alkaline phosphatase substrate was performed according to manufacturer’s instructions (Vector Laboratories, CA, USA). Prism (Version 6.01) was used to calculate EC50 (GraphPad Software, San Diego, CA). Anti- LTpR CBE11 was used as positive control. Figure 3 represents a downstream readout type assay showing agonist activity. 6G9 and 15E2 have comparable activity to the control CBE11. 10G3 also showed sufficient activity.
[0671] As depicted in Figure 4, anti-LTpR mAbs against recombinant LIGHT bound to LTPR on 293T-LTPR cells. Transduced 293T cells stably expressing LTPR (human embryonic kidney cell line; 293T-LTPR) were used for the flow cytometric-based competition-binding analysis. 293T-LTPR cells were co-incubated with fixed concentration of Alexa Fluor 647 conjugated recombinant LIGHT (0.07 pg / niL) and graded concentrations (170 pg / mL to 48 pg / mL) of anti-LTpR human IgGl clones for 60 min at 4°C. The samples were washed and flow cytometry analysis was performed.
[0672] Specific mean fluorescence intensity (MFI) obtained from the binding of LIGHT-AF647 to LTPR on 293T-LTPR cells were used to determine the levels of competition binding. Prism (Version 6.01) was used to calculate IC50 (GraphPad Software, San Diego, CA). Anti-LTpR CBE11 was used as positive control. Figure 4 shows the blocking activity v. SLIGHT. CBE11, 6G9, and 15E2 significantly block SLIGHT binding while 10G3 does not.
[0673] As depicted in Figure 5, anti-LTPR mAbs against recombinant LTaip2 bound LTPR on 293T-LTPR cells. Stably transduced LTPR expressing 293T cells (human embryonic kidney cell line; 293T-LTPR) were used for the flow cytometric-based competition-binding analysis. 293T-LTPR cells were co-incubated with a fixed volume of supernatant containing recombinant LTaip2 (with myc-tag) and graded concentrations ( 170 pg / mL to 48 pg / mL) of anti-Ll'PR human IgGl clones for 60 min at 4°C. The samples were washed. A biotinylated anti-myc 9E10 antibody (2 pg / mL) and streptavidin-AF647 (3 pg / mL) were used for detection. Flow cytometry analysis was performed.
[0674] Specific mean fluorescence intensity (MFI) obtained from the binding of recombinant LTaip2 to LTPR on 293T-LTPR cells were used to determine the levels of competition binding. Prism (Version 6.01) was used to calculate IC50 (GraphPad Software, San Diego,
[0675] 45844288.1 76
[0676] SBMRI 22-006-03 PCT
[0677] CA). Anti-LT0R CBE11 was used as positive control. Figure 5 shows the blocking activity v. LTalB2. CBE11, 6G9, and 15E2 block SLIGHT binding while 10G3 does not.
[0678] Some of these anti-LTpR human antibodies exhibited low scores for non-specific binding, equivalent to comparators, including approved mAb drugs (ustekinumab, briakinumab and bevacizumab) were confirmed by binding with insulin and dsDNA, as determined by O. D. 450 nm (Table 1).
[0679] Table 1. Polyreactive binding score determination on insulin and dsDNA
[0680]
[0681] Some of these anti-LTbR human antibodies exhibited excellent viscosity, solubility and in vivo clearance predicting properties (AC-SINS) (Table 2). The AC-SINS assay has been shown to predict viscosity, solubility issues and in vivo clearance.
[0682] Table 2. Affinity-capture self-interaction nanoparticle spectroscopy scores
[0683]
[0684] Example 2: mAb 10G3 demonstrates a strong biophysical profile and drug-like properties
[0685] mAb 10G3, exhibited good co-binding with LIGHT and species cross-reactivity with mouse LT R.
[0686] Manufacturing and SEC-HPLC purification of 10G3 was achieved to high purity with a monomer percentage of 100%. High purification was achieved with affinity and size exclusion chromatography high-performance liquid chromatography.
[0687] 45844288.1 77
[0688] SBMRI 22-006-03 PCT
[0689] 10G3 exhibited most desirable biophysical features including excellent viscosity, solubility and in vivo clearance predicting properties (AC-SINS) (Table 2). 10G3 also exhibited low scores for non-specific binding, equivalent to comparators, including approved mAb drugs (ustekinumab, briakinumab and bevacizumab) were confirmed by binding with insulin and dsDNA, as determined by O. D. 450 nm (Table 1).
[0690] Summary
[0691] The native ligands LIGHT and LTaip2 or engineered forms of these ligands have significant limitations unsuitable for use as therapeutics in treating human patients with cancer. Multiple reasons, including specificity with other receptors, LIGHT-HVEM, LIGHT inhibitor, DcR3; and practical reasons, including production of complex molecules and stability in vivo; short half-life.
[0692] To overcome these limitations, a panel of unique monoclonal antibodies was created with distinct functional properties that supersede the limitations of the native or engineered forms of LT R ligands. This panel of mAbs recognizes distinct epitopes and displays biophysical characteristics that render the mAbs suitable for use as therapeutics for treating human diseases.
[0693] Using the disclosed screening methods, the discovery of mAb affecting multiple LT^R properties with therapeutic potential was demonstrate. Within this mAb panel mAb were discovered with diverse functions, including:
[0694] • mAbs that inhibit binding of native ligands to LT R;
[0695] • mAbs that bind LTPR in the presence of the native ligands, LIGHT and (LTal P2) expressed on the cell membrane or as soluble proteins;
[0696] • mAbs that activate the LTPR signaling pathway supplanting the native ligands (agonist) with competitive binding for native ligands:
[0697] • mAbs that activate the transcription factor NFKB (agonist);
[0698] • mAbs competitive with the native ligands, LIGHT and LTaip2, that activate the LTPR signaling pathway supplanting the native ligands (antagonist-agonist functionality);
[0699] • mAbs with non-competitive binding of the native ligands that activate the LTPR signaling pathway allowing the native ligands to signal (agonist); and
[0700] • mAbs with competitive binding against the native ligands can be used to generate LTPR inhibitors or antagonists by converting the bivalent from into monovalent forms.
[0701] 78
[0702] 45844288.1
[0703] SBMRI 22-006-03 PCT
[0704] Each functional property listed should guide identification of suitable mAh. Preferably, the mAbs exhibit two or more of these features.
[0705] Currently, there are no approved drugs directed at enhancing or promoting infiltration of immune cells into the TME that create an anti-tumor immune response. Agonists using the native ligands of LTpR are being considered but lack important features to become effective drugs, including short half-life and inactivation by a secreted inhibitory regulator, Decoy Receptor-3 (DcR3). Specific LT0R antibodies bypass the inhibitory effect of DcR3 and have desirable drug like properties, providing clear advantages over the native ligands for LTpR. Furthermore, the antibodies designed here not only avoid competition with the native ligands but also allow co-operative function.
[0706] Example 3: In vivo studies demonstrate anti-tumor efficacy of mAb clone 10G3 Methods
[0707] Three isoforms of LIGHT were prepared, including a soluble form (EL4-LIGHT-t66), as well as intracellular LIGHT (EL4-LIGHT TM), as well as combinations of both membrane bound and soluble LIGHT (EL4-LIGHT) by transduction with retroviral vectors containing the corresponded cDNA.
[0708] Each of three mAbs, 6G9, 10G3 and 15E2, were characterized based on their in vitro binding qualities (Figure 6).
[0709] A mouse EL4 tumor model was created based on subcutaneously injection of E 1.4 cells into syngeneic C57 BL / 6 mice. EL4 cells were injected subcutaneously at 0.1 x 106to 0.5 x 106cells per C57B1 / 6 mouse. Control EL4 cells were transduced with empty retroviral vector (EL4-EV). The growth of EL4 tumors in mice was measured with a caliper over a minimum of 16 days after cell injections (Figure 7).
[0710] Results
[0711] As depicted in Figures 8A-8B, LIGHT-mcdiatcd anti-tumor responses were demonstrated in the EL4 tumor model. The three isoforms of LIGHT, including a soluble form (EL4-LIGHT-t66), intracellular LIGHT (EL4-LIGHT TM), and soluble LIGHT (EL4-LIGHT), as well as the control EL4-EV were injected subcutaneously at 7.5 x 105cells per C57B1 / 6 (B6) mouse in groups of 4 or 5 mice per sample. The growth of EL4-EV and EL4-LIGHT tumors in syngeneic B6 mice was measured with a caliper over a period of 16 days after cell injections. As depicted in Figure 8B, EL4-LIGHT TM (intracellular LIGHT) or EL4-LIGHTt66 (soluble LIGHT) were injected subcutaneously with 2.5 x 105cells per mouse in each group. Tumor growth was monitored over a period of 16 days.
[0712] 45844288.1 79
[0713] SBMRI 22-006-03 PCT
[0714] As depicted in Figures 9A-9B, the LTpR receptor requirement for LIGHT-mediated anti -tumor responses were demonstrated. EL4- LIGHT cells (2.5 x 103cells per mouse) were injected subcutaneously into mice deficient in Lt fir (Figure 9A), and Hvem (Figure 9B), respectively. Mice deficient in LTpR could not reject EL4-LIGHT tumor, indicating that LTPR signaling is essential for LIGHT-mediated anti-tumor responses.
[0715] As depicted in Figures 10A-10B, suppression of tumor growth by preimmunization with LIGHT decorated EL4 cells were demonstrated. A schematic illustration of the design for the LIGHT dependent tumor vaccination scheme is set forth in Figure 10A; Formalin fixed Neutravidin decorated EL4 (EL4-NA) cells (4 xlO6) or human LIGHT-Neutravidin decorated EL4 (EL4-NA-LIGHT) cells were injected subcutaneously into B6 mice (n = 4 or 5 mice). After 14 days, these mice were challenged with live EL4 cells (0.5 x 106cells per mouse). Tumor growth was measured over 17 days. The effect of preinjected EL4-NA-LIGHT cells on challenged EL4 tumor growth is depicted in Figure 10B. Mice vaccinated with EL4-NA-LIGHT showed a reduction of tumor volume compared to the EL4-NA control group. Vaccination using a biotin-based immobilization of LIGHT on EL4 cell surface reduced tumor growth.
[0716] As depicted in Figures 11A-11B, the effect of EL4-CD16a-10G3 vaccination on tumor development was demonstrated. A schematic illustration of the design for 10G3 dependent tumor vaccination is set forth in Figure 11A; Human CD16a-V158 was stably expressed on EL4 cell-surface (EL4-CD16a) using retroviral transduction. Three groups of mice were used in the study, including (i) EL4-CD16a-10G3 (i.e., human 10G3 immobilized EL4-CD16a cells), (ii) EL4-CD16a, and (iii) PBS. For the vaccination, each mouse was injected subcutaneously into C57B1 / 6 mice (n = 5) with corresponded prepared cells containing 0.15 xlO6proliferative cells and 0.85 xlO6non-proliferative cells. No cells were injected in the PBS group. After 14 days, mice without tumor were challenged with live EL4 cells. 0.5 x 106EL4 cells were injected subcutaneously into each mouse. Tumor growth was monitored. The effect of injected EL4-CD16a-10G3 and EL4-CD16a cells on the frequency of tumor development / tumor volume is depicted in Figure 11B; mice vaccinated with EL4-CD16a-10G3 showed a lower frequency of tumor formation compared to the EL4-CD16a control group.
[0717] The observed effects of EL4-CD16a-10G3 vaccination on immune cell infiltration are depicted in Figures 12A-12C. Tumors were collected after 14 days, immunohistochemistry was performed and the percent (%) of positive staining was determined. The percent (%) of positive staining was equal to the area of positive staining
[0718] 45844288.1 80
[0719] SBMRI 22-006-03 PCT
[0720] divided by the total area of staining on a tumor slide-section. Infiltration of CD8+T cells in EL4 tumors is depicted in Figure 12A; infiltration of F4 / 80+macrophages in EL4 tumors is depicted in Figure 12B; and (C) Infiltration of NK1.1+natural killer (NK) cells in EL4 tumors is depicted in Figure 12C. Histology of tumor samples at day 14 indicated that infiltration of CD8 T cells (Figure 12A), Macrophages (Figure 12B), and NK cells (Figure 12C), into the tumor microenvironment increased.
[0721] The observed effects of EL4-CD16a-10G3 vaccination on EL4 tumor cells challenge are depicted in Figures 13A-13B; after vaccination, mice without tumor were challenged with live EL4 cells (0.5 x 106cells per mouse), and tumor growth was monitored. The frequency of tumor formation, as demonstrated by relative % of tumor-free mice, is depicted in Figure 13A; and tumor volume is depicted in Figure 13B.
[0722] The data indicated that 10G3-mediated immunological memory protects against EL4 tumor challenge, as demonstrated by analysis of tumor development (Figure 13A) and tumor volume (Figure 13B).
[0723] The observed effects of EL4-CD16a-10G3 vaccination on immune cell infiltration are depicted in Figures 14A-14C and 15A-15B. Tumors were collected after the tumor challenge, immunohistochemistry was performed, and the percent (%) of positive staining calculated for each sample. The percent (%) of positive staining was equal to the area of positive staining divided by the total area of staining on a tumor slide-section. Infiltration of CD8+T cells in EL4 tumors was determined as the amount of positive CD8 staining (% area) (see Figure 14 A); infiltration of F4 / 80+macrophages in EL4 tumors was determined as the amount of positive F4 / 80 staining (% area) (see Figure 14B); and infiltration of NK1.1+natural killer (NK) cells in EL4 tumors was determined as the amount of positive NK1.1 staining (% area) (see Figure 14C), respectively. Histology of tumor samples collected after EL4 tumor cells challenge indicated that infiltration of CD8 T cells (Figure 14A), Macrophages (Figure 14B), and NK cells (Figure 14C), into the tumor microenvironment increased. These data are summarized in Figures 15A-15B, which depict the percent (%) of tumor infiltrating immune cells.
[0724] Example 4: In vivo studies demonstrate anti-lymphoma efficacy of mAb clone 10G3 Methods
[0725] A study to demonstrate the effect of EL4-CD16a-10G3 vaccination on tumor development was designed. The study assessed inhibition of tumor growth during EL4 cells challenge by vaccinating mice with 10G3 decorated EL4 cells, where 10G3 was immobilized on the EL4 cell-surface.
[0726] 45844288.1 81
[0727] SBMRI 22-006-03 PCT
[0728] Briefly, “EL4-CD16a” cells were generated by expressing CD16a-V158F on the surface of EL4 cells; human CD16a-V158 was stably expressed on EL4 cell-surface (EL4-CD16a) using retroviral transduction.
[0729] For the vaccination, each mouse (C57B1 / 6 mice, (n = 10)) was injected subcutaneously with prepared cells containing 1 x106non-proliferative cells. Three groups of mice were used in the study, including (i) EL4-CD16a-10G3 (z.e., human 10G3 immobilized EL4-CD16a cells), (ii) EL4-CD16a, and (iii) PBS. Vaccination of each of three groups, including PBS (control), as well as EL4-CD16a, and EL4-CD16a-10G3 was carried out via SC injection. No cells were injected in the PBS group.
[0730] After 14 days, mice were challenged with live EL4 cells. EL4 cells are a murine T-cell lymphoma cell line derived from a C57BL / 6 mouse induced by 9,10-dimethyl-l,2-benzanthracene. These lymphoblast- like cells grow in suspension, produce IL-2, and are highly tumorigenic. For tumor challenge, each mouse was injected subcutaneously with 1 x 106non-proliferative (irradiated) EL4 cells. Unmodified EL4-GFP (1.25 x 105cells) were injected into the tumor free mice. Tumor growth was monitored.
[0731] Results
[0732] The effect of injected EL4-CD16a-10G3 cells, EL4-CD16a cells, and PBS on tumor volume is depicted in Figure 16A; mice vaccinated with EL4-CD16a-10G3 showed a reduction of tumor volume compared to the EL4-CD16a and PBS control groups. In addition, the effect of injected EL4-CD16a-10G3 and EL4-CD16a cells on the frequency of tumor regression is depicted in Figure 16B; mice vaccinated with EL4-CD16a-10G3 showed a higher frequency of tumor regression compared to the EL4-CD16a control group. The tumor development of the mice with tumor regression from the EL4-CD16a-10G3 vaccinated group was also recorded, as depicted in Figure 16C.
[0733] Example 5: In vivo studies demonstrate anti-melanoma efficacy of mAb clone 10G3 Methods
[0734] A study to demonstrate the effect of YUMM1.5-CD16a-10G3 vaccination on tumor development was designed.
[0735] Briefly, human CD16a-V158 was stably expressed on YUMM1.5 cell-surface (YUMM1.5-CD16a) using retroviral transduction. For the vaccination, each of three groups of mice (C57B1 / 6 mice (n = 10), including groups (i) YUMM1.5-CD16a-10G3 (z'.e., human 10G3 immobilized EL4-CD16a cells); (ii) YUMM1.5-CD16a; and (iii) PBS control) were injected subcutaneously. No cells were injected in the PBS group.
[0736] 45844288.1 82
[0737] SBMRI 22-006-03 PCT
[0738] After 14 days, mice were challenged with live YUMM1.5 cells, injected subcutaneously into each mouse. Tumor growth was monitored.
[0739] Results
[0740] The effect of injected YUMM1.5-CD16a-10G3 cells, YUMM1.5-CD16a cells, and PBS on tumor volume is depicted in Figure 17A; mice vaccinated with YUMM1.5-CD16a-10G3 showed a reduction of tumor volume compared to the YUMM1.5-CD16a and PBS control groups. In addition, the effect of injected YUMM1.5-CD16a-10G3 and YUMM1.5-CD16a cells on the frequency of tumor development is depicted in Figure 17B; mice vaccinated with EL4-CD16a-10G3 showed a lower frequency of tumor development after YUMM1.5 cells challenge compared to the YUMM1.5-CD16a control group. Four mice out of ten in EL4-CD16a-10G3 vaccination group showed tumor regression (assigned reference numbers Fl, F7, F22 and F28, respectively) are depicted in FIG. 17C.
[0741] Example 6: In vivo studies demonstrate mAb 10G3 and LIGHT enhance LTpR signaling
[0742] Methods
[0743] To assess whether anti-LTpR mAb 10G3 activated 293T-NFKB reporter cells, 293T-NFKB reporter cells (human embryonic kidney cancer cell line expressing exogenous LTpR with NFKB -driven luciferase reporter) were plated in a 96-well plate at a density of 100,000 cells / well. Cells were left to adhere for one hour. Serial dilutions of anti-LTPR human IgGl clone 10G3 (305 ng / mL to 18 μg / mL with fixed concentration of recombinant LIGHT (EC70 level of LTPR activation) (Human LIGHT / TNFSF14 Recombinant Protein, Ref# 664LI025CF, R & D Systems, Minneapolis, MN) were added to cells.
[0744] The samples were incubated at 37°C for 24 hours. Luciferase detection using the One-Step™ Luciferase Assay System was performed according to manufacturer’s instructions (BPS bioscience, San Diego, CA). Prism (Version 6.01) was used for data analysis (GraphPad Software, San Diego, CA). Human IgG (ChromPure Human IgG, whole molecule, Ref# 009-000-003, Jackson ImmunoResearch, West Grove, PA) was used as negative control.
[0745] Results
[0746] A downstream readout type assay showing agonist activity is set forth in Figure 18. The data demonstrated that 10G3 worked co-operatively with recombinant soluble LIGHT to enhance LTPR signaling.
[0747] 45844288.1 83
[0748] SBMRI 22-006-03 PCT
[0749] Example 7: In vivo studies demonstrate mAb 10G3 and LTα1β2 enhance LTβR signaling
[0750] Methods
[0751] To assess whether anti-LTβR mAb 10G3 activated 293T-NFKB reporter cells, 293T-NFkB reporter cells (human embryonic kidney cancer cell line expressing exogenous LTβR with NFκB-driven luciferase reporter) were plated in a 96-well plate at a density of 100,000 cells / well. Cells were left to adhere for one hour. Serial dilutions of anti-LTpR human IgGl clone 10G3 (305 ng / mL to 18 μg / mL) with fixed concentration of recombinant LTα1β2 (EC70 level of LTβR activation) were added to cells. The samples were incubated at 37°C for 24 hours. Luciferase detection using the One-Step™ Luciferase Assay System was performed according to manufacturer’s instructions (BPS bioscience, San Diego, CA). Prism (Version 6.01) was used for data analysis (GraphPad Software, San Diego, CA). Human IgG (ChromPure Human IgG, whole molecule, Ref# 009-000-003, Jackson ImmunoResearch, West Grove, PA).
[0752] Results
[0753] A downstream readout type assay showing agonist activity is set forth in Figure 19. The data demonstrated that 10G3 worked co-operatively with recombinant soluble LTα1β2 to enhance LTβR signaling.
[0754] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
[0755] 45844288.1 84
Claims
SBMRI 22-006-03 PCTCLAIMSWe claim:
1. An antibody or antigen binding fragment thereof comprising(i) complementarity-determining regions (CDRs) of the immunoglobulin heavy variable (IgVH) domain of SEQ ID NO:9, optionally wherein the CDRs comprise amino acid sequences according to SEQ ID NOs: 11-13; and / or(ii) CDRs of the immunoglobulin light variable (IgV ) domain of SEQ ID NO: 10, optionally wherein the CDRs comprise amino acid sequences according to SEQ ID NOs:14-16.
2. The antibody or antigen binding fragment thereof of claim 1, wherein the antibody or antigen binding fragment thereof comprises:an IgVH domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:9; and / oran IgVHdomain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:10.
3. An antibody or antigen binding fragment thereof comprising(i) CDRs of the IgVn domain of SEQ ID NO: 17,optionally wherein the CDRs comprise amino acid sequences according to SEQ ID NOs: 11, 12, 19, and / or(ii) CDRs of the IgVLdomain of SEQ ID NO: 18,optionally wherein the CDRs comprise amino acid sequences according to SEQ ID NOs:20-22.
4. The antibody or antigen binding fragment thereof of claim 3, wherein the antibody or antigen binding fragment thereof comprises:an IgVH domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 17; and / oran IgVL domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 18.
5. An antibody or antigen binding fragment thereof comprising(i) CDRs of the IgVn domain of SEQ ID NO: 1, optionally wherein the CDRs comprise amino acid sequences according to SEQ ID NOs:3-5; and / or(ii) CDRs of the IgVHdomain of SEQ ID NO: 2, optionally wherein the CDRs comprise amino acid sequences according to SEQ ID NOs:6-8.45844288.1 85SBMRI 22-006-03 PCT6. The antibody or antigen binding fragment thereof of claim 5, wherein the antibody or antigen binding fragment thereof comprises:an IgVH domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:1; and / oran IgVL domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:2.
7. The antibody or antigen binding fragment thereof of any one of claims 1 -6, comprising an intact immunoglobulin, or a mono-, di-, or tri-valent or multivalent single chain variable fragment (scFv), Fab, F(ab’)2, minibody, scFv-Fc, diabody, triabody, or tetrabody.
8. The antibody of any one of claims 1-7, wherein the antibody binds to Lymphotoxin P Receptor (LT R) with an EC50 between about 0.01 nM and about 1 nM, inclusive, preferably between about 0.1 nM and about 0.5 nM, inclusive.
9. The antibody or antigen binding fragment thereof of any one of claims 1-8, wherein the antibody or antigen binding fragment thereof is an LTβR agonist.
10. A pharmaceutical composition comprising the antibody according to claim 9 and a pharmaceutically acceptable excipient.
11. The pharmaceutical composition of claim 10, for use in a method of treatment of a proliferative disease or disorder in a subject in need thereof, comprising administering to the subject the pharmaceutical composition in an amount effective to treat or prevent one or more symptoms of the proliferative disease or disorder.
12. The LTβR antagonist of claim 9, for use in formulation of a composition for the treatment of a proliferative disease or disorder in a subject in need thereof, comprising administering the composition to the subject in an amount effective to treat or prevent one or more symptoms of a proliferative disease or disorder.
13. A method of inducing, promoting, or enhancing biosynthesis and secretion of chemokines by immune cells, and / or infiltration of immune cells into a tumor microenvironment (TME) in a subject having a tumor, comprisingadministering to the subject an effective amount of the pharmaceutical composition of claim 10 to induce, promote, or enhance the biosynthesis and secretion of chemokines and / or infiltration of immune cells into the TME in the subject.
14. The method of claim 13, wherein the enhancement of the biosynthesis and secretion of chemokines and / or immune cell infiltration is mediated by LTβR signaling within the TME.45844288.1 86SBMRI 22-006-03 PCT15. The method of claim 14, wherein the TME had low infiltration of immune cells, and / or high presence of immunosuppressive cells prior to the administration of the pharmaceutical composition.
16. The method of claim 15, wherein the immunosuppressive cells are one or more regulatory T cells and / or type II macrophages.
17. The method of any one of claims 13-16, wherein the pharmaceutical composition is administered in an amount effective to recruit immune cells, promote lymphocyte infiltration, and drive immune cell differentiation.
18. The method of any one of claims 13-16, wherein the pharmaceutical composition is administered in an amount effective to recruit cytotoxic T cells into the tumor microenvironment, more than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more than 90%, compared to the level prior to the administration of the pharmaceutical composition.
19. The method of any one of claims 11-18, further comprising administering one or more additional cancer therapies to the subject.
20. The method of claim 19, wherein the administration of the one or more additional cancer therapies is simultaneous or sequential with the administration of the pharmaceutical composition.
21. The method of claim 19 or 20, wherein the additional cancer therapy is selected from the group consisting of conventional chemotherapy, immunotherapy, surgery, and radiation.
22. The method of claim 21, wherein the immunotherapy comprises one or more check point receptor inhibitor(s) selected from the group consisting of PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.
23. The method of any one of claims 13-22, wherein the tumor was resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to the administration of the pharmaceutical composition.
24. The method of any one of claims 19-23, wherein the effective amount of the pharmaceutical composition in combination with the one or more additional cancer therapies is effective to reduce or inhibit proliferation, migration, invasion, motility, and / or metastatic abilities of the cancer cells.
25. The pharmaceutical composition for use according to claim 11, or the LT[3R antagonist for use according to claim 12, or the method according to any one of claims 13-24, wherein the subject has a proliferative disease or disorder is a cancer selected from the group45844288.1 87SBMRI 22-006-03 PCTconsisting of breast cancer, head and neck squamous cell carcinoma, glioblastoma, pancreatic cancer, prostate cancer, lung cancer, melanoma, ovarian cancer, and sarcoma.
26. The method of any one of claims 13-25, the cancer is Triple Negative Breast Cancer.
27. A method of treating cancer in a subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical composition of claim 10 and one or more conventional chemotherapeutic agents and / or immunotherapy to treat or alleviate one or more symptoms of the cancer in the subject.
28. The method of claim 27, wherein the immunotherapy is one or more check point receptor inhibitors selected from the group consisting of PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.
29. The method of claim 27, wherein the one or more conventional chemotherapeutic agent(s) is selected from the group consisting of anti-VEGF antibodies, Receptor Tyrosine Kinase (RTK) inhibitors, MEK inhibitors, and CXCR4 antagonists.
30. The method of claim 27 or 29, wherein the one or more conventional chemotherapeutic agent(s) is selected from the group consisting of bevacizumab, cabozantinib, cobimetinib, and BL8040.
31. The method of any one of claims 27-30, wherein the cancer was resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to the administration of the pharmaceutical composition.
32. The method of any one of claims 27-31, wherein the administration of the one or more conventional chemotherapeutic agent(s) and / or immunotherapy is simultaneous or sequential with the administration of the pharmaceutical composition.
33. The method of any one of claims 27-32, wherein the effective amount of the pharmaceutical composition in combination with the one or more conventional chemotherapeutic agent(s) and / or immunotherapy are effective to reduce or inhibit proliferation, migration, invasion, motility, and / or metastatic abilities of the cancer cells.
34. The method of any one of claims 27-33, wherein the cancer is selected from the group consisting of breast cancer, head and neck squamous cell carcinoma, glioblastoma, pancreatic cancer, lung cancer, melanoma, ovarian cancer, and sarcoma.
35. The method of any one of claims 27-34, the cancer is Triple Negative Breast Cancer.45844288.1 88SBMRI 22-006-03 PCT36. A means for agonizing the Lymphotoxin β Receptor (LTβR) without blocking its natural ligands comprising a compound that binds to LTβR but does not compete with hLIGHT or hLTα1β2 for binding to LTβR.
37. The means of claim 36, wherein the means comprises one or more complementarity-determining regions (CDRs) according to SEQ ID NOs:l 1-16, SEQ ID NOs:ll, 12, 19-22, or SEQ ID NOs:3-8.
38. A method of selecting a molecule that selectively binds to the Lymphotoxin-β Receptor (LTβR), comprising(i) providing an antibody or antigen binding fragment of any one of claims 1-7 and / or a native LTβR-binding ligand as a positive binding control;(ii) providing a first or further sample comprising one or more test molecules;(iii) screening for a LTβR-binding test molecule within the first or further sample, wherein the screening comprises contacting the first or further sample with a LTβR molecule in the presence of the positive binding control; and(iv) selecting a test molecule from the first or further sample as a LTβR-binding molecule when the test molecule remains bound to LTβR in the presence of the native LTβR ligand, or in the presence of the positive binding control.
39. The method of claim 38, wherein the positive binding control is mixed with the first or further sample comprising one or more test molecules prior to contacting the first or further sample with the native LTβR ligand in step (iii).
40. The method of claim 38, wherein the positive binding control is contacted with the native LTβR ligand after the first or further sample comprising one or more test molecules is contacted with the native LTβR ligand in step (iii).
41. The method of any one of claims 38-40, wherein the one or more test molecule comprises a detectable label or dye, andwherein the selecting in step (iv) comprises detecting the label or dye.
42. An LTβR-binding molecule selected according to the method of any one of claims 38 to 41.
43. The LTβR-binding molecule of claim 42, wherein the LTβR-binding molecule comprises an immunoglobulin, or an antigen-binding fragment thereof.
44. The LTβR-binding molecule of claim 42 or 43, wherein the LTβR-binding molecule is conjugated or complexed with a bacterium or viral particle.45844288.1 89SBMRI 22-006-03 PCT45. The LTpR-binding molecule of claim 44, wherein the viral particle comprises a bacteriophage.
46. The method of any one of claims 38-41, further comprising(v) selecting the LTβR-binding molecule as an LTβR agonist or antagonist, comprising contacting the LTβR-binding molecule with cells comprising LTβR expression; and(vi) selecting the LTpR-binding molecule as an agonist when the LTpR-binding molecule induces LT R signaling in the cells, orselecting the LTpR-binding molecule as an LTPR antagonist when the LTpR-binding molecule prevents LT R signaling in cells in the presence of one or more natural LTPR-ligands or functional fragments or variants thereof.
47. An LTβR agonist selected according to the method of claim 46.
48. The LTβR agonist of claim 47, comprising an immunoglobulin comprising two or more antigen-binding Fab domains.
49. An isolated antigen binding Fab domain protein comprising one of the two or more antigen-binding Fab domains of the immunoglobulin of claim 48.
50. An LTβR antagonist selected according to the method of claim 47.
51. An LTβR antagonist comprising an isolated Fab molecule, comprising(i) complementarity-determining regions (CDRs) of the immunoglobulin heavy variable (IgVu) domain of SEQ ID NO: 17, optionally wherein the CDRs comprise amino acid sequences according to SEQ ID NOs:ll, 12, 19, and / or(ii) CDRs of the immunoglobulin heavy variable (IgV ) domain of SEQ ID NO: 18, optionally wherein the CDRs comprise amino acid sequences according to SEQ ID NOs:20-22.
52. The LTPR antagonist of claim 51, wherein the isolated Fab comprises an IgVHdomain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:17; and / oran IgVL domain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 18.
53. An LTβR antagonist comprising an isolated Fab molecule comprising(i) complementarity-determining regions (CDRs) of the immunoglobulin heavy variable (IgVu) domain of SEQ ID NO:1, optionally wherein the CDRs comprise amino acid sequences according to SEQ ID NOs:3-5, and / or45844288.1 90SBMRI 22-006-03 PCT(ii) CDRs of the immunoglobulin heavy variable (IgVH) domain of SEQ ID NO:2, optionally wherein the CDRs comprise amino acid sequences according to SEQ ID NOs:6-8.
54. The LTPR antagonist of claim 53, wherein the isolated Fab comprises an IgVHdomain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:1; and / oran IgVLdomain having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO:2.
55. A pharmaceutical formulation comprising the LTPR antagonist of any one of claims 48-52 and a pharmaceutically acceptable excipient.
56. A method for the treatment of an inflammatory disease or disorder in a subject in need thereof, comprising administering to the subject one or more LT R antagonist(s) in an amount effective to treat or prevent one or more symptoms of an inflammatory disease or disorder in the subject.
57. The method of claim 56, wherein the one or more LT^R antagonist(s) bind to an epitope on LTPR that overlaps with an epitope on LTPR of one or more natural LTPR ligands.
58. The method of claim 57, wherein the one or more natural LTPR ligands is selected from the group consisting of LIGHT and LTai 2.
59. The method of claim 57 or 58, wherein the one or more LTPR antagonist(s) inhibit or reduce the binding between one or more natural LTPR ligands and LTPR.
60. The method of any one of claims 57-59, wherein the one or more LTPR antagonist(s) comprise an isolated antigen binding domain (Fab) of an immunoglobulin.
61. The method of claim 60, wherein the isolated Fab comprises one or more of the LTPR antagonists of any one of claims 48-52.
62. The pharmaceutical formulation of claim 55, for use in a method of treatment of an inflammatory disease or disorder in a subject in need thereof, comprising administering to the subject the formulation in an amount effective to treat or prevent one or more symptoms of an inflammatory disease.
63. The LTPR antagonist of any one of claims 50-54, for use in formulation of a composition for the treatment of an inflammatory disease or disorder in a subject in need thereof, comprising administering the composition to the subject in an amount effective to treat or prevent one or more symptoms of an inflammatory disease.
64. The method of any one of claims 56-61, or the pharmaceutical formulation for use according to claim 62, wherein the inflammatory disease or disorder is selected from the45844288.1 91SBMRI 22-006-03 PCTgroup consisting of asthma, chronic peptic ulcer, tuberculosis, rheumatoid arthritis, periodontitis, ulcerative colitis, Crohn’s disease, sinusitis, active hepatitis, acute bronchitis, appendicitis, ingrown toenail, sore throat, and physical trauma or wound, or a combination thereof.
65. A composition comprising the antibody according to claim 9 conjugated to tumor cells of a subject.
66. A method comprisingadministering an effective amount of the composition of claim 65 to the subject to induce, promote, or enhance the biosynthesis and secretion of chemokines and / or infiltration of immune cells into the TME in the subject.
67. The method of claim 66, wherein the enhancement of the biosynthesis and secretion of chemokines and / or immune cell infiltration is mediated by LTβR signaling within the TME.
68. The method of claim 67, wherein the TME had low infiltration of immune cells, and / or high presence of immunosuppressive cells prior to the administration of the composition.
69. The method of claim 68, wherein the immunosuppressive cells are one or more regulatory T cells and / or type II macrophages.
70. The method of any one of claims 66-69, wherein the composition is administered in an amount effective to recruit immune cells, promote lymphocyte infiltration, and drive immune cell differentiation.
71. The method of any one of claims 66-69, wherein the composition is administered in an amount effective to recruit cytotoxic T cells into the tumor microenvironment, more than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more than 90%, compared to the level prior to the administration of the composition.
72. The method of any one of claims 65-71, further comprising administering one or more additional cancer therapies to the subject.
73. The method of claim 72, wherein the administration of the one or more additional cancer therapies is simultaneous or sequential with the administration of the composition.
74. The method of claim 72 or 73, wherein the additional cancer therapy is selected from the group consisting of conventional chemotherapy, immunotherapy, surgery, and radiation.45844288.1 92SBMRI 22-006-03 PCT75. The method of claim 74, wherein the immunotherapy comprises one or more check point receptor inhibitor(s) selected from the group consisting of PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.
76. The method of any one of claims 66-75, wherein the tumor was resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy, prior to the administration of the composition.
77. The method of any one of claims 72-76, wherein the effective amount of the composition in combination with the one or more additional cancer therapies is effective to reduce or inhibit proliferation, migration, invasion, motility, and / or metastatic abilities of the cancer cells.
78. The pharmaceutical composition of claim 65, for use in a method of treatment of a proliferative disease or disorder in a subject in need thereof, comprising administering to the subject the pharmaceutical composition in an amount effective to treat or prevent one or more symptoms of the proliferative disease or disorder.
79. A method of treating melanoma in a subject, the method comprising administering to the subject a polynucleotide encoding an antibody or antigen binding fragment thereof of any one of claims 1 -9, or a polynucleotide encoding a fusion protein comprising an antibody or antigen binding fragment thereof of any one of claims 1-9.
80. The method of claim 79, wherein the melanoma is refractory melanoma.
81. The method of claim 80, wherein the melanoma is dacarbazine-refractory melanoma, vemurafenib-refractory melanoma, trametinib-refractory melanoma or dasatinib-refractory melanoma.
82. The method of any one of claims 79-81, wherein the melanoma comprises wild type BRAT, mutated BRAT, wild type NRAS, or mutated NRAS.
83. The method of any one of claims 79-82, wherein the melanoma is stage II melanoma, stage III melanoma, or stage IV melanoma.
84. The method of any one of claims 79-83, wherein the subject has previously undergone tumor resection, orwherein the subject receives the method of treatment prior to tumor resection.
85. The method of any one of claims 79-84, further comprising administering one or more additional cancer therapies to the subject.
86. The method of any one of claims 79-84, wherein the administration of the one or more additional cancer therapies is simultaneous or sequential with administering the polynucleotide.45844288.1 93SBMRI 22-006-03 PCT87. The method of claim 85 or 86, wherein the additional cancer therapy comprises an immune checkpoint inhibitor.
88. The method of claim 87, wherein the immune checkpoint inhibitor is pembrolizumab, nivolumab, ipilimumab, relatlimab, or combination thereof89. The method of any one of claims 85-88, wherein the additional cancer therapy comprises a BRAF inhibitor.
90. The method of claim 89, wherein the BRAF inhibitor is dabrafenib, vemurafenib, encorafenib, or combination thereof.
91. The method of any one of claims 85-90, wherein the additional cancer therapy comprises a MEK inhibitor.
92. The method of claim 91, wherein the MEK inhibitor is trametinib, cobimetinib, binimetinib, or combination thereof.
93. The method of claim 85 or 86, wherein the additional cancer therapy is selected from the group consisting of conventional chemotherapy, immunotherapy, surgery, and radiation.
94. The method of claim 93, wherein the immunotherapy comprises one or more check point receptor inhibitor(s) selected from the group consisting of PD-1 antagonists, PD-1 ligand antagonists, and CTLA4 antagonists.
95. The method of any one of claims 79-94, wherein the melanoma was resistant or insensitive to one or more conventional chemotherapeutic agents and / or immunotherapy prior to administering the polynucleotide.
96. The method of any one of claims 79-95, wherein the melanoma is metastatic melanoma.
97. The method of any one of claims 79-96, wherein the melanoma is acral-lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigomaligna melanoma (LMM), malignant melanoma, nodular melanoma subungal melanoma, and superficial spreading melanoma.
98. The method of any one of claims 79-97, wherein the polynucleotide is DNA or RNA.
99. The method of claim 98, wherein the polynucleotide is DNA.
100. The method of claim 99, wherein the DNA is cDNA.
101. The method of claim 98, wherein the polynucleotide is RNA.
102. The method of claim 101, wherein the RNA is mRNA.45844288.1 94SBMRI 22-006-03 PCT103. The method of any one of claims 79-102, wherein the melanoma is metastatic melanoma.
104. The method of any one of claims 79-103, wherein the fusion protein is located on mammalian cells including a surface.
105. The method of claim 104, wherein the fusion protein is located on the surface of a mammalian cell.
106. The method of claim 105, wherein the fusion protein is covalently or non-covalently attached to the surface of the mammalian cell.
107. The method of claim 106, wherein the fusion protein is non-covalently attached to the surface of the mammalian cell by way of hydrophobic interactions.
108. The method of claim 107, wherein the fusion protein further comprises a membrane- anchoring domain and the fusion protein is non-covalently attached to the surface of the mammalian cell by way of hydrophobic interactions with a membrane-anchoring domain.
109. A fusion protein comprising an antibody or antigen binding fragment thereof of any one of claims 1-9.
110. The fusion protein of claim 109 further comprising a signal peptide domain, or method of any one of claims 79-107, wherein the fusion protein further comprises a signal peptide domain.
111. The fusion protein 109 or 110 further comprising a membrane-anchoring domain, or method of claim 109 or 110, wherein the fusion protein further comprises a membrane- anchoring domain.
112. An antibody complex comprising an antibody or antigen binding fragment thereof of any one of claims 1-9, or a fusion protein comprising an antibody or antigen binding fragment thereof of any one of claims 1-9.
113. The antibody complex of claim 112, further comprising a signal peptide domain.
114. The antibody complex 112 or 113, further comprising a membrane- anchoring domain.
115. The antibody complex of any one of claims 112-114 further comprising a cell.
116. The antibody complex of claim 115, wherein the cell is a mammalian cell.
117. The antibody complex of claim 116, wherein the antibody or antigen binding fragment thereof are located on the surface of the mammalian cell.45844288.1 95SBMRI 22-006-03 PCT118. The antibody complex of claim 117, wherein the antibody or antigen binding fragment thereof are covalently or non-covalently attached to the surface of the mammalian cell.
119. The antibody complex of claim 117, wherein the antibody or antigen binding fragment thereof are non-covalently attached to the surface of the mammalian cell by way of hydrophobic interactions.
120. The antibody complex of claim 119, wherein the antibody or antigen binding fragment thereof are non-covalently attached to the surface of the mammalian cell by way of hydrophobic interactions with the membrane-anchoring domain.45844288.1 96
